

**Evidence relating cigarette, cigar and pipe smoking to lung cancer and COPD.
Meta-analysing recent data from three regions.**

Supplementary File 1

Authors

Peter N Lee, Katharine J Coombs, Jan S Hamling

This supplementary file provides the detailed output from the meta-analyses of smoking and lung cancer. This relates to cigarette smoking only as the data on pipe and cigar smoking was too limited to make meta-analysis of these smoking products feasible.

Smoking and Lung cancer: Cigarette Smoking analyses

These analyses are restricted to results for current cigarette smokers versus never smokers.

In the initial analyses, if multiple results are available for a single study

the results to be included in meta-analysis are selected by applying the following criteria:

- 1) Exclusive cigarette smoking rather than non-exclusive.
- 2) A latency rule was applied rather than none being used.
- 3) The longest follow-up period available.
- 4) The greatest amount of adjustment for possible confounding factors.
- 5) Lung cancer was identified by diagnosis rather than by cause of death.
- 6) Results for the sexes separately rather than a single result for the sexes combined:
 - For study NHIS, NRRs 5 and 6 (male, female) are preferred to NRR 2 (sexes combined).
 - For study NIHAARP, NRRs 4 and 2 (male, female) are preferred to NRR 5 (sexes combined).
 - For study NLCS, NRRs 4 and 5 (male, female) are preferred to NRR 1 (sexes combined).
 - For study PLCO, NRR 2 (female) is preferred to NRR 1 (sexes combined).
 - For study SCCS, NRRs 1 and 2 (male, female) are preferred to NRR 3 (sexes combined).
 - For study VLAGT, NRRs 1 and 4 (male, female) are preferred to NRR 3 (sexes combined).

In additional analyses,

the ratio of results for males and females within a single study are reported and meta-analysed;

and the ratios of unadjusted to adjusted results for a single study are reported,

but not meta-analysed because these are not independent findings.

All these analyses are then repeated, reporting only studies in North America and Europe.

Key:

Study ID: Identifier assigned to the study

NRR: Sequence number within the study assigned to the risk estimate

REFID: Identifier assigned to the published paper

YRST: Year of start of baseline

NCASES: Number of lung cancer cases studied

ProductSm: Product smoked

Excl: Exclusive use of the product: 0 = No; x = Yes

Latent: A latency rule was applied, such as ignoring lung cancers in the first two or five years after smoking data were gathered: 0 = No; x = Yes

Study design: Cohort or Nested case control design

Sex: Gender reported by the risk estimate; b = both sexes combined, m = male, f = female

LowAge, HighAge: Age range reported by the risk estimate

YrsFU: Number of years of follow up reported by the risk estimate

Endpoint: The way the lung cancer cases were identified: by diagnosis or by reported death

Adj: Number of adjustment factors applied to the risk estimate

CA1, CA0, CO1, CO0: Numbers of cases (CA)/controls or at risk (CO), exposed (1)/unexposed (0)

RR, RRL, RRU: Relative risk (RR) and confidence interval (RRL to RRU)

Smoking and Lung cancer: Cigarette Smoking analyses

CONTENTS

Table 1: List of all the results - Current cigarette smokers versus never smokers	4
Table 2: List of all the risk estimates - Current cigarette smokers versus never smokers	8
Initial analyses	
Table 3: List of selected results - Current cigarette smokers versus never smokers	12
Table 4: Initial analysis by sex	14
Table 5: Initial analysis by region	16
Table 6: Initial analysis by study population	18
Table 7: Initial analysis by year of start of baseline	20
Table 8: Initial analysis by number of cases in study	22
Table 9: Initial analysis by cigarette smoking exclusively or not	24
Table 10: Initial analysis by latency rule used or not	26
Table 11: Initial analysis by study design	28
Table 12: Initial analysis by lowest age considered in the study	30
Table 13: Initial analysis by lowest age considered: trend without 'Missing'	32
Table 14: Initial analysis by years of follow-up	34
Table 15: Initial analysis by endpoint (died or diagnosed)	36
Table 16: Initial analysis by number of adjustment factors	38
Additional analysis of male/female ratio	
Table 17: List of selected results	40
Table 18: Analysis of the ratio of results for males and females	41
Additional analysis by number of adjustment factors	
Table 19: List of unadjusted and multiply-adjusted results within study	42
Analyses of studies in North America and Europe only	
Table 20: List of selected results - Current cigarette smokers versus never smokers	43
Table 21: Initial analysis by sex	45
Table 22: Initial analysis by region	47
Table 23: Initial analysis by study population	49
Table 24: Initial analysis by year of start of baseline	51
Table 25: Initial analysis by number of cases in study	53
Table 26: Initial analysis by cigarette smoking exclusively or not	55
Table 27: Initial analysis by latency rule used or not	57
Table 28: Initial analysis by study design	59
Table 29: Initial analysis by lowest age considered in the study	61
Table 30: Initial analysis by lowest age considered: trend without 'Missing'	63
Table 31: Initial analysis by years of follow-up	65
Table 32: Initial analysis by endpoint (died or diagnosed)	67

Smoking and Lung cancer: Cigarette Smoking analyses

Table 33: Initial analysis by number of adjustment factors	69
Additional analysis of male/female ratio	
Table 34: List of selected results	71
Table 35: Analysis of the ratio of results for males and females	72
Additional analysis by number of adjustment factors	
Table 36: List of unadjusted and multiply-adjusted results within study	73

Table 1
Smoking and Lung cancer: Cigarette Smoking analyses
List of all the results (not all to be included in any one meta-analysis) - Current cigarette smokers versus never smokers

Study ID	NRR	REFID	Country	Study population	YRST	NCASES	Product Sm	Excl	Latent	Study design	Sex	LowAge	HighAge	YrsFU	Endpoint	Adj
ACE	1	BROWN2010B	USA	Regional	1995	111	Cigarettes	0	0	Cohort	b	18	999	10	Died	0
ACE	2	BROWN2010B	USA	Regional	1995	111	Cigarettes	0	0	Cohort	b	18	999	10	Died	8
AEROBIC	1	SUI2010	USA	Regional	1974	232	Cigarettes	0	0	Cohort	m	20	84	29	Died	0
AGRICAN	1	TUAL2017	France	Regional	2005	664	Cigarettes	0	0	Cohort	m	18	999	6	Diagnosed	1
AGRICAN	2	TUAL2017	France	Regional	2005	664	Cigarettes	0	0	Cohort	f	18	999	6	Diagnosed	1
AHS	1	ANDREQ2017	USA	Pesticide workers	1993	789	Cigarettes	x	0	Cohort	b	*	*	18	Diagnosed	0
AHS	2	ANDREQ2017	USA	Pesticide workers	1993	789	Cigarettes	x	0	Cohort	b	*	*	18	Diagnosed	8
AMIANT	1	SWIATK2017	Poland	Asbestos workers	2000	110	Cigarettes	0	0	Cohort	b	*	*	14	Diagnosed	0
ARIC	1	PRIZME2014	USA	Regional	1987	470	Cigarettes	0	0	Cohort	m	45	64	19	Diagnosed	0
ARIC	2	PRIZME2014	USA	Regional	1987	470	Cigarettes	0	0	Cohort	f	45	64	19	Diagnosed	0
ARIC	3	PRIZME2014	USA	Regional	1987	470	Cigarettes	0	0	Cohort	m	45	64	19	Diagnosed	3
ARIC	4	PRIZME2014	USA	Regional	1987	470	Cigarettes	0	0	Cohort	f	45	64	19	Diagnosed	3
ATP	1	VINER2019	Canada	Regional	2001	210	Cigarettes	0	0	Cohort	m	35	69	16	Diagnosed	0
ATP	2	VINER2019	Canada	Regional	2001	210	Cigarettes	0	0	Cohort	f	35	69	16	Diagnosed	0
ATP	3	VINER2019	Canada	Regional	2001	210	Cigarettes	0	0	Cohort	m	35	69	16	Diagnosed	1
ATP	4	VINER2019	Canada	Regional	2001	210	Cigarettes	0	0	Cohort	f	35	69	16	Diagnosed	1
ATP	5	VINER2019	Canada	Regional	2001	210	Cigarettes	0	0	Cohort	m	35	69	16	Diagnosed	7
ATP	6	VINER2019	Canada	Regional	2001	210	Cigarettes	0	0	Cohort	f	35	69	16	Diagnosed	7
ATP	7	VINER2019	Canada	Regional	2001	210	Cigarettes	0	x	Cohort	m	35	69	16	Diagnosed	0
ATP	8	VINER2019	Canada	Regional	2001	210	Cigarettes	0	x	Cohort	f	35	69	16	Diagnosed	0
ATP	9	VINER2019	Canada	Regional	2001	210	Cigarettes	0	x	Cohort	m	35	69	16	Diagnosed	7
ATP	10	VINER2019	Canada	Regional	2001	210	Cigarettes	0	x	Cohort	f	35	69	16	Diagnosed	7
BIOBANK	1	WONG2020	UK	National	2006	1493	Cigarettes	0	0	Cohort	f	40	73	10	Diagnosed	0
BIOBANK	2	WONG2020	UK	National	2006	1493	Cigarettes	0	0	Cohort	m	40	73	10	Diagnosed	0
BWHS	1	NOMURA2018	USA	National	1995	306	Cigarettes	0	0	Cohort	f	21	69	18	Diagnosed	0
BWHS	2	NOMURA2018	USA	National	1995	306	Cigarettes	0	0	Cohort	f	21	69	18	Diagnosed	1
BWHS	3	NOMURA2018	USA	National	1995	306	Cigarettes	0	0	Cohort	f	21	69	18	Diagnosed	7
CHANCES	1	ORDONE2016	Multiple	International	1982	14041	Cigarettes	0	0	Cohort	b	46	74	29	Diagnosed	0
CHANCES	2	ORDONE2016	Multiple	International	1982	14041	Cigarettes	0	0	Cohort	b	46	74	29	Diagnosed	7
CHANCES	3	ORDONE2016	Multiple	International	1982	14041	Cigarettes	0	0	Cohort	b	46	74	29	Died	0
CHANCES	4	ORDONE2016	Multiple	International	1982	14041	Cigarettes	0	0	Cohort	b	46	74	29	Died	7
COAL	1	GRABER2014	USA	Coal miners	1969	568	Cigarettes	0	0	Cohort	m	*	*	38	Died	7
CPSI	1	THUN2013	USA	National	1959	1293	Cigarettes	x	0	Cohort	m	49	999	6	Died	0
CPSI	2	THUN2013	USA	National	1959	1293	Cigarettes	x	0	Cohort	f	49	999	6	Died	0
CPSI	3	THUN2013	USA	National	1959	1293	Cigarettes	x	0	Cohort	m	49	999	6	Died	1
CPSI	4	THUN2013	USA	National	1959	1293	Cigarettes	x	0	Cohort	f	49	999	6	Died	1
CPSI	5	THUN2013	USA	National	1959	1293	Cigarettes	x	0	Cohort	m	49	999	6	Died	3
CPSI	6	THUN2013	USA	National	1959	1293	Cigarettes	x	0	Cohort	f	49	999	6	Died	3
CPSII	1	THUN2013	USA	National	1982	4957	Cigarettes	x	0	Cohort	m	49	999	6	Died	0
CPSII	2	THUN2013	USA	National	1982	4957	Cigarettes	x	0	Cohort	f	49	999	6	Died	0

Table 1
Smoking and Lung cancer: Cigarette Smoking analyses
List of all the results (not all to be included in any one meta-analysis) - Current cigarette smokers versus never smokers

Study ID	NRR	REFID	Country	Study population	YRST	NCASES	Product Sm	Excl	Latent	Study design	Sex	LowAge	HighAge	YrsFU	Endpoint	Adj
CPSII	3	THUN2013	USA	National	1982	4957	Cigarettes	x	0	Cohort	m	49	999	6	Died	1
CPSII	4	THUN2013	USA	National	1982	4957	Cigarettes	x	0	Cohort	f	49	999	6	Died	1
CPSII	5	THUN2013	USA	National	1982	4957	Cigarettes	x	0	Cohort	m	49	999	6	Died	3
CPSII	6	THUN2013	USA	National	1982	4957	Cigarettes	x	0	Cohort	f	49	999	6	Died	3
EPIC	1	MCCORM2010	Multiple	International	1991	2995	Cigarettes	x	0	Cohort	m	35	70	14	Diagnosed	0
EPIC	3	MCCORM2010	Multiple	International	1991	2995	Cigarettes	x	0	Cohort	m	35	70	14	Diagnosed	5
EPIC	5	AGUDO2012	Multiple	International	1991	2995	Cigarettes	0	0	Cohort	m	30	70	8	Diagnosed	7
EPIC	6	AGUDO2012	Multiple	International	1991	2995	Cigarettes	0	0	Cohort	f	30	70	8	Diagnosed	7
ESTHER	1	YU2020F	Germany	Regional	2000	143	Cigarettes	0	0	Nested CC	b	50	75	17	Diagnosed	0
FRAMING	1	TINDLE2018	USA	Regional	1954	284	Cigarettes	0	0	Cohort	b	*	*	59	Diagnosed	0
FRAMING	2	TINDLE2018	USA	Regional	1954	284	Cigarettes	0	0	Cohort	b	*	*	59	Diagnosed	1
HBC	1	ERIKSS2010	Finland	Regional	2001	121	Cigarettes	0	0	Cohort	b	55	65	5	Diagnosed	1
HPFS	1	ALDELA2011	USA	Medical workers	1986	210	Cigarettes	0	0	Nested CC	m	40	75	14	Diagnosed	0
HPFS	2	ALDELA2011	USA	Medical workers	1986	210	Cigarettes	0	0	Nested CC	m	40	75	14	Diagnosed	2
HPFS	3	ALDELA2011	USA	Medical workers	1986	210	Cigarettes	0	0	Nested CC	m	40	75	14	Diagnosed	4
JP8	1	SAITO2017	Japan	National	1984	4478	Cigarettes	x	0	Cohort	m	35	999	25	Diagnosed	0
JP8	2	SAITO2017	Japan	National	1984	4478	Cigarettes	x	0	Cohort	m	35	999	25	Diagnosed	2
JP8	3	SAITO2017	Japan	National	1984	4478	Cigarettes	x	0	Cohort	m	35	999	25	Diagnosed	5
JP8	4	SAITO2017	Japan	National	1984	4478	Cigarettes	x	x	Cohort	m	35	999	25	Diagnosed	5
JP8	5	SAITO2017	Japan	National	1984	4478	Cigarettes	x	0	Cohort	f	35	999	25	Diagnosed	0
JP8	6	SAITO2017	Japan	National	1984	4478	Cigarettes	x	0	Cohort	f	35	999	25	Diagnosed	2
JP8	7	SAITO2017	Japan	National	1984	4478	Cigarettes	x	0	Cohort	f	35	999	25	Diagnosed	5
JP8	8	SAITO2017	Japan	National	1984	4478	Cigarettes	x	x	Cohort	f	35	999	25	Diagnosed	5
JPHC	1	NARITA2018	Japan	National	1990	1663	Cigarettes	x	0	Cohort	m	40	69	21	Diagnosed	0
JPHC	2	NARITA2018	Japan	National	1990	1663	Cigarettes	x	0	Cohort	f	40	69	21	Diagnosed	0
JPHC	3	ZHA2019	Japan	National	1990	1663	Cigarettes	x	0	Cohort	m	40	69	3	Died	0
JPHC	4	ZHA2019	Japan	National	1990	1663	Cigarettes	x	0	Cohort	m	40	69	3	Died	10
JPHC	5	ZHA2019	Japan	National	1990	1663	Cigarettes	x	0	Cohort	f	40	69	3	Died	0
JPHC	6	ZHA2019	Japan	National	1990	1663	Cigarettes	x	0	Cohort	f	40	69	3	Died	10
KAISER	1	TRAN2013	USA	Regional	1978	1415	Cigarettes	0	0	Cohort	b	*	*	30	Diagnosed	0
KAISER	2	TRAN2013	USA	Regional	1978	1415	Cigarettes	0	0	Cohort	b	*	*	30	Diagnosed	6
KRIS	1	EVERAT2014A	Lithuania	Regional	1972	343	Cigarettes	0	x	Cohort	m	40	59	36	Diagnosed	0
KRIS	2	EVERAT2014A	Lithuania	Regional	1972	343	Cigarettes	0	x	Cohort	m	40	59	36	Diagnosed	1
KRIS	3	EVERAT2014A	Lithuania	Regional	1972	343	Cigarettes	0	x	Cohort	m	40	59	36	Diagnosed	4
LSS	1	CAHOON2017	Japan	Atomic bomb survivors	1950	1597	Cigarettes	x	0	Cohort	m	5	999	59	Diagnosed	0
LSS	2	CAHOON2017	Japan	Atomic bomb survivors	1950	1597	Cigarettes	x	0	Cohort	f	5	999	59	Diagnosed	0
MWOMEN	1	PIRIE2013	UK	National	1996	6331	Cigarettes	x	0	Cohort	f	50	69	15	Died	0
MWOMEN	2	PIRIE2013	UK	National	1996	6331	Cigarettes	x	0	Cohort	f	50	69	15	Died	10
MWOMEN	3	PIRIE2013	UK	National	1996	6331	Cigarettes	x	x	Cohort	f	50	69	15	Died	10
NHANES	1	BITTON2017	USA	National	1988	269	Cigarettes	0	0	Cohort	b	40	999	18	Died	0

Table 1
Smoking and Lung cancer: Cigarette Smoking analyses
List of all the results (not all to be included in any one meta-analysis) - Current cigarette smokers versus never smokers

Study ID	NRR	REFID	Country	Study population	YRST	NCASES	Product Sm	Excl	Latent	Study design	Sex	LowAge	HighAge	YrsFU	Endpoint	Adj
NHIS	1	COLEMA2020	USA	National	1987	7420	Cigarettes	0	0	Cohort	b	18	84	28	Died	0
NHIS	2	COLEMA2020	USA	National	1987	7420	Cigarettes	0	0	Cohort	b	18	84	28	Died	11
NHIS	3	JHA2013	USA	National	1987	7420	Cigarettes	0	x	Cohort	f	25	999	9	Died	0
NHIS	4	JHA2013	USA	National	1987	7420	Cigarettes	0	x	Cohort	m	25	999	9	Died	0
NHIS	5	JHA2013	USA	National	1987	7420	Cigarettes	0	x	Cohort	f	25	79	9	Died	4
NHIS	6	JHA2013	USA	National	1987	7420	Cigarettes	0	x	Cohort	m	25	79	9	Died	4
NHS	1	KENFIE2010	USA	Medical workers	1980	1729	Cigarettes	0	0	Cohort	f	34	59	24	Died	1
NHS	2	KENFIE2010	USA	Medical workers	1980	1729	Cigarettes	0	0	Cohort	f	34	59	24	Died	13
NHS	3	BAIK2010	USA	Medical workers	1980	1729	Cigarettes	0	0	Cohort	f	38	63	24	Diagnosed	0
NIHAARP	1	FREEDM2016	USA	Regional	1995	17846	Cigarettes	x	x	Cohort	f	50	71	11	Diagnosed	0
NIHAARP	2	FREEDM2016	USA	Regional	1995	17846	Cigarettes	x	x	Cohort	f	50	71	11	Diagnosed	5
NIHAARP	3	FREEDM2016	USA	Regional	1995	17846	Cigarettes	x	x	Cohort	m	50	71	11	Diagnosed	0
NIHAARP	4	FREEDM2016	USA	Regional	1995	17846	Cigarettes	x	x	Cohort	m	50	71	11	Diagnosed	5
NIHAARP	5	LEE2017M	USA	Regional	1995	17846	Cigarettes	0	0	Cohort	b	50	71	16	Diagnosed	0
NLCS	1	HART2015	Netherlands	National	1986	3355	Cigarettes	0	0	Nested CC	b	55	69	17	Diagnosed	0
NLCS	4	NIEUWE2019	Netherlands	National	1986	3355	Cigarettes	0	0	Nested CC	m	55	69	20	Diagnosed	0
NLCS	5	NIEUWE2019	Netherlands	National	1986	3355	Cigarettes	0	0	Nested CC	f	55	69	20	Diagnosed	0
NLMS	1	CHRIST2018	USA	National	1985	3890	Cigarettes	x	0	Cohort	b	35	80	26	Died	0
NLMS	3	CHRIST2018	USA	National	1985	3890	Cigarettes	x	0	Cohort	b	35	80	26	Died	1
NLMS	4	CHRIST2018	USA	National	1985	3890	Cigarettes	x	0	Cohort	b	35	80	26	Died	5
NLST	1	DEMENT2020	USA	Construction workers	1998	352	Cigarettes	0	0	Cohort	m	*	*	18	Died	0
NLST	2	DEMENT2020	USA	Construction workers	1998	352	Cigarettes	0	0	Cohort	m	*	*	18	Died	2
NONMET	1	SILVER2012	USA	Non-metal miners	1947	198	Cigarettes	0	0	Nested CC	m	*	*	50	Died	0
NONMET	2	SILVER2012	USA	Non-metal miners	1947	198	Cigarettes	0	0	Nested CC	m	*	*	50	Died	7
NOWAC	1	HANSEN2021	Norway	National	1991	1507	Cigarettes	0	0	Cohort	f	31	70	24	Diagnosed	0
NOWAC	2	HANSEN2021	Norway	National	1991	1507	Cigarettes	0	0	Cohort	f	31	70	24	Diagnosed	1
NOWAC	3	HANSEN2021	Norway	National	1991	1507	Cigarettes	0	0	Cohort	f	31	70	24	Diagnosed	3
PLCO	1	TAMMEM2011A	USA	Regional	1993	1040	Cigarettes	0	0	Cohort	b	55	74	15	Died	0
PLCO	2	ABDELR2020A	USA	Regional	1993	1040	Cigarettes	0	0	Cohort	f	55	74	15	Died	6
QRESEAR	1	HIPPIS2015	UK	National	1998	32187	Cigarettes	0	0	Cohort	m	25	84	15	Diagnosed	0
QRESEAR	2	HIPPIS2015	UK	National	1998	32187	Cigarettes	0	0	Cohort	f	25	84	15	Diagnosed	0
QRESEAR	3	HIPPIS2015	UK	National	1998	32187	Cigarettes	0	0	Cohort	m	25	84	15	Diagnosed	6
QRESEAR	4	HIPPIS2015	UK	National	1998	32187	Cigarettes	0	0	Cohort	f	25	84	15	Diagnosed	6
SCCS	1	SANDER2018	USA	Regional	2002	1334	Cigarettes	0	0	Nested CC	m	40	79	14	Diagnosed	0
SCCS	2	SANDER2018	USA	Regional	2002	1334	Cigarettes	0	0	Nested CC	f	40	79	14	Diagnosed	0
SCCS	3	BLOT2011	USA	Regional	2002	1334	Cigarettes	0	0	Nested CC	b	40	79	7	Diagnosed	10
SHEETME	1	WELCH2015	Multiple	Sheet metal workers	1986	808	Cigarettes	0	0	Cohort	m	*	*	24	Died	0
THIN	1	HORSFA2014	UK	National	2000	1015	Cigarettes	0	0	Cohort	b	30	99	12	Diagnosed	0
THREEC	1	TVERDA2011	Norway	Regional	1974	858	Cigarettes	x	0	Cohort	m	20	49	33	Died	0
THREEC	3	TVERDA2011	Norway	Regional	1974	858	Cigarettes	0	0	Cohort	m	20	49	33	Died	0

Table 1
 Smoking and Lung cancer: Cigarette Smoking analyses
List of all the results (not all to be included in any one meta-analysis) - Current cigarette smokers versus never smokers

Study ID	NRR	REFID	Country	Study population	YRST	NCASES	Product Sm	Excl	Latent	Study design	Sex	LowAge	HighAge	YrsFU	Endpoint	Adj
THREEC	5	TVERDA2011	Norway	Regional	1974	858	Cigarettes	x	0	Cohort	m	20	49	33	Died	10
THREEC	7	HJELLV2013	Norway	Regional	1974	858	Cigarettes	0	x	Cohort	m	35	49	35	Died	0
THREEC	8	HJELLV2013	Norway	Regional	1974	858	Cigarettes	0	x	Cohort	f	35	49	35	Died	0
USA5	1	THUN2013	USA	National	1986	11420	Cigarettes	0	0	Cohort	m	45	999	24	Died	0
USA5	2	THUN2013	USA	National	1986	11420	Cigarettes	0	0	Cohort	f	45	999	24	Died	0
USA5	3	THUN2013	USA	National	1986	11420	Cigarettes	0	0	Cohort	m	45	999	24	Died	1
USA5	4	THUN2013	USA	National	1986	11420	Cigarettes	0	0	Cohort	f	45	999	24	Died	1
USA5	5	THUN2013	USA	National	1986	11420	Cigarettes	0	0	Cohort	m	45	999	24	Died	3
USA5	6	THUN2013	USA	National	1986	11420	Cigarettes	0	0	Cohort	f	45	999	24	Died	3
VETERAN	1	VAINSH2019	USA	Regional	1987	105	Cigarettes	0	0	Cohort	m	21	89	28	Diagnosed	0
VITAL	1	BRASKY2017	USA	Regional	2000	797	Cigarettes	0	0	Cohort	b	50	76	7	Diagnosed	0
VLAGT	1	TAGHIZ2016	Netherlands	Regional	1965	275	Cigarettes	0	0	Cohort	m	20	65	43	Died	0
VLAGT	2	TAGHIZ2016	Netherlands	Regional	1965	275	Cigarettes	0	0	Cohort	f	20	65	43	Died	0
VLAGT	3	TAGHIZ2016	Netherlands	Regional	1965	275	Cigarettes	0	0	Cohort	b	20	65	43	Died	4
VLAGT	4	TAGHIZ2016	Netherlands	Regional	1965	275	Cigarettes	0	0	Cohort	f	20	65	43	Died	3
WHI	1	WANG2015B	USA	National	1993	901	Cigarettes	0	0	Cohort	f	50	79	16	Diagnosed	0
WHI	2	WANG2015B	USA	National	1993	901	Cigarettes	0	0	Cohort	f	50	79	16	Diagnosed	1
WHI	3	WANG2015B	USA	National	1993	901	Cigarettes	0	0	Cohort	f	50	79	16	Diagnosed	15

Table 2
Smoking and Lung cancer: Cigarette Smoking analyses
List of all the risk estimates (not all to be included in any one meta-analysis) - Current cigarette smokers versus never smokers

Study ID	NRR	REFID	CA1	CA0	CO1	CO0	RR	RRL	RRU	Derived
ACE	1	BROWN2010B	27	11	9470	61713	16.00	7.94	32.23	From numbers
ACE	2	BROWN2010B	-	-	-	-	18.56	9.07	37.96	Using RREst
AEROBIC	1	SUI2010	100	35	6840	18088	7.56	5.15	11.09	From numbers
AGRICAN	1	TUAL2017	-	-	-	-	28.84	20.35	40.87	Given in the paper
AGRICAN	2	TUAL2017	-	-	-	-	16.53	9.44	28.95	Given in the paper
AHS	1	ANDREQ2017	262	51	8603	41026	24.50	18.17	33.04	From numbers
AHS	2	ANDREQ2017	-	-	-	-	23.03	17.34	30.59	Given in the paper
AMIANANT	1	SWIATK2017	61	13	2224	2645	5.58	3.07	10.13	From numbers
ARIC	1	PRIZME2014	196	6	27389	31636	37.73	16.75	85.00	From numbers
ARIC	2	PRIZME2014	120	24	31246	73110	11.70	7.55	18.13	From numbers
ARIC	3	PRIZME2014	-	-	-	-	41.41	18.36	93.42	Given in the paper
ARIC	4	PRIZME2014	-	-	-	-	13.13	8.46	20.41	Given in the paper
ATP	1	VINER2019	39	6	1808	4204	15.11	6.41	35.64	From numbers
ATP	2	VINER2019	82	13	2850	7701	17.04	9.51	30.55	From numbers
ATP	3	VINER2019	-	-	-	-	14.71	6.20	34.80	Given in the paper
ATP	4	VINER2019	-	-	-	-	22.10	12.30	39.70	Given in the paper
ATP	5	VINER2019	-	-	-	-	11.33	4.70	27.30	Given in the paper
ATP	6	VINER2019	-	-	-	-	23.51	12.70	43.60	Given in the paper
ATP	7	VINER2019	30	6	1808	4204	11.63	4.85	27.88	From numbers
ATP	8	VINER2019	70	11	2850	7701	17.20	9.12	32.42	From numbers
ATP	9	VINER2019	-	-	-	-	9.33	3.82	22.84	Given in the paper
ATP	10	VINER2019	-	-	-	-	23.40	12.26	44.63	Given in the paper
BIOBANK	1	WONG2020	244	127	19464	134209	13.25	10.70	16.41	From numbers
BIOBANK	2	WONG2020	329	78	22934	98319	18.08	14.13	23.14	From numbers
BWHS	1	NOMURA2018	170	45	118489	537071	17.12	12.33	23.78	From numbers
BWHS	2	NOMURA2018	-	-	-	-	13.13	9.53	18.09	Using RREst
BWHS	3	NOMURA2018	-	-	-	-	11.78	8.55	16.24	Using RREst
CHANCES	1	ORDONE2016	6333	923	128615	321984	17.18	16.04	18.40	From numbers
CHANCES	2	ORDONE2016	-	-	-	-	13.10	9.90	17.30	Given in the paper
CHANCES	3	ORDONE2016	6165	863	140672	346559	17.60	16.39	18.89	From numbers
CHANCES	4	ORDONE2016	-	-	-	-	11.50	8.21	16.10	Given in the paper
COAL	1	GRABER2014	-	-	-	-	9.20	5.30	16.00	Given in the paper
CPSI	1	THUN2013	859	73	72309	79631	12.96	10.21	16.45	From numbers
CPSI	2	THUN2013	79	179	51060	272097	2.35	1.81	3.06	From numbers
CPSI	3	THUN2013	-	-	-	-	12.49	9.80	15.92	Given in the paper
CPSI	4	THUN2013	-	-	-	-	2.74	2.07	3.62	Given in the paper
CPSI	5	THUN2013	-	-	-	-	12.22	9.59	15.58	Given in the paper
CPSI	6	THUN2013	-	-	-	-	2.73	2.07	3.61	Given in the paper
CPSII	1	THUN2013	1887	125	68994	98647	21.58	18.01	25.86	From numbers
CPSII	2	THUN2013	1084	334	81521	277171	11.03	9.76	12.47	From numbers

Table 2
Smoking and Lung cancer: Cigarette Smoking analyses
List of all the risk estimates (not all to be included in any one meta-analysis) - Current cigarette smokers versus never smokers

Study ID	NRR	REFID	CA1	CA0	CO1	CO0	RR	RRL	RRU	Derived
CPSII	3	THUN2013	-	-	-	-	25.30	21.10	30.34	Given in the paper
CPSII	4	THUN2013	-	-	-	-	12.62	11.13	14.31	Given in the paper
CPSII	5	THUN2013	-	-	-	-	23.81	19.85	28.57	Given in the paper
CPSII	6	THUN2013	-	-	-	-	12.65	11.15	14.34	Given in the paper
EPIC	1	MCCORM2010	387	25	17882	37103	32.12	21.44	48.11	Other calculations
EPIC	3	MCCORM2010	-	-	-	-	32.00	21.38	47.90	Other calculations
EPIC	5	AGUDO2012	-	-	-	-	23.30	16.40	33.20	Given in the paper
EPIC	6	AGUDO2012	-	-	-	-	7.53	5.87	9.66	Given in the paper
ESTHER	1	YU2020F	70	17	239	704	12.13	7.00	21.02	From numbers
FRAMING	1	TINDLE2018	139	25	4182	3501	4.65	3.05	7.11	From numbers
FRAMING	2	TINDLE2018	-	-	-	-	7.55	4.94	11.55	Given in the paper
HBC	1	ERIKSS2010	-	-	-	-	4.20	1.60	11.10	Given in the paper
HPFS	1	ALDELA2011	77	19	39	286	29.72	16.26	54.33	From numbers
HPFS	2	ALDELA2011	-	-	-	-	33.48	17.19	65.18	Using RREst
HPFS	3	ALDELA2011	-	-	-	-	12.56	6.02	26.22	Using RREst
JP8	1	SAITO2017	2113	663	85264	31960	1.19	1.10	1.30	From numbers
JP8	2	SAITO2017	-	-	-	-	6.14	3.82	9.84	Given in the paper
JP8	3	SAITO2017	-	-	-	-	4.13	2.94	5.79	Given in the paper
JP8	4	SAITO2017	-	-	-	-	4.24	2.94	6.10	Given in the paper
JP8	5	SAITO2017	281	844	13477	149150	3.68	3.22	4.21	From numbers
JP8	6	SAITO2017	-	-	-	-	3.09	2.46	3.87	Given in the paper
JP8	7	SAITO2017	-	-	-	-	2.40	1.93	2.99	Given in the paper
JP8	8	SAITO2017	-	-	-	-	2.62	2.03	3.38	Given in the paper
JPHC	1	NARITA2018	952	87	21800	10138	5.09	4.09	6.33	From numbers
JPHC	2	NARITA2018	61	375	2600	42155	2.64	2.02	3.45	From numbers
JPHC	3	ZHA2019	504	51	24497	11290	4.55	3.42	6.07	From numbers
JPHC	4	ZHA2019	-	-	-	-	4.70	3.43	6.44	Given in the paper
JPHC	5	ZHA2019	35	155	3172	47649	3.39	2.35	4.89	From numbers
JPHC	6	ZHA2019	-	-	-	-	3.28	2.12	5.05	Given in the paper
KAISER	1	TRAN2013	873	152	33718	62258	10.60	8.93	12.59	From numbers
KAISER	2	TRAN2013	-	-	-	-	13.20	11.10	15.70	Using RREst
KRIS	1	EVERAT2014A	321	22	54692	45231	12.07	7.84	18.58	From numbers
KRIS	2	EVERAT2014A	-	-	-	-	12.60	8.18	19.42	Given in the paper
KRIS	3	EVERAT2014A	-	-	-	-	10.47	6.74	16.25	Given in the paper
LSS	1	CAHOON2017	802	40	284498	65789	4.64	3.38	6.37	From numbers
LSS	2	CAHOON2017	183	392	97082	693805	3.34	2.80	3.98	From numbers
MWOMEN	1	PIRIE2013	5633	698	232461	619774	21.52	19.89	23.27	From numbers
MWOMEN	2	PIRIE2013	-	-	-	-	21.40	19.70	23.20	Given in the paper
MWOMEN	3	PIRIE2013	-	-	-	-	21.20	19.50	23.10	Given in the paper
NHANES	1	BITTON2017	144	17	2374	4853	17.32	10.50	28.56	From numbers

Table 2
Smoking and Lung cancer: Cigarette Smoking analyses
List of all the risk estimates (not all to be included in any one meta-analysis) - Current cigarette smokers versus never smokers

Study ID	NRR	REFID	CA1	CA0	CO1	CO0	RR	RRL	RRU	Derived
NHIS	1	COLEMA2020	5107	761	151742	341578	15.11	14.00	16.30	Other calculations
NHIS	2	COLEMA2020	-	-	-	-	15.11	13.70	16.66	Given in the paper
NHIS	3	JHA2013	289	83	23839	67524	9.86	7.73	12.58	From numbers
NHIS	4	JHA2013	362	52	23348	39289	11.71	8.76	15.66	From numbers
NHIS	5	JHA2013	-	-	-	-	17.80	11.40	27.80	Given in the paper
NHIS	6	JHA2013	-	-	-	-	14.60	9.10	23.40	Given in the paper
NHS	1	KENFIE2010	-	-	-	-	17.83	14.63	21.70	Given in the paper
NHS	2	KENFIE2010	-	-	-	-	23.30	19.00	28.80	Given in the paper
NHS	3	BAIK2010	809	138	15004	48227	18.84	15.75	22.55	From numbers
NIHAARP	1	FREEDM2016	1893	281	31944	82032	17.30	15.27	19.60	From numbers
NIHAARP	2	FREEDM2016	-	-	-	-	19.50	17.20	22.20	Given in the paper
NIHAARP	3	FREEDM2016	2435	175	35901	68748	26.64	22.87	31.05	From numbers
NIHAARP	4	FREEDM2016	-	-	-	-	29.40	25.20	34.30	Given in the paper
NIHAARP	5	LEE2017M	7043	1196	59353	173887	17.25	16.24	18.33	From numbers
NLCS	1	HART2015	2138	228	1334	1694	11.91	10.21	13.89	From numbers
NLCS	4	NIEUWE2019	1502	95	9069	4345	7.57	6.18	9.29	From numbers
NLCS	5	NIEUWE2019	275	103	6540	20158	8.23	6.57	10.30	From numbers
NLMS	1	CHRIST2018	2110	542	66665	203071	11.86	10.79	13.03	From numbers
NLMS	3	CHRIST2018	-	-	-	-	11.64	10.59	12.79	Given in the paper
NLMS	4	CHRIST2018	-	-	-	-	11.82	10.73	13.03	Given in the paper
NLST	1	DEMENT2020	153	7	3472	5813	36.59	17.18	77.97	From numbers
NLST	2	DEMENT2020	-	-	-	-	24.32	10.98	53.85	Given in the paper
NONMET	1	SILVER2012	103	14	191	178	6.86	3.78	12.42	From numbers
NONMET	2	SILVER2012	-	-	-	-	7.97	4.17	15.27	Using RREst
NOWAC	1	HANSEN2021	1082	96	45908	43713	10.73	8.71	13.22	From numbers
NOWAC	2	HANSEN2021	-	-	-	-	13.32	10.83	16.38	Using RREst
NOWAC	3	HANSEN2021	-	-	-	-	11.89	9.66	14.64	Using RREst
PLCO	1	TAMMEM2011A	448	76	7586	32688	25.40	19.94	32.35	From numbers
PLCO	2	ABDELR2020A	-	-	-	-	31.97	25.16	40.63	Given in the paper
QRESEAR	1	HIPPIS2015	12792	2938	658633	1081822	7.15	6.87	7.44	From numbers
QRESEAR	2	HIPPIS2015	8452	3402	522711	1433446	6.81	6.55	7.09	From numbers
QRESEAR	3	HIPPIS2015	-	-	-	-	7.35	4.54	11.90	Using RREst
QRESEAR	4	HIPPIS2015	-	-	-	-	7.13	4.47	11.37	Using RREst
SCCS	1	SANDER2018	505	22	1209	686	13.02	8.41	20.16	From numbers
SCCS	2	SANDER2018	469	54	667	1203	15.66	11.64	21.08	From numbers
SCCS	3	BLOT2011	-	-	-	-	10.10	6.61	15.45	Using RREst
SHEETME	1	WELCH2015	410	53	4400	4503	7.92	5.97	10.51	From numbers
THIN	1	HORSFA2014	372	112	134000	437000	10.83	8.77	13.38	From numbers
THREEC	1	TVERDA2011	407	9	216925	156274	32.58	16.83	63.06	From numbers
THREEC	3	TVERDA2011	431	9	227984	156274	32.83	16.96	63.52	From numbers

Table 2
 Smoking and Lung cancer: Cigarette Smoking analyses
List of all the risk estimates (not all to be included in any one meta-analysis) - Current cigarette smokers versus never smokers

Study ID	NRR	REFID	CA1	CA0	CO1	CO0	RR	RRL	RRU	Derived
THREEC	5	TVERDA2011	-	-	-	-	16.78	10.31	27.33	Given in the paper
THREEC	7	HJELLV2013	521	6	16754	8524	44.18	19.77	98.75	From numbers
THREEC	8	HJELLV2013	273	14	12388	15703	24.72	14.45	42.27	From numbers
USA5	1	THUN2013	1455	357	39218	152656	15.86	14.14	17.80	From numbers
USA5	2	THUN2013	1485	513	51900	263782	14.71	13.31	16.26	From numbers
USA5	3	THUN2013	-	-	-	-	27.32	24.30	30.70	Given in the paper
USA5	4	THUN2013	-	-	-	-	26.18	23.65	28.98	Given in the paper
USA5	5	THUN2013	-	-	-	-	24.97	22.20	28.09	Given in the paper
USA5	6	THUN2013	-	-	-	-	25.66	23.17	28.40	Given in the paper
VETERAN	1	VAINSH2019	54	4	1443	1798	16.82	6.11	46.34	From numbers
VITAL	1	BRASKY2017	251	60	6169	36381	24.67	18.64	32.65	From numbers
VLAGT	1	TAGHIZ2016	164	0	2420	567	77.14	4.81	1236.55	From numbers
VLAGT	2	TAGHIZ2016	31	12	1222	2115	4.47	2.30	8.67	From numbers
VLAGT	3	TAGHIZ2016	-	-	-	-	12.33	6.42	23.69	Using RREst
VLAGT	4	TAGHIZ2016	-	-	-	-	9.27	4.45	19.28	Using RREst
WHI	1	WANG2015B	218	152	4729	39771	12.06	9.83	14.80	From numbers
WHI	2	WANG2015B	-	-	-	-	15.26	12.39	18.79	Given in the paper
WHI	3	WANG2015B	-	-	-	-	13.44	10.80	16.74	Given in the paper

Table 3
Smoking and Lung cancer: Cigarette Smoking analyses
List of the selected results - Initial analyses. Current cigarette smokers versus never smokers, no overlapping results for any study

Study ID	NRR	REFID	Country	Study population	YRST	NCASES	Product Sm	Excl	Latent	Study design	Sex	LowAge	HighAge	YrsFU	Endpoint	Adj
ACE	2	BROWN2010B	USA	Regional	1995	111	Cigarettes	0	0	Cohort	b	18	999	10	Died	8
AEROBIC	1	SUI2010	USA	Regional	1974	232	Cigarettes	0	0	Cohort	m	20	84	29	Died	0
AGRICAN	1	TUAL2017	France	Regional	2005	664	Cigarettes	0	0	Cohort	m	18	999	6	Diagnosed	1
AGRICAN	2	TUAL2017	France	Regional	2005	664	Cigarettes	0	0	Cohort	f	18	999	6	Diagnosed	1
AHS	2	ANDREO2017	USA	Pesticide workers	1993	789	Cigarettes	x	0	Cohort	b	*	*	18	Diagnosed	8
AMIAANT	1	SWIATK2017	Poland	Asbestos workers	2000	110	Cigarettes	0	0	Cohort	b	*	*	14	Diagnosed	0
ARIC	3	PRIZME2014	USA	Regional	1987	470	Cigarettes	0	0	Cohort	m	45	64	19	Diagnosed	3
ARIC	4	PRIZME2014	USA	Regional	1987	470	Cigarettes	0	0	Cohort	f	45	64	19	Diagnosed	3
ATP	9	VINER2019	Canada	Regional	2001	210	Cigarettes	0	x	Cohort	m	35	69	16	Diagnosed	7
ATP	10	VINER2019	Canada	Regional	2001	210	Cigarettes	0	x	Cohort	f	35	69	16	Diagnosed	7
BIOBANK	1	WONG2020	UK	National	2006	1493	Cigarettes	0	0	Cohort	f	40	73	10	Diagnosed	0
BIOBANK	2	WONG2020	UK	National	2006	1493	Cigarettes	0	0	Cohort	m	40	73	10	Diagnosed	0
BWHS	3	NOMURA2018	USA	National	1995	306	Cigarettes	0	0	Cohort	f	21	69	18	Diagnosed	7
CHANCES	2	ORDONE2016	Multiple	International	1982	14041	Cigarettes	0	0	Cohort	b	46	74	29	Diagnosed	7
COAL	1	GRABER2014	USA	Coal miners	1969	568	Cigarettes	0	0	Cohort	m	*	*	38	Died	7
CPSI	5	THUN2013	USA	National	1959	1293	Cigarettes	x	0	Cohort	m	49	999	6	Died	3
CPSI	6	THUN2013	USA	National	1959	1293	Cigarettes	x	0	Cohort	f	49	999	6	Died	3
CPSII	5	THUN2013	USA	National	1982	4957	Cigarettes	x	0	Cohort	m	49	999	6	Died	3
CPSII	6	THUN2013	USA	National	1982	4957	Cigarettes	x	0	Cohort	f	49	999	6	Died	3
EPIC	3	MCCORM2010	Multiple	International	1991	2995	Cigarettes	x	0	Cohort	m	35	70	14	Diagnosed	5
EPIC	6	AGUDO2012	Multiple	International	1991	2995	Cigarettes	0	0	Cohort	f	30	70	8	Diagnosed	7
ESTHER	1	YU2020F	Germany	Regional	2000	143	Cigarettes	0	0	Nested CC	b	50	75	17	Diagnosed	0
FRAMING	2	TINDLE2018	USA	Regional	1954	284	Cigarettes	0	0	Cohort	b	*	*	59	Diagnosed	1
HBC	1	ERIKSS2010	Finland	Regional	2001	121	Cigarettes	0	0	Cohort	b	55	65	5	Diagnosed	1
HPFS	3	ALDELA2011	USA	Medical workers	1986	210	Cigarettes	0	0	Nested CC	m	40	75	14	Diagnosed	4
JP8	4	SAITO2017	Japan	National	1984	4478	Cigarettes	x	x	Cohort	m	35	999	25	Diagnosed	5
JP8	8	SAITO2017	Japan	National	1984	4478	Cigarettes	x	x	Cohort	f	35	999	25	Diagnosed	5
JPHC	1	NARITA2018	Japan	National	1990	1663	Cigarettes	x	0	Cohort	m	40	69	21	Diagnosed	0
JPHC	2	NARITA2018	Japan	National	1990	1663	Cigarettes	x	0	Cohort	f	40	69	21	Diagnosed	0
KAISER	2	TRAN2013	USA	Regional	1978	1415	Cigarettes	0	0	Cohort	b	*	*	30	Diagnosed	6
KRIS	3	EVERAT2014A	Lithuania	Regional	1972	343	Cigarettes	0	x	Cohort	m	40	59	36	Diagnosed	4
LSS	1	CAHOON2017	Japan	Atomic bomb survivors	1950	1597	Cigarettes	x	0	Cohort	m	5	999	59	Diagnosed	0
LSS	2	CAHOON2017	Japan	Atomic bomb survivors	1950	1597	Cigarettes	x	0	Cohort	f	5	999	59	Diagnosed	0
MWOMEN	3	PIRIE2013	UK	National	1996	6331	Cigarettes	x	x	Cohort	f	50	69	15	Died	10
NHANES	1	BITTON2017	USA	National	1988	269	Cigarettes	0	0	Cohort	b	40	999	18	Died	0
NHIS	5	JHA2013	USA	National	1987	7420	Cigarettes	0	x	Cohort	f	25	79	9	Died	4
NHIS	6	JHA2013	USA	National	1987	7420	Cigarettes	0	x	Cohort	m	25	79	9	Died	4
NHS	2	KENFIE2010	USA	Medical workers	1980	1729	Cigarettes	0	0	Cohort	f	34	59	24	Died	13
NIHAARP	2	FREEDM2016	USA	Regional	1995	17846	Cigarettes	x	x	Cohort	f	50	71	11	Diagnosed	5
NIHAARP	4	FREEDM2016	USA	Regional	1995	17846	Cigarettes	x	x	Cohort	m	50	71	11	Diagnosed	5

Table 3
Smoking and Lung cancer: Cigarette Smoking analyses
List of the selected results - Initial analyses. Current cigarette smokers versus never smokers, no overlapping results for any study

Study ID	NRR	REFID	Country	Study population	YRST	NCASES	Product Sm	Excl	Latent	Study design	Sex	LowAge	HighAge	YrsFU	Endpoint	Adj
NLCS	4	NIEUWE2019	Netherlands	National	1986	3355	Cigarettes	0	0	Nested CC	m	55	69	20	Diagnosed	0
NLCS	5	NIEUWE2019	Netherlands	National	1986	3355	Cigarettes	0	0	Nested CC	f	55	69	20	Diagnosed	0
NLMS	4	CHRIST2018	USA	National	1985	3890	Cigarettes	x	0	Cohort	b	35	80	26	Died	5
NLST	2	DEMENT2020	USA	Construction workers	1998	352	Cigarettes	0	0	Cohort	m	*	*	18	Died	2
NONMET	2	SILVER2012	USA	Non-metal miners	1947	198	Cigarettes	0	0	Nested CC	m	*	*	50	Died	7
NOWAC	3	HANSEN2021	Norway	National	1991	1507	Cigarettes	0	0	Cohort	f	31	70	24	Diagnosed	3
PLCO	2	ABDEL2020A	USA	Regional	1993	1040	Cigarettes	0	0	Cohort	f	55	74	15	Died	6
QRESEAR	3	HIPPIS2015	UK	National	1998	32187	Cigarettes	0	0	Cohort	m	25	84	15	Diagnosed	6
QRESEAR	4	HIPPIS2015	UK	National	1998	32187	Cigarettes	0	0	Cohort	f	25	84	15	Diagnosed	6
SCCS	1	SANDER2018	USA	Regional	2002	1334	Cigarettes	0	0	Nested CC	m	40	79	14	Diagnosed	0
SCCS	2	SANDER2018	USA	Regional	2002	1334	Cigarettes	0	0	Nested CC	f	40	79	14	Diagnosed	0
SHEETME	1	WELCH2015	Multiple	Sheet metal workers	1986	808	Cigarettes	0	0	Cohort	m	*	*	24	Died	0
THIN	1	HORSFA2014	UK	National	2000	1015	Cigarettes	0	0	Cohort	b	30	99	12	Diagnosed	0
THREEC	5	TVERDA2011	Norway	Regional	1974	858	Cigarettes	x	0	Cohort	m	20	49	33	Died	10
THREEC	8	HJELLV2013	Norway	Regional	1974	858	Cigarettes	0	x	Cohort	f	35	49	35	Died	0
USA5	5	THUN2013	USA	National	1986	11420	Cigarettes	0	0	Cohort	m	45	999	24	Died	3
USA5	6	THUN2013	USA	National	1986	11420	Cigarettes	0	0	Cohort	f	45	999	24	Died	3
VETERAN	1	VAINSH2019	USA	Regional	1987	105	Cigarettes	0	0	Cohort	m	21	89	28	Diagnosed	0
VITAL	1	BRASKY2017	USA	Regional	2000	797	Cigarettes	0	0	Cohort	b	50	76	7	Diagnosed	0
VLAGT	1	TAGHIZ2016	Netherlands	Regional	1965	275	Cigarettes	0	0	Cohort	m	20	65	43	Died	0
VLAGT	4	TAGHIZ2016	Netherlands	Regional	1965	275	Cigarettes	0	0	Cohort	f	20	65	43	Died	3
WHI	3	WANG2015B	USA	National	1993	901	Cigarettes	0	0	Cohort	f	50	79	16	Diagnosed	15

Table 4
Smoking and Lung cancer: Cigarette Smoking analyses
Initial analysis by sex

Combined

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*ACE	2	-	-	-	-	18.56 (9.07- 37.96)	
*AHS	2	-	-	-	-	23.03 (17.34- 30.59)	
*AMIAANT	1	61	2224	13	2645	5.58 (3.07- 10.13)	
*CHANCES	2	-	-	-	-	13.10 (9.90- 17.30)	
ESTHER	1	70	239	17	704	12.13 (7.00- 21.02)	
*FRAMING	2	-	-	-	-	7.55 (4.94- 11.55)	
*HBC	1	-	-	-	-	4.20 (1.60- 11.10)	
*KAISER	2	-	-	-	-	13.20 (11.10- 15.70)	
*NHANES	1	144	2374	17	4853	17.32 (10.50- 28.56)	
*NLMS	4	-	-	-	-	11.82 (10.73- 13.03)	
*THIN	1	372	134000	112	437000	10.83 (8.77- 13.38)	
*VITAL	1	251	6169	60	36381	24.67 (18.64- 32.65)	
Partial Totals		898	145006	219	481583		

*prospective study

Male

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*AEROBIC	1	100	6840	35	18088	7.56 (5.15- 11.09)	
*AGRICAN	1	-	-	-	-	28.84 (20.35- 40.87)	
*ARIC	3	-	-	-	-	41.41 (18.36- 93.42)	
*ATP	9	-	-	-	-	9.33 (3.82- 22.84)	
*BIOBANK	2	329	22934	78	98319	18.08 (14.13- 23.14)	
*COAL	1	-	-	-	-	9.20 (5.30- 16.00)	
*CPSI	5	-	-	-	-	12.22 (9.59- 15.58)	
*CPSII	5	-	-	-	-	23.81 (19.85- 28.57)	
*EPIC	3	-	-	-	-	32.00 (21.38- 47.90)	
*HPFS	3	-	-	-	-	12.56 (6.02- 26.22)	
*JP8	4	-	-	-	-	4.24 (2.94- 6.10)	
*JPHC	1	952	21800	87	10138	5.09 (4.09- 6.33)	
*KRIS	3	-	-	-	-	10.47 (6.74- 16.25)	
*LSS	1	802	284498	40	65789	4.64 (3.38- 6.37)	
*NHIS	6	-	-	-	-	14.60 (9.10- 23.40)	
*NIHAARP	4	-	-	-	-	29.40 (25.20- 34.30)	
*NLCS	4	1502	9069	95	4345	7.57 (6.18- 9.29)	
*NLST	2	-	-	-	-	24.32 (10.98- 53.85)	
NONMET	2	-	-	-	-	7.97 (4.17- 15.27)	
*QRESEAR	3	-	-	-	-	7.35 (4.54- 11.90)	
SCCS	1	505	1209	22	686	13.02 (8.41- 20.16)	
*SHEETME	1	410	4400	53	4503	7.92 (5.97- 10.51)	
*THREEC	5	-	-	-	-	16.78 (10.31- 27.33)	
*USA5	5	-	-	-	-	24.97 (22.20- 28.09)	
*VETERAN	1	54	1443	4	1798	16.82 (6.11- 46.34)	
*VLAGT	1	164	2420	0	567	77.14~(4.81-1236.55)	
Partial Totals		4818	354613	414	204233		

*prospective study

Female

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*AGRICAN	2	-	-	-	-	16.53 (9.44- 28.95)	
*ARIC	4	-	-	-	-	13.13 (8.46- 20.41)	
*ATP	10	-	-	-	-	23.40 (12.26- 44.63)	
*BIOBANK	1	244	19464	127	134209	13.25 (10.70- 16.41)	
*BWHS	3	-	-	-	-	11.78 (8.55- 16.24)	
*CPSI	6	-	-	-	-	2.73 (2.07- 3.61)	
*CPSII	6	-	-	-	-	12.65 (11.15- 14.34)	
*EPIC	6	-	-	-	-	7.53 (5.87- 9.66)	
*JP8	8	-	-	-	-	2.62 (2.03- 3.38)	
*JPHC	2	61	2600	375	42155	2.64 (2.02- 3.45)	
*LSS	2	183	97082	392	693805	3.34 (2.80- 3.98)	
*MWOMEN	3	-	-	-	-	21.20 (19.50- 23.10)	
*NHIS	5	-	-	-	-	17.80 (11.40- 27.80)	
*NHS	2	-	-	-	-	23.30 (19.00- 28.80)	
*NIHAARP	2	-	-	-	-	19.50 (17.20- 22.20)	
*NLCS	5	275	6540	103	20158	8.23 (6.57- 10.30)	
*NOWAC	3	-	-	-	-	11.89 (9.66- 14.64)	
*PLCO	2	-	-	-	-	31.97 (25.16- 40.63)	
*QRESEAR	4	-	-	-	-	7.13 (4.47- 11.37)	
SCCS	2	469	667	54	1203	15.66 (11.64- 21.08)	
*THREEC	8	273	12388	14	15703	24.72 (14.45- 42.27)	
*USA5	6	-	-	-	-	25.66 (23.17- 28.40)	
*VLAGT	4	-	-	-	-	9.27 (4.45- 19.28)	

Table 4
Smoking and Lung cancer: Cigarette Smoking analyses
Initial analysis by sex

Female

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*WHI	3	-	-	-	-	13.44	(10.80- 16.74)
Partial Totals		1505	138741	1065	907233		

*prospective study

	RR Sex			Total
	1	2	3	
	Combined	Male	Female	

RR Data

N	12	26	24	62
NS	12	26	24	62
Wt	839.01	1192.15	2398.42	4429.58
Het Chi	63.57	497.05	1096.69	1674.66
Het df	11	25	23	61
Het P	***	***	***	***
Fixed RR	12.80	15.45	14.31	14.30
RRl	11.97	14.60	13.75	13.89
RRu	13.70	16.35	14.89	14.73
P	+++	+++	+++	+++
Random RR	12.93	12.95	11.32	12.14
RRl	10.55	9.82	8.46	10.30
RRu	15.84	17.08	15.15	14.30
P	+++	+++	+++	+++
Asymm P	N.S.	N.S.	(*)	*
Between Chi		17.35	7.66	17.35
Between df		1	1	2
Between P		+++	++	***
Btwn (F) P		N.S.	N.S.	N.S.
Btwn (R) P		N.S.	N.S.	N.S.

Table 5
Smoking and Lung cancer: Cigarette Smoking analyses
Initial analysis by region

N America

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*ACE	2	-	-	-	-	18.56 (9.07- 37.96)	
*AEROBIC	1	100	6840	35	18088	7.56 (5.15- 11.09)	
*AHS	2	-	-	-	-	23.03 (17.34- 30.59)	
*ARIC	3	-	-	-	-	41.41 (18.36- 93.42)	
*ARIC	4	-	-	-	-	13.13 (8.46- 20.41)	
Subtotal ARIC						17.03 (11.56- 25.09)	
*ATP	9	-	-	-	-	9.33 (3.82- 22.84)	
*ATP	10	-	-	-	-	23.40 (12.26- 44.63)	
Subtotal ATP						17.07 (10.11- 28.82)	
*BWHS	3	-	-	-	-	11.78 (8.55- 16.24)	
*COAL	1	-	-	-	-	9.20 (5.30- 16.00)	
*CPSI	5	-	-	-	-	12.22 (9.59- 15.58)	
*CPSI	6	-	-	-	-	2.73 (2.07- 3.61)	
Subtotal CPSI						6.39 (5.33- 7.68)	
*CPSII	5	-	-	-	-	23.81 (19.85- 28.57)	
*CPSII	6	-	-	-	-	12.65 (11.15- 14.34)	
Subtotal CPSII						15.52 (13.99- 17.21)	
*FRAMING	2	-	-	-	-	7.55 (4.94- 11.55)	
*HFPS	3	-	-	-	-	12.56 (6.02- 26.22)	
*KAISER	2	-	-	-	-	13.20 (11.10- 15.70)	
*NHANES	1	144	2374	17	4853	17.32 (10.50- 28.56)	
*NHIS	6	-	-	-	-	14.60 (9.10- 23.40)	
*NHIS	5	-	-	-	-	17.80 (11.40- 27.80)	
Subtotal NHIS						16.21 (11.72- 22.42)	
*NHS	2	-	-	-	-	23.30 (19.00- 28.80)	
*NIHAARP	4	-	-	-	-	29.40 (25.20- 34.30)	
*NIHAARP	2	-	-	-	-	19.50 (17.20- 22.20)	
Subtotal NIHAARP						23.04 (20.89- 25.42)	
*NLMS	4	-	-	-	-	11.82 (10.73- 13.03)	
*NLST	2	-	-	-	-	24.32 (10.98- 53.85)	
NONMET	2	-	-	-	-	7.97 (4.17- 15.27)	
*PLCO	2	-	-	-	-	31.97 (25.16- 40.63)	
SCCS	1	505	1209	22	686	13.02 (8.41- 20.16)	
SCCS	2	469	667	54	1203	15.66 (11.64- 21.08)	
Subtotal SCCS						14.78 (11.56- 18.89)	
*SHEETME	1	410	4400	53	4503	7.92 (5.97- 10.51)	
*USA5	5	-	-	-	-	24.97 (22.20- 28.09)	
*USA5	6	-	-	-	-	25.66 (23.17- 28.40)	
Subtotal USA5						25.36 (23.48- 27.39)	
*VETERAN	1	54	1443	4	1798	16.82 (6.11- 46.34)	
*VITAL	1	251	6169	60	36381	24.67 (18.64- 32.65)	
*WHI	3	-	-	-	-	13.44 (10.80- 16.74)	
Partial Totals		1933	23102	245	67512		

*prospective study

Europe

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*AGRICAN	1	-	-	-	-	28.84 (20.35- 40.87)	
*AGRICAN	2	-	-	-	-	16.53 (9.44- 28.95)	
Subtotal AGRICAN						24.69 (18.36- 33.20)	
*AMIAANT	1	61	2224	13	2645	5.58 (3.07- 10.13)	
*BIOBANK	2	329	22934	78	98319	18.08 (14.13- 23.14)	
*BIOBANK	1	244	19464	127	134209	13.25 (10.70- 16.41)	
Subtotal BIOBANK						15.14 (12.88- 17.80)	
*EPIC	3	-	-	-	-	32.00 (21.38- 47.90)	
*EPIC	6	-	-	-	-	7.53 (5.87- 9.66)	
Subtotal EPIC						11.23 (9.08- 13.88)	
ESTHER	1	70	239	17	704	12.13 (7.00- 21.02)	
*HBC	1	-	-	-	-	4.20 (1.60- 11.10)	
*KRIS	3	-	-	-	-	10.47 (6.74- 16.25)	
*MWOMEN	3	-	-	-	-	21.20 (19.50- 23.10)	
*NLCS	4	1502	9069	95	4345	7.57 (6.18- 9.29)	
*NLCS	5	275	6540	103	20158	8.23 (6.57- 10.30)	
Subtotal NLCS						7.86 (6.76- 9.15)	
*NOWAC	3	-	-	-	-	11.89 (9.66- 14.64)	
*QRESEAR	3	-	-	-	-	7.35 (4.54- 11.90)	
*QRESEAR	4	-	-	-	-	7.13 (4.47- 11.37)	
Subtotal QRESEAR						7.24 (5.17- 10.12)	
*THIN	1	372	134000	112	437000	10.83 (8.77- 13.38)	
*THREEC	5	-	-	-	-	16.78 (10.31- 27.33)	
*THREEC	8	273	12388	14	15703	24.72 (14.45- 42.27)	
Subtotal THREEC						19.99 (13.94- 28.68)	

Table 5
Smoking and Lung cancer: Cigarette Smoking analyses
Initial analysis by region

Europe

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*VLAGT	1	164	2420	0	567	77.14~	(4.81-1236.55)
*VLAGT	4	-	-	-	-	9.27	(4.45- 19.28)
Subtotal VLAGT						10.64	(5.24- 21.62)
Partial Totals		3290	209278	559	713650		

*prospective study

Japan

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*JP8	4	-	-	-	-	4.24	(2.94- 6.10)
*JP8	8	-	-	-	-	2.62	(2.03- 3.38)
Subtotal JP8						3.07	(2.49- 3.78)
*JPHC	1	952	21800	87	10138	5.09	(4.09- 6.33)
*JPHC	2	61	2600	375	42155	2.64	(2.02- 3.45)
Subtotal JPHC						3.91	(3.30- 4.64)
*LSS	1	802	284498	40	65789	4.64	(3.38- 6.37)
*LSS	2	183	97082	392	693805	3.34	(2.80- 3.98)
Subtotal LSS						3.60	(3.09- 4.20)
Partial Totals		1998	405980	894	811887		

*prospective study

Multi

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*CHANCES	2	-	-	-	-	13.10	(9.90- 17.30)
Partial Totals		0	0	0	0		

*prospective study

	Region				Total
	1 N America	2 Europe	3 Japan	4 Multi	

RR Data

N	34	21	6	1	62
NS	26	14	3	1	44
Wt	2720.98	1274.00	385.28	49.32	4429.58
Het Chi	563.74	253.31	24.74	0.00	1674.66
Het df	33	20	5	0	61
Het P	***	***	***	N.S.	***
Fixed RR	17.16	14.78	3.57	13.10	14.30
RRl	16.53	13.99	3.24	9.91	13.89
RRu	17.82	15.62	3.95	17.32	14.73
P	+++	+++	+++	+++	+++
Random RR	15.15	12.30	3.61	13.10	12.14
RRl	12.77	9.77	2.87	9.91	10.30
RRu	17.96	15.49	4.55	17.32	14.30
P	+++	+++	+++	+++	+++
Asymm P	N.S.	(*)	N.S.		*
Between Chi		19.32	830.63	3.54	832.88
Between df		1	1	1	3
Between P		---	---	(-)	***
Btwn (F) P		N.S.	---	N.S.	***
Btwn (R) P		N.S.	---	N.S.	***

Table 6
Smoking and Lung cancer: Cigarette Smoking analyses
Initial analysis by study population

International

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*CHANCES	2	-	-	-	-	13.10	(9.90- 17.30)
*EPIC	3	-	-	-	-	32.00	(21.38- 47.90)
*EPIC	6	-	-	-	-	7.53	(5.87- 9.66)
Subtotal EPIC						11.23	(9.08- 13.88)
Partial Totals		0	0	0	0		

*prospective study

National

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*BIOBANK	2	329	22934	78	98319	18.08	(14.13- 23.14)
*BIOBANK	1	244	19464	127	134209	13.25	(10.70- 16.41)
Subtotal BIOBANK						15.14	(12.88- 17.80)
*BWHS	3	-	-	-	-	11.78	(8.55- 16.24)
*CPSI	5	-	-	-	-	12.22	(9.59- 15.58)
*CPSI	6	-	-	-	-	2.73	(2.07- 3.61)
Subtotal CPSI						6.39	(5.33- 7.68)
*CPSII	5	-	-	-	-	23.81	(19.85- 28.57)
*CPSII	6	-	-	-	-	12.65	(11.15- 14.34)
Subtotal CPSII						15.52	(13.99- 17.21)
*JP8	4	-	-	-	-	4.24	(2.94- 6.10)
*JP8	8	-	-	-	-	2.62	(2.03- 3.38)
Subtotal JP8						3.07	(2.49- 3.78)
*JPHC	1	952	21800	87	10138	5.09	(4.09- 6.33)
*JPHC	2	61	2600	375	42155	2.64	(2.02- 3.45)
Subtotal JPHC						3.91	(3.30- 4.64)
*MWOMEN	3	-	-	-	-	21.20	(19.50- 23.10)
*NHANES	1	144	2374	17	4853	17.32	(10.50- 28.56)
*NHIS	6	-	-	-	-	14.60	(9.10- 23.40)
*NHIS	5	-	-	-	-	17.80	(11.40- 27.80)
Subtotal NHIS						16.21	(11.72- 22.42)
*NLCS	4	1502	9069	95	4345	7.57	(6.18- 9.29)
*NLCS	5	275	6540	103	20158	8.23	(6.57- 10.30)
Subtotal NLCS						7.86	(6.76- 9.15)
*NLMS	4	-	-	-	-	11.82	(10.73- 13.03)
*NOWAC	3	-	-	-	-	11.89	(9.66- 14.64)
*QRESEAR	3	-	-	-	-	7.35	(4.54- 11.90)
*QRESEAR	4	-	-	-	-	7.13	(4.47- 11.37)
Subtotal QRESEAR						7.24	(5.17- 10.12)
*THIN	1	372	134000	112	437000	10.83	(8.77- 13.38)
*USA5	5	-	-	-	-	24.97	(22.20- 28.09)
*USA5	6	-	-	-	-	25.66	(23.17- 28.40)
Subtotal USA5						25.36	(23.48- 27.39)
*WHI	3	-	-	-	-	13.44	(10.80- 16.74)
Partial Totals		3879	218781	994	751177		

*prospective study

Regional

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*ACE	2	-	-	-	-	18.56	(9.07- 37.96)
*AEROBIC	1	100	6840	35	18088	7.56	(5.15- 11.09)
*AGRICAN	1	-	-	-	-	28.84	(20.35- 40.87)
*AGRICAN	2	-	-	-	-	16.53	(9.44- 28.95)
Subtotal AGRICAN						24.69	(18.36- 33.20)
*ARIC	3	-	-	-	-	41.41	(18.36- 93.42)
*ARIC	4	-	-	-	-	13.13	(8.46- 20.41)
Subtotal ARIC						17.03	(11.56- 25.09)
*ATP	9	-	-	-	-	9.33	(3.82- 22.84)
*ATP	10	-	-	-	-	23.40	(12.26- 44.63)
Subtotal ATP						17.07	(10.11- 28.82)
ESTHER	1	70	239	17	704	12.13	(7.00- 21.02)
*FRAMING	2	-	-	-	-	7.55	(4.94- 11.55)
*HBC	1	-	-	-	-	4.20	(1.60- 11.10)
*KAISER	2	-	-	-	-	13.20	(11.10- 15.70)
*KRIS	3	-	-	-	-	10.47	(6.74- 16.25)
*NIHAARP	4	-	-	-	-	29.40	(25.20- 34.30)
*NIHAARP	2	-	-	-	-	19.50	(17.20- 22.20)
Subtotal NIHAARP						23.04	(20.89- 25.42)
*PLCO	2	-	-	-	-	31.97	(25.16- 40.63)
SCCS	1	505	1209	22	686	13.02	(8.41- 20.16)
SCCS	2	469	667	54	1203	15.66	(11.64- 21.08)
Subtotal SCCS						14.78	(11.56- 18.89)

Table 6
Smoking and Lung cancer: Cigarette Smoking analyses
Initial analysis by study population

Regional

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*THREEC	5	-	-	-	-	16.78 (10.31- 27.33)	
*THREEC	8	273	12388	14	15703	24.72 (14.45- 42.27)	
Subtotal THREEC						19.99 (13.94- 28.68)	
*VETERAN	1	54	1443	4	1798	16.82 (6.11- 46.34)	
*VITAL	1	251	6169	60	36381	24.67 (18.64- 32.65)	
*VLAGT	1	164	2420	0	567	77.14~(4.81-1236.55)	
*VLAGT	4	-	-	-	-	9.27 (4.45- 19.28)	
Subtotal VLAGT						10.64 (5.24- 21.62)	
Partial Totals		1886	31375	206	75130		

*prospective study

Specific

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*AHS	2	-	-	-	-	23.03 (17.34- 30.59)	
*AMIANI	1	61	2224	13	2645	5.58 (3.07- 10.13)	
*COAL	1	-	-	-	-	9.20 (5.30- 16.00)	
*HPFS	3	-	-	-	-	12.56 (6.02- 26.22)	
*LSS	1	802	284498	40	65789	4.64 (3.38- 6.37)	
*LSS	2	183	97082	392	693805	3.34 (2.80- 3.98)	
Subtotal LSS						3.60 (3.09- 4.20)	
*NHS	2	-	-	-	-	23.30 (19.00- 28.80)	
*NLST	2	-	-	-	-	24.32 (10.98- 53.85)	
NONMET	2	-	-	-	-	7.97 (4.17- 15.27)	
*SHEETME	1	410	4400	53	4503	7.92 (5.97- 10.51)	
Partial Totals		1456	388204	498	766742		

*prospective study

	Study population				Total
	1	2	3	4	
	Internati	National	Regional	Specific	

RR Data

N	3	25	24	10	62
NS	2	16	17	9	44
Wt	134.86	2980.80	920.72	393.21	4429.58
Het Chi	36.53	1027.48	153.79	271.04	1674.66
Het df	2	24	23	9	61
Het P	***	***	***	***	***
Fixed RR	11.88	14.17	18.96	8.47	14.30
RRl	10.03	13.67	17.77	7.68	13.89
RRu	14.06	14.68	20.22	9.35	14.73
P	+++	+++	+++	+++	+++
Random RR	14.45	10.26	16.27	9.71	12.14
RRl	6.85	8.03	13.39	5.41	10.30
RRu	30.50	13.12	19.77	17.42	14.30
P	+++	+++	+++	+++	+++
Asymm P	N.S.	**	N.S.	N.S.	*
Between Chi		4.00	25.70	11.46	185.81
Between df		1	1	1	3
Between P		+	+++	---	***
Btwn (F) P		N.S.	(+)	N.S.	(*)
Btwn (R) P		N.S.	N.S.	N.S.	*

Table 7
Smoking and Lung cancer: Cigarette Smoking analyses
Initial analysis by year of start of baseline

<1980

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*AEROBIC	1	100	6840	35	18088	7.56	(5.15- 11.09)
*COAL	1	-	-	-	-	9.20	(5.30- 16.00)
*CPSI	5	-	-	-	-	12.22	(9.59- 15.58)
*CPSI	6	-	-	-	-	2.73	(2.07- 3.61)
Subtotal CPSI						6.39	(5.33- 7.68)
*FRAMING	2	-	-	-	-	7.55	(4.94- 11.55)
*KAISER	2	-	-	-	-	13.20	(11.10- 15.70)
*KRIS	3	-	-	-	-	10.47	(6.74- 16.25)
*LSS	1	802	284498	40	65789	4.64	(3.38- 6.37)
*LSS	2	183	97082	392	693805	3.34	(2.80- 3.98)
Subtotal LSS						3.60	(3.09- 4.20)
NONMET	2	-	-	-	-	7.97	(4.17- 15.27)
*THREEC	5	-	-	-	-	16.78	(10.31- 27.33)
*THREEC	8	273	12388	14	15703	24.72	(14.45- 42.27)
Subtotal THREEC						19.99	(13.94- 28.68)
*VLAGT	1	164	2420	0	567	77.14	(4.81-1236.55)
*VLAGT	4	-	-	-	-	9.27	(4.45- 19.28)
Subtotal VLAGT						10.64	(5.24- 21.62)
Partial Totals		1522	403228	481	793952		

*prospective study

1980-89

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*ARIC	3	-	-	-	-	41.41	(18.36- 93.42)
*ARIC	4	-	-	-	-	13.13	(8.46- 20.41)
Subtotal ARIC						17.03	(11.56- 25.09)
*CHANCES	2	-	-	-	-	13.10	(9.90- 17.30)
*CPSII	5	-	-	-	-	23.81	(19.85- 28.57)
*CPSII	6	-	-	-	-	12.65	(11.15- 14.34)
Subtotal CPSII						15.52	(13.99- 17.21)
*HPFS	3	-	-	-	-	12.56	(6.02- 26.22)
*JP8	4	-	-	-	-	4.24	(2.94- 6.10)
*JP8	8	-	-	-	-	2.62	(2.03- 3.38)
Subtotal JP8						3.07	(2.49- 3.78)
*NHANES	1	144	2374	17	4853	17.32	(10.50- 28.56)
*NHIS	6	-	-	-	-	14.60	(9.10- 23.40)
*NHIS	5	-	-	-	-	17.80	(11.40- 27.80)
Subtotal NHIS						16.21	(11.72- 22.42)
*NHS	2	-	-	-	-	23.30	(19.00- 28.80)
*NLCS	4	1502	9069	95	4345	7.57	(6.18- 9.29)
*NLCS	5	275	6540	103	20158	8.23	(6.57- 10.30)
Subtotal NLCS						7.86	(6.76- 9.15)
*NLMS	4	-	-	-	-	11.82	(10.73- 13.03)
*SHEETME	1	410	4400	53	4503	7.92	(5.97- 10.51)
*USA5	5	-	-	-	-	24.97	(22.20- 28.09)
*USA5	6	-	-	-	-	25.66	(23.17- 28.40)
Subtotal USA5						25.36	(23.48- 27.39)
*VETERAN	1	54	1443	4	1798	16.82	(6.11- 46.34)
Partial Totals		2385	23826	272	35657		

*prospective study

1990-99

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*ACE	2	-	-	-	-	18.56	(9.07- 37.96)
*AHS	2	-	-	-	-	23.03	(17.34- 30.59)
*BWHS	3	-	-	-	-	11.78	(8.55- 16.24)
*EPIC	3	-	-	-	-	32.00	(21.38- 47.90)
*EPIC	6	-	-	-	-	7.53	(5.87- 9.66)
Subtotal EPIC						11.23	(9.08- 13.88)
*JPHC	1	952	21800	87	10138	5.09	(4.09- 6.33)
*JPHC	2	61	2600	375	42155	2.64	(2.02- 3.45)
Subtotal JPHC						3.91	(3.30- 4.64)
*MWOMEN	3	-	-	-	-	21.20	(19.50- 23.10)
*NIHAARP	4	-	-	-	-	29.40	(25.20- 34.30)
*NIHAARP	2	-	-	-	-	19.50	(17.20- 22.20)
Subtotal NIHAARP						23.04	(20.89- 25.42)
*NLST	2	-	-	-	-	24.32	(10.98- 53.85)
*NOWAC	3	-	-	-	-	11.89	(9.66- 14.64)
*PLCO	2	-	-	-	-	31.97	(25.16- 40.63)
*QRESEAR	3	-	-	-	-	7.35	(4.54- 11.90)
*QRESEAR	4	-	-	-	-	7.13	(4.47- 11.37)

Table 7
Smoking and Lung cancer: Cigarette Smoking analyses
Initial analysis by year of start of baseline

1990-99

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
Subtotal QRESEAR						7.24 (5.17- 10.12)	
*WHI	3	-	-	-	-	13.44 (10.80- 16.74)	
Partial Totals		1013	24400	462	52293		

*prospective study

2000+'

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*AGRICAN	1	-	-	-	-	28.84 (20.35- 40.87)	
*AGRICAN	2	-	-	-	-	16.53 (9.44- 28.95)	
Subtotal AGRICAN						24.69 (18.36- 33.20)	
*AMIAN	1	61	2224	13	2645	5.58 (3.07- 10.13)	
*ATP	9	-	-	-	-	9.33 (3.82- 22.84)	
*ATP	10	-	-	-	-	23.40 (12.26- 44.63)	
Subtotal ATP						17.07 (10.11- 28.82)	
*BIOBANK	2	329	22934	78	98319	18.08 (14.13- 23.14)	
*BIOBANK	1	244	19464	127	134209	13.25 (10.70- 16.41)	
Subtotal BIOBANK						15.14 (12.88- 17.80)	
ESTHER	1	70	239	17	704	12.13 (7.00- 21.02)	
*HBC	1	-	-	-	-	4.20 (1.60- 11.10)	
SCCS	1	505	1209	22	686	13.02 (8.41- 20.16)	
SCCS	2	469	667	54	1203	15.66 (11.64- 21.08)	
Subtotal SCCS						14.78 (11.56- 18.89)	
*THIN	1	372	134000	112	437000	10.83 (8.77- 13.38)	
*VITAL	1	251	6169	60	36381	24.67 (18.64- 32.65)	
Partial Totals		2301	186906	483	711147		

*prospective study

	Year of start of baseline				Total	Trend
	1 <1980	2 1980-89	3 1990-99	4 2000+'		

RR Data

N	14	19	16	13	62	
NS	10	13	12	9	44	
Wt	531.89	1945.04	1521.34	431.32	4429.58	
Het Chi	232.12	575.43	510.22	59.52	1674.66	
Het df	13	18	15	12	61	
Het P	***	***	***	***	***	
Fixed RR	7.17	15.13	16.70	15.06	14.30	
RRl	6.59	14.47	15.88	13.71	13.89	
RRu	7.81	15.82	17.56	16.55	14.73	
P	+++	+++	+++	+++	+++	
Random RR	8.65	12.92	13.45	14.38	12.14	
RRl	5.83	9.83	9.76	11.40	10.30	
RRu	12.83	16.98	18.53	18.15	14.30	
P	+++	+++	+++	+++	+++	
Asymm P	N.S.	N.S.	N.S.	N.S.	*	
Between Chi		232.92	281.59	131.22	297.37	139.53
Between df		1	1	1	3	1
Between P		+++	+++	+++	***	+++
Btwn (F) P		++	++	++	**	+
Btwn (R) P		N.S.	(+)	+	N.S.	(+)

Table 8
Smoking and Lung cancer: Cigarette Smoking analyses
Initial analysis by number of cases in the study

<500

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*ACE	2	-	-	-	-	18.56 (9.07- 37.96)	
*AEROBIC	1	100	6840	35	18088	7.56 (5.15- 11.09)	
*AMIAANT	1	61	2224	13	2645	5.58 (3.07- 10.13)	
*ARIC	3	-	-	-	-	41.41 (18.36- 93.42)	
*ARIC	4	-	-	-	-	13.13 (8.46- 20.41)	
Subtotal ARIC						17.03 (11.56- 25.09)	
*ATP	9	-	-	-	-	9.33 (3.82- 22.84)	
*ATP	10	-	-	-	-	23.40 (12.26- 44.63)	
Subtotal ATP						17.07 (10.11- 28.82)	
*BWHS	3	-	-	-	-	11.78 (8.55- 16.24)	
ESTHER	1	70	239	17	704	12.13 (7.00- 21.02)	
*FRAMING	2	-	-	-	-	7.55 (4.94- 11.55)	
*HBC	1	-	-	-	-	4.20 (1.60- 11.10)	
*HFPS	3	-	-	-	-	12.56 (6.02- 26.22)	
*KRIS	3	-	-	-	-	10.47 (6.74- 16.25)	
*NHANES	1	144	2374	17	4853	17.32 (10.50- 28.56)	
*NLST	2	-	-	-	-	24.32 (10.98- 53.85)	
NONMET	2	-	-	-	-	7.97 (4.17- 15.27)	
*VETERAN	1	54	1443	4	1798	16.82 (6.11- 46.34)	
*VLAGT	1	164	2420	0	567	77.14~ (4.81-1236.55)	
*VLAGT	4	-	-	-	-	9.27 (4.45- 19.28)	
Subtotal VLAGT						10.64 (5.24- 21.62)	
Partial Totals		593	15540	86	28655		
*prospective study							

500-1999

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*AGRICAN	1	-	-	-	-	28.84 (20.35- 40.87)	
*AGRICAN	2	-	-	-	-	16.53 (9.44- 28.95)	
Subtotal AGRICAN						24.69 (18.36- 33.20)	
*AHS	2	-	-	-	-	23.03 (17.34- 30.59)	
*BIOBANK	2	329	22934	78	98319	18.08 (14.13- 23.14)	
*BIOBANK	1	244	19464	127	134209	13.25 (10.70- 16.41)	
Subtotal BIOBANK						15.14 (12.88- 17.80)	
*COAL	1	-	-	-	-	9.20 (5.30- 16.00)	
*CPSI	5	-	-	-	-	12.22 (9.59- 15.58)	
*CPSI	6	-	-	-	-	2.73 (2.07- 3.61)	
Subtotal CPSI						6.39 (5.33- 7.68)	
*JPHC	1	952	21800	87	10138	5.09 (4.09- 6.33)	
*JPHC	2	61	2600	375	42155	2.64 (2.02- 3.45)	
Subtotal JPHC						3.91 (3.30- 4.64)	
*KAISER	2	-	-	-	-	13.20 (11.10- 15.70)	
*LSS	1	802	284498	40	65789	4.64 (3.38- 6.37)	
*LSS	2	183	97082	392	693805	3.34 (2.80- 3.98)	
Subtotal LSS						3.60 (3.09- 4.20)	
*NHS	2	-	-	-	-	23.30 (19.00- 28.80)	
*NOWAC	3	-	-	-	-	11.89 (9.66- 14.64)	
*PLCO	2	-	-	-	-	31.97 (25.16- 40.63)	
SCCS	1	505	1209	22	686	13.02 (8.41- 20.16)	
SCCS	2	469	667	54	1203	15.66 (11.64- 21.08)	
Subtotal SCCS						14.78 (11.56- 18.89)	
*SHEETME	1	410	4400	53	4503	7.92 (5.97- 10.51)	
*THIN	1	372	134000	112	437000	10.83 (8.77- 13.38)	
*THREEC	5	-	-	-	-	16.78 (10.31- 27.33)	
*THREEC	8	273	12388	14	15703	24.72 (14.45- 42.27)	
Subtotal THREEC						19.99 (13.94- 28.68)	
*VITAL	1	251	6169	60	36381	24.67 (18.64- 32.65)	
*WHI	3	-	-	-	-	13.44 (10.80- 16.74)	
Partial Totals		4851	607211	1414	1539891		
*prospective study							

Table 8
Smoking and Lung cancer: Cigarette Smoking analyses
Initial analysis by number of cases in the study

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*CHANCES	2	-	-	-	-	13.10 (9.90- 17.30)	
*CPSII	5	-	-	-	-	23.81 (19.85- 28.57)	
*CPSII	6	-	-	-	-	12.65 (11.15- 14.34)	
Subtotal CPSII						15.52 (13.99- 17.21)	
*EPIC	3	-	-	-	-	32.00 (21.38- 47.90)	
*EPIC	6	-	-	-	-	7.53 (5.87- 9.66)	
Subtotal EPIC						11.23 (9.08- 13.88)	
*JP8	4	-	-	-	-	4.24 (2.94- 6.10)	
*JP8	8	-	-	-	-	2.62 (2.03- 3.38)	
Subtotal JP8						3.07 (2.49- 3.78)	
*MWOMEN	3	-	-	-	-	21.20 (19.50- 23.10)	
*NHIS	6	-	-	-	-	14.60 (9.10- 23.40)	
*NHIS	5	-	-	-	-	17.80 (11.40- 27.80)	
Subtotal NHIS						16.21 (11.72- 22.42)	
*NIHAARP	4	-	-	-	-	29.40 (25.20- 34.30)	
*NIHAARP	2	-	-	-	-	19.50 (17.20- 22.20)	
Subtotal NIHAARP						23.04 (20.89- 25.42)	
*NLCS	4	1502	9069	95	4345	7.57 (6.18- 9.29)	
*NLCS	5	275	6540	103	20158	8.23 (6.57- 10.30)	
Subtotal NLCS						7.86 (6.76- 9.15)	
*NLMS	4	-	-	-	-	11.82 (10.73- 13.03)	
*QRESEAR	3	-	-	-	-	7.35 (4.54- 11.90)	
*QRESEAR	4	-	-	-	-	7.13 (4.47- 11.37)	
Subtotal QRESEAR						7.24 (5.17- 10.12)	
*USA5	5	-	-	-	-	24.97 (22.20- 28.09)	
*USA5	6	-	-	-	-	25.66 (23.17- 28.40)	
Subtotal USA5						25.36 (23.48- 27.39)	
Partial Totals		1777	15609	198	24503		

*prospective study

	Number of lung cancer cases			Total	Trend
	1 <500	2 500-1999	3 2000+		

RR Data

N	19	24	19	62	
NS	16	17	11	44	
Wt	228.31	1392.11	2809.16	4429.58	
Het Chi	44.73	725.60	712.33	1674.66	
Het df	18	23	18	61	
Het P	***	***	***	***	
Fixed RR	11.30	10.81	16.75	14.30	
RRl	9.93	10.25	16.14	13.89	
RRu	12.86	11.39	17.38	14.73	
P	+++	+++	+++	+++	
Random RR	11.90	11.68	12.76	12.14	
RRl	9.55	8.65	9.99	10.30	
RRu	14.83	15.75	16.31	14.30	
P	+++	+++	+++	+++	
Asymm P	N.S.	N.S.	(*)	*	
Between Chi		0.39	32.70	191.99	161.38
Between df		1	1	2	1
Between P		N.S.	+++	***	+++
Btwn (F) P		N.S.	N.S.	*	+
Btwn (R) P		N.S.	N.S.	N.S.	N.S.

Table 9
Smoking and Lung cancer: Cigarette Smoking analyses
Initial analysis by cigarette smoking exclusively or not

absent							
STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*ACE	2	-	-	-	-	18.56 (9.07- 37.96)	
*AEROBIC	1	100	6840	35	18088	7.56 (5.15- 11.09)	
*AGRICAN	1	-	-	-	-	28.84 (20.35- 40.87)	
*AGRICAN	2	-	-	-	-	16.53 (9.44- 28.95)	
Subtotal AGRICAN						24.69 (18.36- 33.20)	
*AMIAANT	1	61	2224	13	2645	5.58 (3.07- 10.13)	
*ARIC	3	-	-	-	-	41.41 (18.36- 93.42)	
*ARIC	4	-	-	-	-	13.13 (8.46- 20.41)	
Subtotal ARIC						17.03 (11.56- 25.09)	
*ATP	9	-	-	-	-	9.33 (3.82- 22.84)	
*ATP	10	-	-	-	-	23.40 (12.26- 44.63)	
Subtotal ATP						17.07 (10.11- 28.82)	
*BIOBANK	2	329	22934	78	98319	18.08 (14.13- 23.14)	
*BIOBANK	1	244	19464	127	134209	13.25 (10.70- 16.41)	
Subtotal BIOBANK						15.14 (12.88- 17.80)	
*BWHS	3	-	-	-	-	11.78 (8.55- 16.24)	
*CHANCES	2	-	-	-	-	13.10 (9.90- 17.30)	
*COAL	1	-	-	-	-	9.20 (5.30- 16.00)	
*EPIC	6	-	-	-	-	7.53 (5.87- 9.66)	
ESTHER	1	70	239	17	704	12.13 (7.00- 21.02)	
*FRAMING	2	-	-	-	-	7.55 (4.94- 11.55)	
*HBC	1	-	-	-	-	4.20 (1.60- 11.10)	
*HPFS	3	-	-	-	-	12.56 (6.02- 26.22)	
*KAISER	2	-	-	-	-	13.20 (11.10- 15.70)	
*KRIS	3	-	-	-	-	10.47 (6.74- 16.25)	
*NHANES	1	144	2374	17	4853	17.32 (10.50- 28.56)	
*NHIS	6	-	-	-	-	14.60 (9.10- 23.40)	
*NHIS	5	-	-	-	-	17.80 (11.40- 27.80)	
Subtotal NHIS						16.21 (11.72- 22.42)	
*NHS	2	-	-	-	-	23.30 (19.00- 28.80)	
*NLCS	4	1502	9069	95	4345	7.57 (6.18- 9.29)	
*NLCS	5	275	6540	103	20158	8.23 (6.57- 10.30)	
Subtotal NLCS						7.86 (6.76- 9.15)	
*NLST	2	-	-	-	-	24.32 (10.98- 53.85)	
NONMET	2	-	-	-	-	7.97 (4.17- 15.27)	
*NOWAC	3	-	-	-	-	11.89 (9.66- 14.64)	
*PLCO	2	-	-	-	-	31.97 (25.16- 40.63)	
*QRESEAR	3	-	-	-	-	7.35 (4.54- 11.90)	
*QRESEAR	4	-	-	-	-	7.13 (4.47- 11.37)	
Subtotal QRESEAR						7.24 (5.17- 10.12)	
SCCS	1	505	1209	22	686	13.02 (8.41- 20.16)	
SCCS	2	469	667	54	1203	15.66 (11.64- 21.08)	
Subtotal SCCS						14.78 (11.56- 18.89)	
*SHEETME	1	410	4400	53	4503	7.92 (5.97- 10.51)	
*THIN	1	372	134000	112	437000	10.83 (8.77- 13.38)	
*THREEC	8	273	12388	14	15703	24.72 (14.45- 42.27)	
*USA5	5	-	-	-	-	24.97 (22.20- 28.09)	
*USA5	6	-	-	-	-	25.66 (23.17- 28.40)	
Subtotal USA5						25.36 (23.48- 27.39)	
*VETERAN	1	54	1443	4	1798	16.82 (6.11- 46.34)	
*VITAL	1	251	6169	60	36381	24.67 (18.64- 32.65)	
*VLAGT	1	164	2420	0	567	77.14~(4.81-1236.55)	
*VLAGT	4	-	-	-	-	9.27 (4.45- 19.28)	
Subtotal VLAGT						10.64 (5.24- 21.62)	
*WHI	3	-	-	-	-	13.44 (10.80- 16.74)	
Partial Totals		5223	232380	804	781162		
*prospective study							

Table 9
Smoking and Lung cancer: Cigarette Smoking analyses
Initial analysis by cigarette smoking exclusively or not

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*AHS	2	-	-	-	-	23.03 (17.34- 30.59)	
*CPSI	5	-	-	-	-	12.22 (9.59- 15.58)	
*CPSI	6	-	-	-	-	2.73 (2.07- 3.61)	
Subtotal CPSI						6.39 (5.33- 7.68)	
*CPSII	5	-	-	-	-	23.81 (19.85- 28.57)	
*CPSII	6	-	-	-	-	12.65 (11.15- 14.34)	
Subtotal CPSII						15.52 (13.99- 17.21)	
*EPIC	3	-	-	-	-	32.00 (21.38- 47.90)	
*JP8	4	-	-	-	-	4.24 (2.94- 6.10)	
*JP8	8	-	-	-	-	2.62 (2.03- 3.38)	
Subtotal JP8						3.07 (2.49- 3.78)	
*JPHC	1	952	21800	87	10138	5.09 (4.09- 6.33)	
*JPHC	2	61	2600	375	42155	2.64 (2.02- 3.45)	
Subtotal JPHC						3.91 (3.30- 4.64)	
*LSS	1	802	284498	40	65789	4.64 (3.38- 6.37)	
*LSS	2	183	97082	392	693805	3.34 (2.80- 3.98)	
Subtotal LSS						3.60 (3.09- 4.20)	
*MWOMEN	3	-	-	-	-	21.20 (19.50- 23.10)	
*NIHAARP	4	-	-	-	-	29.40 (25.20- 34.30)	
*NIHAARP	2	-	-	-	-	19.50 (17.20- 22.20)	
Subtotal NIHAARP						23.04 (20.89- 25.42)	
*NLMS	4	-	-	-	-	11.82 (10.73- 13.03)	
*THREEC	5	-	-	-	-	16.78 (10.31- 27.33)	
Partial Totals		1998	405980	894	811887		

*prospective study

RR Description: Exclusive use of the product

	1	2	Total
	absent	present	Total

RR Data

N	45	17	62
NS	35	11	46
Wt	2142.95	2286.63	4429.58
Het Chi	482.02	1144.67	1674.66
Het df	44	16	61
Het P	***	***	***
Fixed RR	15.92	12.93	14.30
RRl	15.26	12.41	13.89
RRu	16.61	13.47	14.73
P	+++	+++	+++
Random RR	13.47	9.50	12.14
RRl	11.55	6.61	10.30
RRu	15.72	13.64	14.30
P	+++	+++	+++
Asymm P	*	(*)	*
Between Chi		47.97	47.97
Between df		1	1
Between P		---	***
Btwn (F) P		N.S.	N.S.
Btwn (R) P		(-)	(*)

Table 10
Smoking and Lung cancer: Cigarette Smoking analyses
Initial analysis by latency rule used or not

absent		Numbers exposed		Non-exposed		RR	95.00%CI
STUDY	NRR	Case	Cont	Case	Cont		
*ACE	2	-	-	-	-	18.56 (9.07- 37.96)	
*AEROBIC	1	100	6840	35	18088	7.56 (5.15- 11.09)	
*AGRICAN	1	-	-	-	-	28.84 (20.35- 40.87)	
*AGRICAN	2	-	-	-	-	16.53 (9.44- 28.95)	
Subtotal AGRICAN						24.69 (18.36- 33.20)	
*AHS	2	-	-	-	-	23.03 (17.34- 30.59)	
*AMIANT	1	61	2224	13	2645	5.58 (3.07- 10.13)	
*ARIC	3	-	-	-	-	41.41 (18.36- 93.42)	
*ARIC	4	-	-	-	-	13.13 (8.46- 20.41)	
Subtotal ARIC						17.03 (11.56- 25.09)	
*BIOBANK	2	329	22934	78	98319	18.08 (14.13- 23.14)	
*BIOBANK	1	244	19464	127	134209	13.25 (10.70- 16.41)	
Subtotal BIOBANK						15.14 (12.88- 17.80)	
*BWHS	3	-	-	-	-	11.78 (8.55- 16.24)	
*CHANCES	2	-	-	-	-	13.10 (9.90- 17.30)	
*COAL	1	-	-	-	-	9.20 (5.30- 16.00)	
*CPSI	5	-	-	-	-	12.22 (9.59- 15.58)	
*CPSI	6	-	-	-	-	2.73 (2.07- 3.61)	
Subtotal CPSI						6.39 (5.33- 7.68)	
*CPSII	5	-	-	-	-	23.81 (19.85- 28.57)	
*CPSII	6	-	-	-	-	12.65 (11.15- 14.34)	
Subtotal CPSII						15.52 (13.99- 17.21)	
*EPIC	3	-	-	-	-	32.00 (21.38- 47.90)	
*EPIC	6	-	-	-	-	7.53 (5.87- 9.66)	
Subtotal EPIC						11.23 (9.08- 13.88)	
ESTHER	1	70	239	17	704	12.13 (7.00- 21.02)	
*FRAMING	2	-	-	-	-	7.55 (4.94- 11.55)	
*HBC	1	-	-	-	-	4.20 (1.60- 11.10)	
*HFPS	3	-	-	-	-	12.56 (6.02- 26.22)	
*JPHC	1	952	21800	87	10138	5.09 (4.09- 6.33)	
*JPHC	2	61	2600	375	42155	2.64 (2.02- 3.45)	
Subtotal JPHC						3.91 (3.30- 4.64)	
*KAISER	2	-	-	-	-	13.20 (11.10- 15.70)	
*LSS	1	802	284498	40	65789	4.64 (3.38- 6.37)	
*LSS	2	183	97082	392	693805	3.34 (2.80- 3.98)	
Subtotal LSS						3.60 (3.09- 4.20)	
*NHANES	1	144	2374	17	4853	17.32 (10.50- 28.56)	
*NHS	2	-	-	-	-	23.30 (19.00- 28.80)	
*NLCS	4	1502	9069	95	4345	7.57 (6.18- 9.29)	
*NLCS	5	275	6540	103	20158	8.23 (6.57- 10.30)	
Subtotal NLCS						7.86 (6.76- 9.15)	
*NLMS	4	-	-	-	-	11.82 (10.73- 13.03)	
*NLST	2	-	-	-	-	24.32 (10.98- 53.85)	
NONMET	2	-	-	-	-	7.97 (4.17- 15.27)	
*NOWAC	3	-	-	-	-	11.89 (9.66- 14.64)	
*PLCO	2	-	-	-	-	31.97 (25.16- 40.63)	
*QRESEAR	3	-	-	-	-	7.35 (4.54- 11.90)	
*QRESEAR	4	-	-	-	-	7.13 (4.47- 11.37)	
Subtotal QRESEAR						7.24 (5.17- 10.12)	
SCCS	1	505	1209	22	686	13.02 (8.41- 20.16)	
SCCS	2	469	667	54	1203	15.66 (11.64- 21.08)	
Subtotal SCCS						14.78 (11.56- 18.89)	
*SHEETME	1	410	4400	53	4503	7.92 (5.97- 10.51)	
*THIN	1	372	134000	112	437000	10.83 (8.77- 13.38)	
*THREEC	5	-	-	-	-	16.78 (10.31- 27.33)	
*USA5	5	-	-	-	-	24.97 (22.20- 28.09)	
*USA5	6	-	-	-	-	25.66 (23.17- 28.40)	
Subtotal USA5						25.36 (23.48- 27.39)	
*VETERAN	1	54	1443	4	1798	16.82 (6.11- 46.34)	
*VITAL	1	251	6169	60	36381	24.67 (18.64- 32.65)	
*VLAGT	1	164	2420	0	567	77.14~ (4.81-1236.55)	
*VLAGT	4	-	-	-	-	9.27 (4.45- 19.28)	
Subtotal VLAGT						10.64 (5.24- 21.62)	
*WHI	3	-	-	-	-	13.44 (10.80- 16.74)	
Partial Totals		6948	625972	1684	1577346		
*prospective study							

Table 10
Smoking and Lung cancer: Cigarette Smoking analyses
Initial analysis by latency rule used or not

present

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*ATP	9	-	-	-	-	9.33 (3.82- 22.84)	
*ATP	10	-	-	-	-	23.40 (12.26- 44.63)	
Subtotal ATP						17.07 (10.11- 28.82)	
*JP8	4	-	-	-	-	4.24 (2.94- 6.10)	
*JP8	8	-	-	-	-	2.62 (2.03- 3.38)	
Subtotal JP8						3.07 (2.49- 3.78)	
*KRIS	3	-	-	-	-	10.47 (6.74- 16.25)	
*MWOMEN	3	-	-	-	-	21.20 (19.50- 23.10)	
*NHIS	6	-	-	-	-	14.60 (9.10- 23.40)	
*NHIS	5	-	-	-	-	17.80 (11.40- 27.80)	
Subtotal NHIS						16.21 (11.72- 22.42)	
*NIHAARP	4	-	-	-	-	29.40 (25.20- 34.30)	
*NIHAARP	2	-	-	-	-	19.50 (17.20- 22.20)	
Subtotal NIHAARP						23.04 (20.89- 25.42)	
*THREEC	8	273	12388	14	15703	24.72 (14.45- 42.27)	
Partial Totals		273	12388	14	15703		

*prospective study

RR Description: Latency rule applied in case definition

1 2
absent present Total

RR Data

N	51	11	62
NS	38	7	45
Wt	3324.89	1104.69	4429.58
Het Chi	1239.76	344.91	1674.66
Het df	50	10	61
Het P	***	***	***
Fixed RR	13.17	18.31	14.30
RRl	12.73	17.27	13.89
RRu	13.63	19.43	14.73
P	+++	+++	+++
Random RR	11.93	13.13	12.14
RRl	9.97	8.69	10.30
RRu	14.28	19.83	14.30
P	+++	+++	+++
Asymm P	N.S.	N.S.	*
Between Chi		89.99	89.99
Between df		1	1
Between P		+++	***
Btwn (F) P		(+)	(*)
Btwn (R) P		N.S.	N.S.

Table 11
Smoking and Lung cancer: Cigarette Smoking analyses
Initial analysis by study design

Cohort	STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
			Case	Cont	Case	Cont		
	*ACE	2	-	-	-	-	18.56 (9.07- 37.96)	
	*AEROBIC	1	100	6840	35	18088	7.56 (5.15- 11.09)	
	*AGRICAN	1	-	-	-	-	28.84 (20.35- 40.87)	
	*AGRICAN	2	-	-	-	-	16.53 (9.44- 28.95)	
	Subtotal AGRICAN						24.69 (18.36- 33.20)	
	*AHS	2	-	-	-	-	23.03 (17.34- 30.59)	
	*AMIANT	1	61	2224	13	2645	5.58 (3.07- 10.13)	
	*ARIC	3	-	-	-	-	41.41 (18.36- 93.42)	
	*ARIC	4	-	-	-	-	13.13 (8.46- 20.41)	
	Subtotal ARIC						17.03 (11.56- 25.09)	
	*ATP	9	-	-	-	-	9.33 (3.82- 22.84)	
	*ATP	10	-	-	-	-	23.40 (12.26- 44.63)	
	Subtotal ATP						17.07 (10.11- 28.82)	
	*BIOBANK	2	329	22934	78	98319	18.08 (14.13- 23.14)	
	*BIOBANK	1	244	19464	127	134209	13.25 (10.70- 16.41)	
	Subtotal BIOBANK						15.14 (12.88- 17.80)	
	*BWHS	3	-	-	-	-	11.78 (8.55- 16.24)	
	*CHANCES	2	-	-	-	-	13.10 (9.90- 17.30)	
	*COAL	1	-	-	-	-	9.20 (5.30- 16.00)	
	*CPSI	5	-	-	-	-	12.22 (9.59- 15.58)	
	*CPSI	6	-	-	-	-	2.73 (2.07- 3.61)	
	Subtotal CPSI						6.39 (5.33- 7.68)	
	*CPSII	5	-	-	-	-	23.81 (19.85- 28.57)	
	*CPSII	6	-	-	-	-	12.65 (11.15- 14.34)	
	Subtotal CPSII						15.52 (13.99- 17.21)	
	*EPIC	3	-	-	-	-	32.00 (21.38- 47.90)	
	*EPIC	6	-	-	-	-	7.53 (5.87- 9.66)	
	Subtotal EPIC						11.23 (9.08- 13.88)	
	*FRAMING	2	-	-	-	-	7.55 (4.94- 11.55)	
	*HBC	1	-	-	-	-	4.20 (1.60- 11.10)	
	*JP8	4	-	-	-	-	4.24 (2.94- 6.10)	
	*JP8	8	-	-	-	-	2.62 (2.03- 3.38)	
	Subtotal JP8						3.07 (2.49- 3.78)	
	*JPHC	1	952	21800	87	10138	5.09 (4.09- 6.33)	
	*JPHC	2	61	2600	375	42155	2.64 (2.02- 3.45)	
	Subtotal JPHC						3.91 (3.30- 4.64)	
	*KAISER	2	-	-	-	-	13.20 (11.10- 15.70)	
	*KRIS	3	-	-	-	-	10.47 (6.74- 16.25)	
	*LSS	1	802	284498	40	65789	4.64 (3.38- 6.37)	
	*LSS	2	183	97082	392	693805	3.34 (2.80- 3.98)	
	Subtotal LSS						3.60 (3.09- 4.20)	
	*MWOMEN	3	-	-	-	-	21.20 (19.50- 23.10)	
	*NHANES	1	144	2374	17	4853	17.32 (10.50- 28.56)	
	*NHIS	6	-	-	-	-	14.60 (9.10- 23.40)	
	*NHIS	5	-	-	-	-	17.80 (11.40- 27.80)	
	Subtotal NHIS						16.21 (11.72- 22.42)	
	*NHS	2	-	-	-	-	23.30 (19.00- 28.80)	
	*NIHAARP	4	-	-	-	-	29.40 (25.20- 34.30)	
	*NIHAARP	2	-	-	-	-	19.50 (17.20- 22.20)	
	Subtotal NIHAARP						23.04 (20.89- 25.42)	
	*NLMS	4	-	-	-	-	11.82 (10.73- 13.03)	
	*NLST	2	-	-	-	-	24.32 (10.98- 53.85)	
	*NOWAC	3	-	-	-	-	11.89 (9.66- 14.64)	
	*PLCO	2	-	-	-	-	31.97 (25.16- 40.63)	
	*QRESEAR	3	-	-	-	-	7.35 (4.54- 11.90)	
	*QRESEAR	4	-	-	-	-	7.13 (4.47- 11.37)	
	Subtotal QRESEAR						7.24 (5.17- 10.12)	
	*SHEETME	1	410	4400	53	4503	7.92 (5.97- 10.51)	
	*THIN	1	372	134000	112	437000	10.83 (8.77- 13.38)	
	*THREEC	5	-	-	-	-	16.78 (10.31- 27.33)	
	*THREEC	8	273	12388	14	15703	24.72 (14.45- 42.27)	
	Subtotal THREEC						19.99 (13.94- 28.68)	
	*USA5	5	-	-	-	-	24.97 (22.20- 28.09)	
	*USA5	6	-	-	-	-	25.66 (23.17- 28.40)	
	Subtotal USA5						25.36 (23.48- 27.39)	
	*VETERAN	1	54	1443	4	1798	16.82 (6.11- 46.34)	
	*VITAL	1	251	6169	60	36381	24.67 (18.64- 32.65)	
	*VLAGT	1	164	2420	0	567	77.14~ (4.81-1236.55)	
	*VLAGT	4	-	-	-	-	9.27 (4.45- 19.28)	
	Subtotal VLAGT						10.64 (5.24- 21.62)	
	*WHI	3	-	-	-	-	13.44 (10.80- 16.74)	
	Partial Totals		4400	620636	1407	1565953		
	*prospective study							

Table 11
Smoking and Lung cancer: Cigarette Smoking analyses
Initial analysis by study design

Nested CC

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
ESTHER	1	70	239	17	704	12.13	(7.00- 21.02)
*HPFS	3	-	-	-	-	12.56	(6.02- 26.22)
*NLCS	4	1502	9069	95	4345	7.57	(6.18- 9.29)
*NLCS	5	275	6540	103	20158	8.23	(6.57- 10.30)
Subtotal NLCS						7.86	(6.76- 9.15)
NONMET	2	-	-	-	-	7.97	(4.17- 15.27)
SCCS	1	505	1209	22	686	13.02	(8.41- 20.16)
SCCS	2	469	667	54	1203	15.66	(11.64- 21.08)
Subtotal SCCS						14.78	(11.56- 18.89)
Partial Totals		2821	17724	291	27096		

*prospective study

RR Description: Study design
1 2
Cohort Nested CC Total

RR Data

N	55	7	62
NS	39	5	44
Wt	4168.79	260.79	4429.58
Het Chi	1607.34	20.77	1674.66
Het df	54	6	61
Het P	***	**	***
Fixed RR	14.67	9.49	14.30
RRl	14.23	8.41	13.89
RRu	15.13	10.72	14.73
P	+++	+++	+++
Random RR	12.35	10.41	12.14
RRl	10.35	8.04	10.30
RRu	14.73	13.48	14.30
P	+++	+++	+++
Asymm P	*	N.S.	*
Between Chi		46.55	46.55
Between df		1	1
Between P		---	***
Btwn (F) P		N.S.	N.S.
Btwn (R) P		N.S.	N.S.

Table 12
Smoking and Lung cancer: Cigarette Smoking analyses
Initial analysis by lowest age considered in the study

<30

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*ACE	2	-	-	-	-	18.56 (9.07- 37.96)	
*AEROBIC	1	100	6840	35	18088	7.56 (5.15- 11.09)	
*AGRICAN	1	-	-	-	-	28.84 (20.35- 40.87)	
*AGRICAN	2	-	-	-	-	16.53 (9.44- 28.95)	
Subtotal AGRICAN						24.69 (18.36- 33.20)	
*BWHS	3	-	-	-	-	11.78 (8.55- 16.24)	
*LSS	1	802	284498	40	65789	4.64 (3.38- 6.37)	
*LSS	2	183	97082	392	693805	3.34 (2.80- 3.98)	
Subtotal LSS						3.60 (3.09- 4.20)	
*NHIS	6	-	-	-	-	14.60 (9.10- 23.40)	
*NHIS	5	-	-	-	-	17.80 (11.40- 27.80)	
Subtotal NHIS						16.21 (11.72- 22.42)	
*QRESEAR	3	-	-	-	-	7.35 (4.54- 11.90)	
*QRESEAR	4	-	-	-	-	7.13 (4.47- 11.37)	
Subtotal QRESEAR						7.24 (5.17- 10.12)	
*THREEC	5	-	-	-	-	16.78 (10.31- 27.33)	
*VETERAN	1	54	1443	4	1798	16.82 (6.11- 46.34)	
*VLAGT	1	164	2420	0	567	77.14~ (4.81-1236.55)	
*VLAGT	4	-	-	-	-	9.27 (4.45- 19.28)	
Subtotal VLAGT						10.64 (5.24- 21.62)	
Partial Totals		1303	392283	471	780047		
*prospective study							

30-39

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*ATP	9	-	-	-	-	9.33 (3.82- 22.84)	
*ATP	10	-	-	-	-	23.40 (12.26- 44.63)	
Subtotal ATP						17.07 (10.11- 28.82)	
*EPIC	3	-	-	-	-	32.00 (21.38- 47.90)	
*EPIC	6	-	-	-	-	7.53 (5.87- 9.66)	
Subtotal EPIC						11.23 (9.08- 13.88)	
*JP8	4	-	-	-	-	4.24 (2.94- 6.10)	
*JP8	8	-	-	-	-	2.62 (2.03- 3.38)	
Subtotal JP8						3.07 (2.49- 3.78)	
*NHS	2	-	-	-	-	23.30 (19.00- 28.80)	
*NLMS	4	-	-	-	-	11.82 (10.73- 13.03)	
*NOWAC	3	-	-	-	-	11.89 (9.66- 14.64)	
*THIN	1	372	134000	112	437000	10.83 (8.77- 13.38)	
*THREEC	8	273	12388	14	15703	24.72 (14.45- 42.27)	
Partial Totals		645	146388	126	452703		
*prospective study							

40-48

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*ARIC	3	-	-	-	-	41.41 (18.36- 93.42)	
*ARIC	4	-	-	-	-	13.13 (8.46- 20.41)	
Subtotal ARIC						17.03 (11.56- 25.09)	
*BIOBANK	2	329	22934	78	98319	18.08 (14.13- 23.14)	
*BIOBANK	1	244	19464	127	134209	13.25 (10.70- 16.41)	
Subtotal BIOBANK						15.14 (12.88- 17.80)	
*CHANCES	2	-	-	-	-	13.10 (9.90- 17.30)	
*HPFS	3	-	-	-	-	12.56 (6.02- 26.22)	
*JPHC	1	952	21800	87	10138	5.09 (4.09- 6.33)	
*JPHC	2	61	2600	375	42155	2.64 (2.02- 3.45)	
Subtotal JPHC						3.91 (3.30- 4.64)	
*KRIS	3	-	-	-	-	10.47 (6.74- 16.25)	
*NHANES	1	144	2374	17	4853	17.32 (10.50- 28.56)	
SCCS	1	505	1209	22	686	13.02 (8.41- 20.16)	
SCCS	2	469	667	54	1203	15.66 (11.64- 21.08)	
Subtotal SCCS						14.78 (11.56- 18.89)	
*USA5	5	-	-	-	-	24.97 (22.20- 28.09)	
*USA5	6	-	-	-	-	25.66 (23.17- 28.40)	
Subtotal USA5						25.36 (23.48- 27.39)	
Partial Totals		2704	71048	760	291563		
*prospective study							

Table 12
Smoking and Lung cancer: Cigarette Smoking analyses
Initial analysis by lowest age considered in the study

49+

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*CPSI	5	-	-	-	-	12.22 (9.59- 15.58)	
*CPSI	6	-	-	-	-	2.73 (2.07- 3.61)	
Subtotal CPSI						6.39 (5.33- 7.68)	
*CPSII	5	-	-	-	-	23.81 (19.85- 28.57)	
*CPSII	6	-	-	-	-	12.65 (11.15- 14.34)	
Subtotal CPSII						15.52 (13.99- 17.21)	
ESTHER	1	70	239	17	704	12.13 (7.00- 21.02)	
*HBC	1	-	-	-	-	4.20 (1.60- 11.10)	
*MWOMEN	3	-	-	-	-	21.20 (19.50- 23.10)	
*NIHAARP	4	-	-	-	-	29.40 (25.20- 34.30)	
*NIHAARP	2	-	-	-	-	19.50 (17.20- 22.20)	
Subtotal NIHAARP						23.04 (20.89- 25.42)	
*NLCS	4	1502	9069	95	4345	7.57 (6.18- 9.29)	
*NLCS	5	275	6540	103	20158	8.23 (6.57- 10.30)	
Subtotal NLCS						7.86 (6.76- 9.15)	
*PLCO	2	-	-	-	-	31.97 (25.16- 40.63)	
*VITAL	1	251	6169	60	36381	24.67 (18.64- 32.65)	
*WHI	3	-	-	-	-	13.44 (10.80- 16.74)	
Partial Totals		2098	22017	275	61588		

*prospective study

Missing

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*AHS	2	-	-	-	-	23.03 (17.34- 30.59)	
*AMIAANT	1	61	2224	13	2645	5.58 (3.07- 10.13)	
*COAL	1	-	-	-	-	9.20 (5.30- 16.00)	
*FRAMING	2	-	-	-	-	7.55 (4.94- 11.55)	
*KAISER	2	-	-	-	-	13.20 (11.10- 15.70)	
*NLST	2	-	-	-	-	24.32 (10.98- 53.85)	
NONMET	2	-	-	-	-	7.97 (4.17- 15.27)	
*SHEETME	1	410	4400	53	4503	7.92 (5.97- 10.51)	
Partial Totals		471	6624	66	7148		

*prospective study

Lowest age included, grouped

1 2 3 4 5
<30 30-39 40-48 49+ Missing Total

RR Data

N	15	11	14	14	8	62
NS	10	8	9	10	8	45
Wt	376.10	872.10	1110.73	1787.31	283.35	4429.58
Het Chi	207.62	250.47	429.03	434.27	46.06	1674.66
Het df	14	10	13	13	7	61
Het P	***	***	***	***	***	***
Fixed RR	7.54	11.10	17.18	16.96	12.10	14.30
RRl	6.82	10.39	16.20	16.19	10.77	13.89
RRu	8.35	11.86	18.23	17.77	13.60	14.73
P	+++	+++	+++	+++	+++	+++
Random RR	11.30	11.41	13.29	13.62	10.79	12.14
RRl	7.37	7.80	9.15	10.22	7.64	10.30
RRu	17.33	16.70	19.30	18.16	15.23	14.30
P	+++	+++	+++	+++	+++	+++
Asymm P	*	N.S.	N.S.	N.S.	N.S.	*
Between Chi		39.20	190.41	203.95	36.09	307.21
Between df		1	1	1	1	4
Between P		+++	+++	+++	+++	***
Btwn (F) P		N.S.	++	++	(+)	*
Btwn (R) P		N.S.	N.S.	N.S.	N.S.	N.S.

Table 13
Smoking and Lung cancer: Cigarette Smoking analyses
Initial analysis by lowest age considered: trend without 'Missing'

<30

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*ACE	2	-	-	-	-	18.56 (9.07- 37.96)	
*AEROBIC	1	100	6840	35	18088	7.56 (5.15- 11.09)	
*AGRICAN	1	-	-	-	-	28.84 (20.35- 40.87)	
*AGRICAN	2	-	-	-	-	16.53 (9.44- 28.95)	
Subtotal AGRICAN						24.69 (18.36- 33.20)	
*BWHs	3	-	-	-	-	11.78 (8.55- 16.24)	
*LSS	1	802	284498	40	65789	4.64 (3.38- 6.37)	
*LSS	2	183	97082	392	693805	3.34 (2.80- 3.98)	
Subtotal LSS						3.60 (3.09- 4.20)	
*NHIS	6	-	-	-	-	14.60 (9.10- 23.40)	
*NHIS	5	-	-	-	-	17.80 (11.40- 27.80)	
Subtotal NHIS						16.21 (11.72- 22.42)	
*QRESEAR	3	-	-	-	-	7.35 (4.54- 11.90)	
*QRESEAR	4	-	-	-	-	7.13 (4.47- 11.37)	
Subtotal QRESEAR						7.24 (5.17- 10.12)	
*THREEC	5	-	-	-	-	16.78 (10.31- 27.33)	
*VETERAN	1	54	1443	4	1798	16.82 (6.11- 46.34)	
*VLAGT	1	164	2420	0	567	77.14~ (4.81-1236.55)	
*VLAGT	4	-	-	-	-	9.27 (4.45- 19.28)	
Subtotal VLAGT						10.64 (5.24- 21.62)	
Partial Totals		1303	392283	471	780047		

*prospective study

30-39

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*ATP	9	-	-	-	-	9.33 (3.82- 22.84)	
*ATP	10	-	-	-	-	23.40 (12.26- 44.63)	
Subtotal ATP						17.07 (10.11- 28.82)	
*EPIC	3	-	-	-	-	32.00 (21.38- 47.90)	
*EPIC	6	-	-	-	-	7.53 (5.87- 9.66)	
Subtotal EPIC						11.23 (9.08- 13.88)	
*JP8	4	-	-	-	-	4.24 (2.94- 6.10)	
*JP8	8	-	-	-	-	2.62 (2.03- 3.38)	
Subtotal JP8						3.07 (2.49- 3.78)	
*NHS	2	-	-	-	-	23.30 (19.00- 28.80)	
*NLMS	4	-	-	-	-	11.82 (10.73- 13.03)	
*NOWAC	3	-	-	-	-	11.89 (9.66- 14.64)	
*THIN	1	372	134000	112	437000	10.83 (8.77- 13.38)	
*THREEC	8	273	12388	14	15703	24.72 (14.45- 42.27)	
Partial Totals		645	146388	126	452703		

*prospective study

40-48

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*ARIC	3	-	-	-	-	41.41 (18.36- 93.42)	
*ARIC	4	-	-	-	-	13.13 (8.46- 20.41)	
Subtotal ARIC						17.03 (11.56- 25.09)	
*BIOBANK	2	329	22934	78	98319	18.08 (14.13- 23.14)	
*BIOBANK	1	244	19464	127	134209	13.25 (10.70- 16.41)	
Subtotal BIOBANK						15.14 (12.88- 17.80)	
*CHANCES	2	-	-	-	-	13.10 (9.90- 17.30)	
*HPFS	3	-	-	-	-	12.56 (6.02- 26.22)	
*JPHC	1	952	21800	87	10138	5.09 (4.09- 6.33)	
*JPHC	2	61	2600	375	42155	2.64 (2.02- 3.45)	
Subtotal JPHC						3.91 (3.30- 4.64)	
*KRIS	3	-	-	-	-	10.47 (6.74- 16.25)	
*NHANES	1	144	2374	17	4853	17.32 (10.50- 28.56)	
SCCS	1	505	1209	22	686	13.02 (8.41- 20.16)	
SCCS	2	469	667	54	1203	15.66 (11.64- 21.08)	
Subtotal SCCS						14.78 (11.56- 18.89)	
*USA5	5	-	-	-	-	24.97 (22.20- 28.09)	
*USA5	6	-	-	-	-	25.66 (23.17- 28.40)	
Subtotal USA5						25.36 (23.48- 27.39)	
Partial Totals		2704	71048	760	291563		

*prospective study

Table 13
Smoking and Lung cancer: Cigarette Smoking analyses
Initial analysis by lowest age considered: trend without 'Missing'

49+

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*CPSI	5	-	-	-	-	12.22 (9.59- 15.58)	
*CPSI	6	-	-	-	-	2.73 (2.07- 3.61)	
Subtotal CPSI						6.39 (5.33- 7.68)	
*CPSII	5	-	-	-	-	23.81 (19.85- 28.57)	
*CPSII	6	-	-	-	-	12.65 (11.15- 14.34)	
Subtotal CPSII						15.52 (13.99- 17.21)	
ESTHER	1	70	239	17	704	12.13 (7.00- 21.02)	
*HBC	1	-	-	-	-	4.20 (1.60- 11.10)	
*MWOMEN	3	-	-	-	-	21.20 (19.50- 23.10)	
*NIHAARP	4	-	-	-	-	29.40 (25.20- 34.30)	
*NIHAARP	2	-	-	-	-	19.50 (17.20- 22.20)	
Subtotal NIHAARP						23.04 (20.89- 25.42)	
*NLCS	4	1502	9069	95	4345	7.57 (6.18- 9.29)	
*NLCS	5	275	6540	103	20158	8.23 (6.57- 10.30)	
Subtotal NLCS						7.86 (6.76- 9.15)	
*PLCO	2	-	-	-	-	31.97 (25.16- 40.63)	
*VITAL	1	251	6169	60	36381	24.67 (18.64- 32.65)	
*WHI	3	-	-	-	-	13.44 (10.80- 16.74)	
Partial Totals		2098	22017	275	61588		

*prospective study

Lowest age included, grouped, excluding Missing

	1	2	3	4	Total	Trend
	<30	30-39	40-48	49+		

RR Data

N	15	11	14	14	54	
NS	10	8	9	10	37	
Wt	376.10	872.10	1110.73	1787.31	4146.23	
Het Chi	207.62	250.47	429.03	434.27	1620.16	
Het df	14	10	13	13	53	
Het P	***	***	***	***	***	
Fixed RR	7.54	11.10	17.18	16.96	14.47	
RRl	6.82	10.39	16.20	16.19	14.03	
RRu	8.35	11.86	18.23	17.77	14.91	
P	+++	+++	+++	+++	+++	
Random RR	11.30	11.41	13.29	13.62	12.36	
RRl	7.37	7.80	9.15	10.22	10.33	
RRu	17.33	16.70	19.30	18.16	14.78	
P	+++	+++	+++	+++	+++	
Asymm P	*	N.S.	N.S.	N.S.	(*)	
Between Chi		39.20	190.41	203.95	298.77	243.00
Between df		1	1	1	3	1
Between P		+++	+++	+++	***	+++
Btwn (F) P		N.S.	++	++	*	++
Btwn (R) P		N.S.	N.S.	N.S.	N.S.	N.S.

Table 14
Smoking and Lung cancer: Cigarette Smoking analyses
Initial analysis by years of follow-up

<10

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*AGRICAN	1	-	-	-	-	28.84	(20.35- 40.87)
*AGRICAN	2	-	-	-	-	16.53	(9.44- 28.95)
Subtotal AGRICAN						24.69	(18.36- 33.20)
*CPSI	5	-	-	-	-	12.22	(9.59- 15.58)
*CPSI	6	-	-	-	-	2.73	(2.07- 3.61)
Subtotal CPSI						6.39	(5.33- 7.68)
*CPSII	5	-	-	-	-	23.81	(19.85- 28.57)
*CPSII	6	-	-	-	-	12.65	(11.15- 14.34)
Subtotal CPSII						15.52	(13.99- 17.21)
*EPIC	6	-	-	-	-	7.53	(5.87- 9.66)
*HBC	1	-	-	-	-	4.20	(1.60- 11.10)
*NHIS	6	-	-	-	-	14.60	(9.10- 23.40)
*NHIS	5	-	-	-	-	17.80	(11.40- 27.80)
Subtotal NHIS						16.21	(11.72- 22.42)
*VITAL	1	251	6169	60	36381	24.67	(18.64- 32.65)
Partial Totals		251	6169	60	36381		

*prospective study

10-<15

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*ACE	2	-	-	-	-	18.56	(9.07- 37.96)
*AMIAN	1	61	2224	13	2645	5.58	(3.07- 10.13)
*BIOBANK	2	329	22934	78	98319	18.08	(14.13- 23.14)
*BIOBANK	1	244	19464	127	134209	13.25	(10.70- 16.41)
Subtotal BIOBANK						15.14	(12.88- 17.80)
*EPIC	3	-	-	-	-	32.00	(21.38- 47.90)
*HPFS	3	-	-	-	-	12.56	(6.02- 26.22)
*NIHAARP	4	-	-	-	-	29.40	(25.20- 34.30)
*NIHAARP	2	-	-	-	-	19.50	(17.20- 22.20)
Subtotal NIHAARP						23.04	(20.89- 25.42)
SCCS	1	505	1209	22	686	13.02	(8.41- 20.16)
SCCS	2	469	667	54	1203	15.66	(11.64- 21.08)
Subtotal SCCS						14.78	(11.56- 18.89)
*THIN	1	372	134000	112	437000	10.83	(8.77- 13.38)
Partial Totals		1980	180498	406	674062		

*prospective study

15-<20

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*AHS	2	-	-	-	-	23.03	(17.34- 30.59)
*ARIC	3	-	-	-	-	41.41	(18.36- 93.42)
*ARIC	4	-	-	-	-	13.13	(8.46- 20.41)
Subtotal ARIC						17.03	(11.56- 25.09)
*ATP	9	-	-	-	-	9.33	(3.82- 22.84)
*ATP	10	-	-	-	-	23.40	(12.26- 44.63)
Subtotal ATP						17.07	(10.11- 28.82)
*BWHS	3	-	-	-	-	11.78	(8.55- 16.24)
ESTHER	1	70	239	17	704	12.13	(7.00- 21.02)
*MWOMEN	3	-	-	-	-	21.20	(19.50- 23.10)
*NHANES	1	144	2374	17	4853	17.32	(10.50- 28.56)
*NLST	2	-	-	-	-	24.32	(10.98- 53.85)
*PLCO	2	-	-	-	-	31.97	(25.16- 40.63)
*QRESEAR	3	-	-	-	-	7.35	(4.54- 11.90)
*QRESEAR	4	-	-	-	-	7.13	(4.47- 11.37)
Subtotal QRESEAR						7.24	(5.17- 10.12)
*WHI	3	-	-	-	-	13.44	(10.80- 16.74)
Partial Totals		214	2613	34	5557		

*prospective study

Table 14
Smoking and Lung cancer: Cigarette Smoking analyses
Initial analysis by years of follow-up

20-<30

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*AEROBIC	1	100	6840	35	18088	7.56	(5.15- 11.09)
*CHANCES	2	-	-	-	-	13.10	(9.90- 17.30)
*JP8	4	-	-	-	-	4.24	(2.94- 6.10)
*JP8	8	-	-	-	-	2.62	(2.03- 3.38)
Subtotal JP8						3.07	(2.49- 3.78)
*JPHC	1	952	21800	87	10138	5.09	(4.09- 6.33)
*JPHC	2	61	2600	375	42155	2.64	(2.02- 3.45)
Subtotal JPHC						3.91	(3.30- 4.64)
*NHS	2	-	-	-	-	23.30	(19.00- 28.80)
*NLCS	4	1502	9069	95	4345	7.57	(6.18- 9.29)
*NLCS	5	275	6540	103	20158	8.23	(6.57- 10.30)
Subtotal NLCS						7.86	(6.76- 9.15)
*NLMS	4	-	-	-	-	11.82	(10.73- 13.03)
*NOWAC	3	-	-	-	-	11.89	(9.66- 14.64)
*SHEETME	1	410	4400	53	4503	7.92	(5.97- 10.51)
*USA5	5	-	-	-	-	24.97	(22.20- 28.09)
*USA5	6	-	-	-	-	25.66	(23.17- 28.40)
Subtotal USA5						25.36	(23.48- 27.39)
*VETERAN	1	54	1443	4	1798	16.82	(6.11- 46.34)
Partial Totals		3354	52692	752	101185		

*prospective study

30+

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*COAL	1	-	-	-	-	9.20	(5.30- 16.00)
*FRAMING	2	-	-	-	-	7.55	(4.94- 11.55)
*KAISER	2	-	-	-	-	13.20	(11.10- 15.70)
*KRIS	3	-	-	-	-	10.47	(6.74- 16.25)
*LSS	1	802	284498	40	65789	4.64	(3.38- 6.37)
*LSS	2	183	97082	392	693805	3.34	(2.80- 3.98)
Subtotal LSS						3.60	(3.09- 4.20)
NONMET	2	-	-	-	-	7.97	(4.17- 15.27)
*THREEC	5	-	-	-	-	16.78	(10.31- 27.33)
*THREEC	8	273	12388	14	15703	24.72	(14.45- 42.27)
Subtotal THREEC						19.99	(13.94- 28.68)
*VLAGT	1	164	2420	0	567	77.14	(4.81-1236.55)
*VLAGT	4	-	-	-	-	9.27	(4.45- 19.28)
Subtotal VLAGT						10.64	(5.24- 21.62)
Partial Totals		1422	396388	446	775864		

*prospective study

Years follow-up, grouped

1 2 3 4 5
<10 10-<15 15-<20 20-<30 30+ Total Trend

RR Data

N	11	11	14	15	11	62	
NS	7	8	11	11	8	45	
Wt	668.81	743.64	875.21	1751.04	390.90	4429.58	
Het Chi	230.34	96.75	88.18	781.63	166.83	1674.66	
Het df	10	10	13	14	10	61	
Het P	***	***	***	***	***	***	
Fixed RR	13.22	18.37	19.31	13.22	7.39	14.30	
RRl	12.25	17.09	18.07	12.61	6.69	13.89	
RRu	14.26	19.74	20.63	13.85	8.16	14.73	
P	+++	+++	+++	+++	+++	+++	
Random RR	12.63	16.05	16.05	9.08	9.57	12.14	
RRl	8.49	12.48	12.69	6.26	6.01	10.30	
RRu	18.80	20.65	20.30	13.15	15.26	14.30	
P	+++	+++	+++	+++	+++	+++	
Asymm P	N.S.	N.S.	N.S.	*	N.S.	*	
Between Chi		38.16	54.52	0.00	83.36	310.92	80.69
Between df		1	1	1	1	4	1
Between P		+++	+++	N.S.	---	***	---
Btwn (F) P		N.S.	(+)	N.S.	(-)	*	(-)
Btwn (R) P		N.S.	N.S.	N.S.	N.S.	*	(-)

Table 15
Smoking and Lung cancer: Cigarette Smoking analyses
Initial analysis by endpoint

Died

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*ACE	2	-	-	-	-	18.56 (9.07- 37.96)	
*AEROBIC	1	100	6840	35	18088	7.56 (5.15- 11.09)	
*COAL	1	-	-	-	-	9.20 (5.30- 16.00)	
*CPSI	5	-	-	-	-	12.22 (9.59- 15.58)	
*CPSI	6	-	-	-	-	2.73 (2.07- 3.61)	
Subtotal CPSI						6.39 (5.33- 7.68)	
*CPSII	5	-	-	-	-	23.81 (19.85- 28.57)	
*CPSII	6	-	-	-	-	12.65 (11.15- 14.34)	
Subtotal CPSII						15.52 (13.99- 17.21)	
*MWOMEN	3	-	-	-	-	21.20 (19.50- 23.10)	
*NHANES	1	144	2374	17	4853	17.32 (10.50- 28.56)	
*NHIS	6	-	-	-	-	14.60 (9.10- 23.40)	
*NHIS	5	-	-	-	-	17.80 (11.40- 27.80)	
Subtotal NHIS						16.21 (11.72- 22.42)	
*NHS	2	-	-	-	-	23.30 (19.00- 28.80)	
*NLMS	4	-	-	-	-	11.82 (10.73- 13.03)	
*NLST	2	-	-	-	-	24.32 (10.98- 53.85)	
NONMET	2	-	-	-	-	7.97 (4.17- 15.27)	
*PLCO	2	-	-	-	-	31.97 (25.16- 40.63)	
*SHEETME	1	410	4400	53	4503	7.92 (5.97- 10.51)	
*THREEC	5	-	-	-	-	16.78 (10.31- 27.33)	
*THREEC	8	273	12388	14	15703	24.72 (14.45- 42.27)	
Subtotal THREEC						19.99 (13.94- 28.68)	
*USA5	5	-	-	-	-	24.97 (22.20- 28.09)	
*USA5	6	-	-	-	-	25.66 (23.17- 28.40)	
Subtotal USA5						25.36 (23.48- 27.39)	
*VLAGT	1	164	2420	0	567	77.14~(4.81-1236.55)	
*VLAGT	4	-	-	-	-	9.27 (4.45- 19.28)	
Subtotal VLAGT						10.64 (5.24- 21.62)	
Partial Totals		1091	28422	119	43714		
*prospective study							

Diagnosed

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*AGRICAN	1	-	-	-	-	28.84 (20.35- 40.87)	
*AGRICAN	2	-	-	-	-	16.53 (9.44- 28.95)	
Subtotal AGRICAN						24.69 (18.36- 33.20)	
*AHS	2	-	-	-	-	23.03 (17.34- 30.59)	
*AMIAANT	1	61	2224	13	2645	5.58 (3.07- 10.13)	
*ARIC	3	-	-	-	-	41.41 (18.36- 93.42)	
*ARIC	4	-	-	-	-	13.13 (8.46- 20.41)	
Subtotal ARIC						17.03 (11.56- 25.09)	
*ATP	9	-	-	-	-	9.33 (3.82- 22.84)	
*ATP	10	-	-	-	-	23.40 (12.26- 44.63)	
Subtotal ATP						17.07 (10.11- 28.82)	
*BIOBANK	2	329	22934	78	98319	18.08 (14.13- 23.14)	
*BIOBANK	1	244	19464	127	134209	13.25 (10.70- 16.41)	
Subtotal BIOBANK						15.14 (12.88- 17.80)	
*BWHS	3	-	-	-	-	11.78 (8.55- 16.24)	
*CHANCES	2	-	-	-	-	13.10 (9.90- 17.30)	
*EPIC	3	-	-	-	-	32.00 (21.38- 47.90)	
*EPIC	6	-	-	-	-	7.53 (5.87- 9.66)	
Subtotal EPIC						11.23 (9.08- 13.88)	
ESTHER	1	70	239	17	704	12.13 (7.00- 21.02)	
*FRAMING	2	-	-	-	-	7.55 (4.94- 11.55)	
*HBC	1	-	-	-	-	4.20 (1.60- 11.10)	
*HPFS	3	-	-	-	-	12.56 (6.02- 26.22)	
*JP8	4	-	-	-	-	4.24 (2.94- 6.10)	
*JP8	8	-	-	-	-	2.62 (2.03- 3.38)	
Subtotal JP8						3.07 (2.49- 3.78)	
*JPHC	1	952	21800	87	10138	5.09 (4.09- 6.33)	
*JPHC	2	61	2600	375	42155	2.64 (2.02- 3.45)	
Subtotal JPHC						3.91 (3.30- 4.64)	
*KAISER	2	-	-	-	-	13.20 (11.10- 15.70)	
*KRIS	3	-	-	-	-	10.47 (6.74- 16.25)	
*LSS	1	802	284498	40	65789	4.64 (3.38- 6.37)	
*LSS	2	183	97082	392	693805	3.34 (2.80- 3.98)	
Subtotal LSS						3.60 (3.09- 4.20)	
*NIHAARP	4	-	-	-	-	29.40 (25.20- 34.30)	
*NIHAARP	2	-	-	-	-	19.50 (17.20- 22.20)	
Subtotal NIHAARP						23.04 (20.89- 25.42)	
*NLCS	4	1502	9069	95	4345	7.57 (6.18- 9.29)	

Table 15
Smoking and Lung cancer: Cigarette Smoking analyses
Initial analysis by endpoint

Diagnosed

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*NLCS	5	275	6540	103	20158	8.23	(6.57- 10.30)
Subtotal NLCS						7.86	(6.76- 9.15)
*NOWAC	3	-	-	-	-	11.89	(9.66- 14.64)
*QRESEAR	3	-	-	-	-	7.35	(4.54- 11.90)
*QRESEAR	4	-	-	-	-	7.13	(4.47- 11.37)
Subtotal QRESEAR						7.24	(5.17- 10.12)
SCCS	1	505	1209	22	686	13.02	(8.41- 20.16)
SCCS	2	469	667	54	1203	15.66	(11.64- 21.08)
Subtotal SCCS						14.78	(11.56- 18.89)
*THIN	1	372	134000	112	437000	10.83	(8.77- 13.38)
*VETERAN	1	54	1443	4	1798	16.82	(6.11- 46.34)
*VITAL	1	251	6169	60	36381	24.67	(18.64- 32.65)
*WHI	3	-	-	-	-	13.44	(10.80- 16.74)
Partial Totals		6130	609938	1579	1549335		

*prospective study

RR Description:Endpoint reported

	1	2	Total
Died			
Diagnosed			

RR Data

	N	23	39	62
NS		17	27	44
Wt	2418.74	2010.84	4429.58	
Het Chi	486.00	958.30	1674.66	
Het df	22	38	61	
Het P	***	***	***	
Fixed RR	17.61	11.14	14.30	
RRl	16.92	10.66	13.89	
RRu	18.32	11.63	14.73	
P	+++	+++	+++	
Random RR	14.85	10.82	12.14	
RRl	11.99	8.61	10.30	
RRu	18.38	13.60	14.30	
P	+++	+++	+++	
Asymm P	N.S.	N.S.	*	
Between Chi		230.35	230.35	
Between df		1	1	
Between P		---	***	
Btwn (F) P		--	**	
Btwn (R) P		-	*	

Table 16
Smoking and Lung cancer: Cigarette Smoking analyses
Initial analysis by number of adjustment factors

Unadj		Numbers exposed		Non-exposed		RR	95.00%CI
STUDY	NRR	Case	Cont	Case	Cont		
*AEROBIC	1	100	6840	35	18088	7.56	(5.15- 11.09)
*AMIANT	1	61	2224	13	2645	5.58	(3.07- 10.13)
*BIOBANK	2	329	22934	78	98319	18.08	(14.13- 23.14)
*BIOBANK	1	244	19464	127	134209	13.25	(10.70- 16.41)
Subtotal BIOBANK						15.14	(12.88- 17.80)
ESTHER	1	70	239	17	704	12.13	(7.00- 21.02)
*JPHC	1	952	21800	87	10138	5.09	(4.09- 6.33)
*JPHC	2	61	2600	375	42155	2.64	(2.02- 3.45)
Subtotal JPHC						3.91	(3.30- 4.64)
*LSS	1	802	284498	40	65789	4.64	(3.38- 6.37)
*LSS	2	183	97082	392	693805	3.34	(2.80- 3.98)
Subtotal LSS						3.60	(3.09- 4.20)
*NHANES	1	144	2374	17	4853	17.32	(10.50- 28.56)
*NLCS	4	1502	9069	95	4345	7.57	(6.18- 9.29)
*NLCS	5	275	6540	103	20158	8.23	(6.57- 10.30)
Subtotal NLCS						7.86	(6.76- 9.15)
SCCS	1	505	1209	22	686	13.02	(8.41- 20.16)
SCCS	2	469	667	54	1203	15.66	(11.64- 21.08)
Subtotal SCCS						14.78	(11.56- 18.89)
*SHEETME	1	410	4400	53	4503	7.92	(5.97- 10.51)
*THIN	1	372	134000	112	437000	10.83	(8.77- 13.38)
*THREEC	8	273	12388	14	15703	24.72	(14.45- 42.27)
*VETERAN	1	54	1443	4	1798	16.82	(6.11- 46.34)
*VITAL	1	251	6169	60	36381	24.67	(18.64- 32.65)
*VLAGT	1	164	2420	0	567	77.14	(4.81-1236.55)
Totals		7221	638360	1698	1593049		

*prospective study

Age-only

Age-only		Numbers exposed		Non-exposed		RR	95.00%CI
STUDY	NRR	Case	Cont	Case	Cont		
*AGRICAN	1	-	-	-	-	28.84	(20.35- 40.87)
*AGRICAN	2	-	-	-	-	16.53	(9.44- 28.95)
Subtotal AGRICAN						24.69	(18.36- 33.20)
*FRAMING	2	-	-	-	-	7.55	(4.94- 11.55)
*HBC	1	-	-	-	-	4.20	(1.60- 11.10)
Partial Totals		0	0	0	0		

*prospective study

More adj

More adj		Numbers exposed		Non-exposed		RR	95.00%CI
STUDY	NRR	Case	Cont	Case	Cont		
*ACE	2	-	-	-	-	18.56	(9.07- 37.96)
*AHS	2	-	-	-	-	23.03	(17.34- 30.59)
*ARIC	3	-	-	-	-	41.41	(18.36- 93.42)
*ARIC	4	-	-	-	-	13.13	(8.46- 20.41)
Subtotal ARIC						17.03	(11.56- 25.09)
*ATP	9	-	-	-	-	9.33	(3.82- 22.84)
*ATP	10	-	-	-	-	23.40	(12.26- 44.63)
Subtotal ATP						17.07	(10.11- 28.82)
*BWHS	3	-	-	-	-	11.78	(8.55- 16.24)
*CHANCES	2	-	-	-	-	13.10	(9.90- 17.30)
*COAL	1	-	-	-	-	9.20	(5.30- 16.00)
*CPSI	5	-	-	-	-	12.22	(9.59- 15.58)
*CPSI	6	-	-	-	-	2.73	(2.07- 3.61)
Subtotal CPSI						6.39	(5.33- 7.68)
*CPSII	5	-	-	-	-	23.81	(19.85- 28.57)
*CPSII	6	-	-	-	-	12.65	(11.15- 14.34)
Subtotal CPSII						15.52	(13.99- 17.21)
*EPIC	3	-	-	-	-	32.00	(21.38- 47.90)
*EPIC	6	-	-	-	-	7.53	(5.87- 9.66)
Subtotal EPIC						11.23	(9.08- 13.88)
*HPFS	3	-	-	-	-	12.56	(6.02- 26.22)
*JP8	4	-	-	-	-	4.24	(2.94- 6.10)
*JP8	8	-	-	-	-	2.62	(2.03- 3.38)
Subtotal JP8						3.07	(2.49- 3.78)
*KAISER	2	-	-	-	-	13.20	(11.10- 15.70)
*KRIS	3	-	-	-	-	10.47	(6.74- 16.25)
*MWOMEN	3	-	-	-	-	21.20	(19.50- 23.10)
*NHIS	6	-	-	-	-	14.60	(9.10- 23.40)
*NHIS	5	-	-	-	-	17.80	(11.40- 27.80)
Subtotal NHIS						16.21	(11.72- 22.42)
*NHS	2	-	-	-	-	23.30	(19.00- 28.80)

Table 16
Smoking and Lung cancer: Cigarette Smoking analyses
Initial analysis by number of adjustment factors

More adj

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI	
		Case	Cont	Case	Cont			
*NIHAARP	4	-	-	-	-	29.40	(25.20-	34.30)
*NIHAARP	2	-	-	-	-	19.50	(17.20-	22.20)
Subtotal NIHAARP						23.04	(20.89-	25.42)
*NLMS	4	-	-	-	-	11.82	(10.73-	13.03)
*NLST	2	-	-	-	-	24.32	(10.98-	53.85)
NONMET	2	-	-	-	-	7.97	(4.17-	15.27)
*NOWAC	3	-	-	-	-	11.89	(9.66-	14.64)
*PLCO	2	-	-	-	-	31.97	(25.16-	40.63)
*QRESEAR	3	-	-	-	-	7.35	(4.54-	11.90)
*QRESEAR	4	-	-	-	-	7.13	(4.47-	11.37)
Subtotal QRESEAR						7.24	(5.17-	10.12)
*THREEC	5	-	-	-	-	16.78	(10.31-	27.33)
*USA5	5	-	-	-	-	24.97	(22.20-	28.09)
*USA5	6	-	-	-	-	25.66	(23.17-	28.40)
Subtotal USA5						25.36	(23.48-	27.39)
*VLAGT	4	-	-	-	-	9.27	(4.45-	19.28)
*WHI	3	-	-	-	-	13.44	(10.80-	16.74)
Partial Totals		0	0	0	0			

*prospective study

Number of adjustment factors, grouped

	1	2	3		
	Unadj	Age-only	More adj	Total	Trend

RR Data

N	20	4	38	62	
NS	15	3	28	46	
Wt	941.88	69.23	3418.47	4429.58	
Het Chi	381.72	30.24	881.00	1674.66	
Het df	19	3	37	61	
Het P	***	***	***	***	
Fixed RR	8.13	15.44	16.68	14.30	
RRl	7.63	12.20	16.13	13.89	
RRu	8.67	19.54	17.25	14.73	
P	+++	+++	+++	+++	
Random RR	9.65	11.80	13.68	12.14	
RRl	7.13	5.24	11.46	10.30	
RRu	13.05	26.56	16.34	14.30	
P	+++	+++	+++	+++	
Asymm P	N.S.	N.S.	(*)	*	
Between Chi		26.52	381.29	381.70	376.32
Between df		1	1	2	1
Between P		+++	+++	***	+++
Btwn (F) P		N.S.	+++	***	+++
Btwn (R) P		N.S.	(+)	N.S.	(+)

Table 17
Smoking and Lung cancer: Cigarette Smoking analyses
List of the selected results with RR values for male/female (M/F) ratio - Current cigarette smokers versus never smokers

Study ID	NRR M	RR Male	RRL M	RRU M	NRR F	RR Female	RRL F	RRU F	RR M/F	RRL M/F	RRU M/F
AGRICAN	1	28.84	20.35	40.87	2	16.53	9.44	28.95	1.74	0.90	3.38
ARIC	3	41.41	18.36	93.42	4	13.13	8.46	20.41	3.15	1.25	7.95
ATP	9	9.33	3.82	22.84	10	23.40	12.26	44.63	0.40	0.13	1.20
BIOBANK	2	18.08	14.13	23.14	1	13.25	10.70	16.41	1.36	0.98	1.89
CPSI	5	12.22	9.59	15.58	6	2.73	2.07	3.61	4.48	3.09	6.47
CPSII	5	23.81	19.85	28.57	6	12.65	11.15	14.34	1.88	1.51	2.35
EPIC	5	23.30	16.40	33.20	6	7.53	5.87	9.66	3.09	2.01	4.76
JP8	4	4.24	2.94	6.10	8	2.62	2.03	3.38	1.62	1.04	2.53
JPHC	1	5.09	4.09	6.33	2	2.64	2.02	3.45	1.93	1.37	2.73
LSS	1	4.64	3.38	6.37	2	3.34	2.80	3.98	1.39	0.97	2.00
NHIS	6	14.60	9.10	23.40	5	17.80	11.40	27.80	0.82	0.43	1.57
NIHAARP	4	29.40	25.20	34.30	2	19.50	17.20	22.20	1.51	1.23	1.84
NLCS	4	7.57	6.18	9.29	5	8.23	6.57	10.30	0.92	0.68	1.25
QRESEAR	3	7.35	4.54	11.90	4	7.13	4.47	11.37	1.03	0.53	2.02
SCCS	1	13.02	8.41	20.16	2	15.66	11.64	21.08	0.83	0.49	1.41
THREEC	7	44.18	19.77	98.75	8	24.72	14.45	42.27	1.79	0.68	4.70
USA5	5	24.97	22.20	28.09	6	25.66	23.17	28.40	0.97	0.83	1.14
VLAGT	1	77.14	4.81	1236.55	2	4.47	2.30	8.67	17.25	1.00	299.01

Table 18
Smoking and Lung cancer: Cigarette Smoking analyses
Meta-analysis analysis of M/F ratio

1

STUDY	NRR	Numbers exposed Non-exposed				RR	95.00%CI
		Case	Cont	Case	Cont		
*AGRICAN	2	-	-	-	-	1.74 (0.90- 3.38)	
*ARIC	4	-	-	-	-	3.15 (1.25- 7.95)	
*ATP	10	-	-	-	-	0.40 (0.13- 1.20)	
*BIOBANK	1	-	-	-	-	1.36 (0.98- 1.89)	
*CPSI	6	-	-	-	-	4.48 (3.09- 6.47)	
*CPSII	6	-	-	-	-	1.88 (1.51- 2.35)	
*EPIC	6	-	-	-	-	3.09 (2.01- 4.76)	
*JP8	8	-	-	-	-	1.62 (1.04- 2.53)	
*JPHC	2	-	-	-	-	1.93 (1.37- 2.73)	
*LSS	2	-	-	-	-	1.39 (0.97- 2.00)	
*NHIS	5	-	-	-	-	0.82 (0.43- 1.57)	
*NIHAARP	2	-	-	-	-	1.51 (1.23- 1.84)	
*NLCS	5	-	-	-	-	0.92 (0.68- 1.25)	
*QRESEAR	4	-	-	-	-	1.03 (0.53- 2.02)	
SCCS	2	-	-	-	-	0.83 (0.49- 1.41)	
*THREEC	8	-	-	-	-	1.79 (0.68- 4.70)	
*USA5	6	-	-	-	-	0.97 (0.83- 1.14)	
*VLAGT	2	-	-	-	-	17.25 (1.00- 299.01)	
Partial Totals		0.00	0.00	0.00	0.00		

*prospective study

Group
1
1 Total

M/F ratio

N	18	18
NS	18	18
Wt	592.92	592.92
Het Chi	109.22	109.22
Het df	17	17
Het P	***	***
Fixed RR	1.41	1.41
RRl	1.30	1.30
RRu	1.53	1.53
P	+++	+++
Random RR	1.52	1.52
RRl	1.20	1.20
RRu	1.92	1.92
P	+++	+++
Asymm P	N.S.	N.S.
Between Chi		
Between df		
Between P		N.S.
Btwn (F) P		N.S.
Btwn (R) P		N.S.

Table 19
Smoking and Lung cancer: Cigarette Smoking analyses
List of the selected results together with the ratio of the RR values for multiply-adjusted/unadjusted - Current cigarette

Study ID	Sex	NRR adjust	Adj	RR adjust	NRR unadj	RR unadj	adj/unadj RR ratio
ACE	b	2	8	18.56	1	16.00	1.16
AHS	b	2	8	23.03	1	24.50	0.94
ARIC	m	3	3	41.41	1	37.73	1.10
ARIC	f	4	3	13.13	2	11.70	1.12
ATP	m	9	7	9.33	7	11.63	0.80
ATP	f	10	7	23.40	8	17.20	1.36
BWHS	f	3	7	11.78	1	17.12	0.69
CHANCES	b	2	7	13.10	1	17.18	0.76
CPSI	m	5	3	12.22	1	12.96	0.94
CPSI	f	6	3	2.73	2	2.35	1.16
CPSII	m	5	3	23.81	1	21.58	1.10
CPSII	f	6	3	12.65	2	11.03	1.15
EPIC	m	3	5	32.00	1	32.12	1.00
HPFS	m	3	4	12.56	1	29.72	0.42
JP8	m	3	5	4.13	1	1.19	3.46
JP8	f	7	5	2.40	5	3.68	0.65
JPHC	m	4	10	4.70	3	4.55	1.03
JPHC	f	6	10	3.28	5	3.39	0.97
KAISER	b	2	6	13.20	1	10.60	1.24
KRIS	m	3	4	10.47	1	12.07	0.87
MWOMEN	f	2	10	21.40	1	21.52	0.99
NHIS	f	5	4	17.80	3	9.86	1.80
NHIS	m	6	4	14.60	4	11.71	1.25
NIHAARP	f	2	5	19.50	1	17.30	1.13
NIHAARP	m	4	5	29.40	3	26.64	1.10
NLMS	b	4	5	11.82	1	11.86	1.00
NLST	m	2	2	24.32	1	36.59	0.66
NONMET	m	2	7	7.97	1	6.86	1.16
NOWAC	f	3	3	11.89	1	10.73	1.11
QRESEAR	m	3	6	7.35	1	7.15	1.03
QRESEAR	f	4	6	7.13	2	6.81	1.05
THREEC	m	5	10	16.78	1	32.58	0.52
USA5	m	5	3	24.97	1	15.86	1.57
USA5	f	6	3	25.66	2	14.71	1.74
VLAGT	f	4	3	9.27	2	4.47	2.07
WHI	f	3	15	13.44	1	12.06	1.11

Table 20
Smoking and Lung cancer: Cigarette Smoking analyses
Studies in North America and Europe only
List of the selected results - Initial analyses. Current cigarette smokers versus never smokers, no overlapping results for any study

Study ID	NRR	REFID	Country	Study population	YRST	NCASES	Product Sm	Excl	Latent	Study design	Sex	LowAge	HighAge	YrsFU	Endpoint	Adj
ACE	2	BROWN2010B	USA	Regional	1995	111	Cigarettes	0	0	Cohort	b	18	999	10	Died	8
AEROBIC	1	SUI2010	USA	Regional	1974	232	Cigarettes	0	0	Cohort	m	20	84	29	Died	0
AGRICAN	1	TUAL2017	France	Regional	2005	664	Cigarettes	0	0	Cohort	m	18	999	6	Diagnosed	1
AGRICAN	2	TUAL2017	France	Regional	2005	664	Cigarettes	0	0	Cohort	f	18	999	6	Diagnosed	1
AHS	2	ANDREO2017	USA	Pesticide workers	1993	789	Cigarettes	x	0	Cohort	b	*	*	18	Diagnosed	8
AMIANT	1	SWIATK2017	Poland	Asbestos workers	2000	110	Cigarettes	0	0	Cohort	b	*	*	14	Diagnosed	0
ARIC	3	PRIZME2014	USA	Regional	1987	470	Cigarettes	0	0	Cohort	m	45	64	19	Diagnosed	3
ARIC	4	PRIZME2014	USA	Regional	1987	470	Cigarettes	0	0	Cohort	f	45	64	19	Diagnosed	3
ATP	9	VINER2019	Canada	Regional	2001	210	Cigarettes	0	x	Cohort	m	35	69	16	Diagnosed	7
ATP	10	VINER2019	Canada	Regional	2001	210	Cigarettes	0	x	Cohort	f	35	69	16	Diagnosed	7
BIOBANK	1	WONG2020	UK	National	2006	1493	Cigarettes	0	0	Cohort	f	40	73	10	Diagnosed	0
BIOBANK	2	WONG2020	UK	National	2006	1493	Cigarettes	0	0	Cohort	m	40	73	10	Diagnosed	0
BWHS	3	NOMURA2018	USA	National	1995	306	Cigarettes	0	0	Cohort	f	21	69	18	Diagnosed	7
CHANCES	2	ORDONE2016	Multiple	International	1982	14041	Cigarettes	0	0	Cohort	b	46	74	29	Diagnosed	7
COAL	1	GRABER2014	USA	Coal miners	1969	568	Cigarettes	0	0	Cohort	m	*	*	38	Died	7
CPSI	5	THUN2013	USA	National	1959	1293	Cigarettes	x	0	Cohort	m	49	999	6	Died	3
CPSI	6	THUN2013	USA	National	1959	1293	Cigarettes	x	0	Cohort	f	49	999	6	Died	3
CPSII	5	THUN2013	USA	National	1982	4957	Cigarettes	x	0	Cohort	m	49	999	6	Died	3
CPSII	6	THUN2013	USA	National	1982	4957	Cigarettes	x	0	Cohort	f	49	999	6	Died	3
EPIC	3	MCCORM2010	Multiple	International	1991	2995	Cigarettes	x	0	Cohort	m	35	70	14	Diagnosed	5
EPIC	6	AGUDO2012	Multiple	International	1991	2995	Cigarettes	0	0	Cohort	f	30	70	8	Diagnosed	7
ESTHER	1	YU2020F	Germany	Regional	2000	143	Cigarettes	0	0	Nested CC	b	50	75	17	Diagnosed	0
FRAMING	2	TINDLE2018	USA	Regional	1954	284	Cigarettes	0	0	Cohort	b	*	*	59	Diagnosed	1
HBC	1	ERIKSS2010	Finland	Regional	2001	121	Cigarettes	0	0	Cohort	b	55	65	5	Diagnosed	1
HPFS	3	ALDELA2011	USA	Medical workers	1986	210	Cigarettes	0	0	Nested CC	m	40	75	14	Diagnosed	4
KAISER	2	TRAN2013	USA	Regional	1978	1415	Cigarettes	0	0	Cohort	b	*	*	30	Diagnosed	6
KRIS	3	EVERAT2014A	Lithuania	Regional	1972	343	Cigarettes	0	x	Cohort	m	40	59	36	Diagnosed	4
MWOMEN	3	PIRIE2013	UK	National	1996	6331	Cigarettes	x	x	Cohort	f	50	69	15	Died	10
NHANES	1	BITTON2017	USA	National	1988	269	Cigarettes	0	0	Cohort	b	40	999	18	Died	0
NHIS	5	JHA2013	USA	National	1987	7420	Cigarettes	0	x	Cohort	f	25	79	9	Died	4
NHIS	6	JHA2013	USA	National	1987	7420	Cigarettes	0	x	Cohort	m	25	79	9	Died	4
NHS	2	KENFIE2010	USA	Medical workers	1980	1729	Cigarettes	0	0	Cohort	f	34	59	24	Died	13
NIHAARP	2	FREEDM2016	USA	Regional	1995	17846	Cigarettes	x	x	Cohort	f	50	71	11	Diagnosed	5
NIHAARP	4	FREEDM2016	USA	Regional	1995	17846	Cigarettes	x	x	Cohort	m	50	71	11	Diagnosed	5
NLCS	4	NIEUWE2019	Netherlands	National	1986	3355	Cigarettes	0	0	Nested CC	m	55	69	20	Diagnosed	0
NLCS	5	NIEUWE2019	Netherlands	National	1986	3355	Cigarettes	0	0	Nested CC	f	55	69	20	Diagnosed	0
NLMS	4	CHRIST2018	USA	National	1985	3890	Cigarettes	x	0	Cohort	b	35	80	26	Died	5
NLST	2	DEMENT2020	USA	Construction workers	1998	352	Cigarettes	0	0	Cohort	m	*	*	18	Died	2
NONMET	2	SILVER2012	USA	Non-metal miners	1947	198	Cigarettes	0	0	Nested CC	m	*	*	50	Died	7

Table 20
Smoking and Lung cancer: Cigarette Smoking analyses
Studies in North America and Europe only
List of the selected results - Initial analyses. Current cigarette smokers versus never smokers, no overlapping results for any study

Study ID	NRR	REFID	Country	Study population	YRST	NCASES	Product Sm	Excl	Latent	Study design	Sex	LowAge	HighAge	YrsFU	Endpoint	Adj
NOWAC	3	HANSEN2021	Norway	National	1991	1507	Cigarettes	0	0	Cohort	f	31	70	24	Diagnosed	3
PLCO	2	ABDELR2020A	USA	Regional	1993	1040	Cigarettes	0	0	Cohort	f	55	74	15	Died	6
QRESEAR	3	HIPPIS2015	UK	National	1998	32187	Cigarettes	0	0	Cohort	m	25	84	15	Diagnosed	6
QRESEAR	4	HIPPIS2015	UK	National	1998	32187	Cigarettes	0	0	Cohort	f	25	84	15	Diagnosed	6
SCCS	1	SANDER2018	USA	Regional	2002	1334	Cigarettes	0	0	Nested CC	m	40	79	14	Diagnosed	0
SCCS	2	SANDER2018	USA	Regional	2002	1334	Cigarettes	0	0	Nested CC	f	40	79	14	Diagnosed	0
SHEETME	1	WELCH2015	Multiple	Sheet metal workers	1986	808	Cigarettes	0	0	Cohort	m	*	*	24	Died	0
THIN	1	HORSFA2014	UK	National	2000	1015	Cigarettes	0	0	Cohort	b	30	99	12	Diagnosed	0
THREEC	5	TVERDA2011	Norway	Regional	1974	858	Cigarettes	x	0	Cohort	m	20	49	33	Died	10
THREEC	8	HJELLV2013	Norway	Regional	1974	858	Cigarettes	0	x	Cohort	f	35	49	35	Died	0
USA5	5	THUN2013	USA	National	1986	11420	Cigarettes	0	0	Cohort	m	45	999	24	Died	3
USA5	6	THUN2013	USA	National	1986	11420	Cigarettes	0	0	Cohort	f	45	999	24	Died	3
VETERAN	1	VAINSH2019	USA	Regional	1987	105	Cigarettes	0	0	Cohort	m	21	89	28	Diagnosed	0
VITAL	1	BRASKY2017	USA	Regional	2000	797	Cigarettes	0	0	Cohort	b	50	76	7	Diagnosed	0
VLAGT	1	TAGHIZ2016	Netherlands	Regional	1965	275	Cigarettes	0	0	Cohort	m	20	65	43	Died	0
VLAGT	4	TAGHIZ2016	Netherlands	Regional	1965	275	Cigarettes	0	0	Cohort	f	20	65	43	Died	3
WHI	3	WANG2015B	USA	National	1993	901	Cigarettes	0	0	Cohort	f	50	79	16	Diagnosed	15

Table 21
Smoking and Lung cancer: Cigarette Smoking analyses
Studies in North America and Europe only
Initial analysis by sex

Combined

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*ACE	2	-	-	-	-	18.56 (9.07- 37.96)	
*AHS	2	-	-	-	-	23.03 (17.34- 30.59)	
*AMIAN	1	61	2224	13	2645	5.58 (3.07- 10.13)	
*CHANCES	2	-	-	-	-	13.10 (9.90- 17.30)	
ESTHER	1	70	239	17	704	12.13 (7.00- 21.02)	
*FRAMING	2	-	-	-	-	7.55 (4.94- 11.55)	
*HBC	1	-	-	-	-	4.20 (1.60- 11.10)	
*KAISER	2	-	-	-	-	13.20 (11.10- 15.70)	
*NHANES	1	144	2374	17	4853	17.32 (10.50- 28.56)	
*NLMS	4	-	-	-	-	11.82 (10.73- 13.03)	
*THIN	1	372	134000	112	437000	10.83 (8.77- 13.38)	
*VITAL	1	251	6169	60	36381	24.67 (18.64- 32.65)	
Partial Totals		898	145006	219	481583		

*prospective study

Male

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*AEROBIC	1	100	6840	35	18088	7.56 (5.15- 11.09)	
*AGRICAN	1	-	-	-	-	28.84 (20.35- 40.87)	
*ARIC	3	-	-	-	-	41.41 (18.36- 93.42)	
*ATP	9	-	-	-	-	9.33 (3.82- 22.84)	
*BIOBANK	2	329	22934	78	98319	18.08 (14.13- 23.14)	
*COAL	1	-	-	-	-	9.20 (5.30- 16.00)	
*CPSI	5	-	-	-	-	12.22 (9.59- 15.58)	
*CPSII	5	-	-	-	-	23.81 (19.85- 28.57)	
*EPIC	3	-	-	-	-	32.00 (21.38- 47.90)	
*HFPS	3	-	-	-	-	12.56 (6.02- 26.22)	
*KRIS	3	-	-	-	-	10.47 (6.74- 16.25)	
*NHIS	6	-	-	-	-	14.60 (9.10- 23.40)	
*NIHAARP	4	-	-	-	-	29.40 (25.20- 34.30)	
*NLCS	4	1502	9069	95	4345	7.57 (6.18- 9.29)	
*NLST	2	-	-	-	-	24.32 (10.98- 53.85)	
NONMET	2	-	-	-	-	7.97 (4.17- 15.27)	
*QRESEAR	3	-	-	-	-	7.35 (4.54- 11.90)	
SCCS	1	505	1209	22	686	13.02 (8.41- 20.16)	
*SHEETME	1	410	4400	53	4503	7.92 (5.97- 10.51)	
*THREEC	5	-	-	-	-	16.78 (10.31- 27.33)	
*USA5	5	-	-	-	-	24.97 (22.20- 28.09)	
*VETERAN	1	54	1443	4	1798	16.82 (6.11- 46.34)	
*VLAGT	1	164	2420	0	567	77.14~(4.81-1236.55)	
Partial Totals		3064	48315	287	128306		

*prospective study

Female

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*AGRICAN	2	-	-	-	-	16.53 (9.44- 28.95)	
*ARIC	4	-	-	-	-	13.13 (8.46- 20.41)	
*ATP	10	-	-	-	-	23.40 (12.26- 44.63)	
*BIOBANK	1	244	19464	127	134209	13.25 (10.70- 16.41)	
*BWHS	3	-	-	-	-	11.78 (8.55- 16.24)	
*CPSI	6	-	-	-	-	2.73 (2.07- 3.61)	
*CPSII	6	-	-	-	-	12.65 (11.15- 14.34)	
*EPIC	6	-	-	-	-	7.53 (5.87- 9.66)	
*MWOMEN	3	-	-	-	-	21.20 (19.50- 23.10)	
*NHIS	5	-	-	-	-	17.80 (11.40- 27.80)	
*NHS	2	-	-	-	-	23.30 (19.00- 28.80)	
*NIHAARP	2	-	-	-	-	19.50 (17.20- 22.20)	
*NLCS	5	275	6540	103	20158	8.23 (6.57- 10.30)	
*NOWAC	3	-	-	-	-	11.89 (9.66- 14.64)	
*PLCO	2	-	-	-	-	31.97 (25.16- 40.63)	
*QRESEAR	4	-	-	-	-	7.13 (4.47- 11.37)	
SCCS	2	469	667	54	1203	15.66 (11.64- 21.08)	
*THREEC	8	273	12388	14	15703	24.72 (14.45- 42.27)	
*USA5	6	-	-	-	-	25.66 (23.17- 28.40)	
*VLAGT	4	-	-	-	-	9.27 (4.45- 19.28)	
*WHI	3	-	-	-	-	13.44 (10.80- 16.74)	
Partial Totals		1261	39059	298	171273		

*prospective study

Table 21
Smoking and Lung cancer: Cigarette Smoking analyses
Studies in North America and Europe only
Initial analysis by sex

	RR Sex			Total
	1 Combined	2 Male	3 Female	
RR Data				
N	12	23	21	56
NS	12	23	21	56
Wt	839.01	1044.54	2160.76	4044.30
Het Chi	63.57	265.61	443.85	838.77
Het df	11	22	20	55
Het P	***	***	***	***
Fixed RR	12.80	18.23	17.00	16.32
RRl	11.97	17.15	16.30	15.83
RRu	13.70	19.37	17.73	16.83
P	+++	+++	+++	+++
Random RR	12.93	15.00	13.89	14.01
RRl	10.55	11.82	11.19	12.27
RRu	15.84	19.05	17.24	15.99
P	+++	+++	+++	+++
Asymm P	N.S.	N.S.	(*)	*
Between Chi		58.00	48.59	65.75
Between df		1	1	2
Between P		+++	+++	***
Btwn (F) P		+	(+)	N.S.
Btwn (R) P		N.S.	N.S.	N.S.

Table 22
Smoking and Lung cancer: Cigarette Smoking analyses
Studies in North America and Europe only
Initial analysis by region

N America

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*ACE	2	-	-	-	-	18.56 (9.07- 37.96)	
*AEROBIC	1	100	6840	35	18088	7.56 (5.15- 11.09)	
*AHS	2	-	-	-	-	23.03 (17.34- 30.59)	
*ARIC	3	-	-	-	-	41.41 (18.36- 93.42)	
*ARIC	4	-	-	-	-	13.13 (8.46- 20.41)	
Subtotal ARIC						17.03 (11.56- 25.09)	
*ATP	9	-	-	-	-	9.33 (3.82- 22.84)	
*ATP	10	-	-	-	-	23.40 (12.26- 44.63)	
Subtotal ATP						17.07 (10.11- 28.82)	
*BWHS	3	-	-	-	-	11.78 (8.55- 16.24)	
*COAL	1	-	-	-	-	9.20 (5.30- 16.00)	
*CPSI	5	-	-	-	-	12.22 (9.59- 15.58)	
*CPSI	6	-	-	-	-	2.73 (2.07- 3.61)	
Subtotal CPSI						6.39 (5.33- 7.68)	
*CPSII	5	-	-	-	-	23.81 (19.85- 28.57)	
*CPSII	6	-	-	-	-	12.65 (11.15- 14.34)	
Subtotal CPSII						15.52 (13.99- 17.21)	
*FRAMING	2	-	-	-	-	7.55 (4.94- 11.55)	
*HPFS	3	-	-	-	-	12.56 (6.02- 26.22)	
*KAISER	2	-	-	-	-	13.20 (11.10- 15.70)	
*NHANES	1	144	2374	17	4853	17.32 (10.50- 28.56)	
*NHIS	6	-	-	-	-	14.60 (9.10- 23.40)	
*NHIS	5	-	-	-	-	17.80 (11.40- 27.80)	
Subtotal NHIS						16.21 (11.72- 22.42)	
*NHS	2	-	-	-	-	23.30 (19.00- 28.80)	
*NIHAARP	4	-	-	-	-	29.40 (25.20- 34.30)	
*NIHAARP	2	-	-	-	-	19.50 (17.20- 22.20)	
Subtotal NIHAARP						23.04 (20.89- 25.42)	
*NLMS	4	-	-	-	-	11.82 (10.73- 13.03)	
*NLST	2	-	-	-	-	24.32 (10.98- 53.85)	
NONMET	2	-	-	-	-	7.97 (4.17- 15.27)	
*PLCO	2	-	-	-	-	31.97 (25.16- 40.63)	
SCCS	1	505	1209	22	686	13.02 (8.41- 20.16)	
SCCS	2	469	667	54	1203	15.66 (11.64- 21.08)	
Subtotal SCCS						14.78 (11.56- 18.89)	
*SHEETME	1	410	4400	53	4503	7.92 (5.97- 10.51)	
*USA5	5	-	-	-	-	24.97 (22.20- 28.09)	
*USA5	6	-	-	-	-	25.66 (23.17- 28.40)	
Subtotal USA5						25.36 (23.48- 27.39)	
*VETERAN	1	54	1443	4	1798	16.82 (6.11- 46.34)	
*VITAL	1	251	6169	60	36381	24.67 (18.64- 32.65)	
*WHI	3	-	-	-	-	13.44 (10.80- 16.74)	
Partial Totals		1933	23102	245	67512		

*prospective study

Europe

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*AGRICAN	1	-	-	-	-	28.84 (20.35- 40.87)	
*AGRICAN	2	-	-	-	-	16.53 (9.44- 28.95)	
Subtotal AGRICAN						24.69 (18.36- 33.20)	
*AMIAN	1	61	2224	13	2645	5.58 (3.07- 10.13)	
*BIOBANK	2	329	22934	78	98319	18.08 (14.13- 23.14)	
*BIOBANK	1	244	19464	127	134209	13.25 (10.70- 16.41)	
Subtotal BIOBANK						15.14 (12.88- 17.80)	
*EPIC	3	-	-	-	-	32.00 (21.38- 47.90)	
*EPIC	6	-	-	-	-	7.53 (5.87- 9.66)	
Subtotal EPIC						11.23 (9.08- 13.88)	
ESTHER	1	70	239	17	704	12.13 (7.00- 21.02)	
*HBC	1	-	-	-	-	4.20 (1.60- 11.10)	
*KRIS	3	-	-	-	-	10.47 (6.74- 16.25)	
*MWOMEN	3	-	-	-	-	21.20 (19.50- 23.10)	
*NLCS	4	1502	9069	95	4345	7.57 (6.18- 9.29)	
*NLCS	5	275	6540	103	20158	8.23 (6.57- 10.30)	
Subtotal NLCS						7.86 (6.76- 9.15)	
*NOWAC	3	-	-	-	-	11.89 (9.66- 14.64)	
*QRESEAR	3	-	-	-	-	7.35 (4.54- 11.90)	
*QRESEAR	4	-	-	-	-	7.13 (4.47- 11.37)	
Subtotal QRESEAR						7.24 (5.17- 10.12)	
*THIN	1	372	134000	112	437000	10.83 (8.77- 13.38)	
*THREEC	5	-	-	-	-	16.78 (10.31- 27.33)	
*THREEC	8	273	12388	14	15703	24.72 (14.45- 42.27)	

Table 22
Smoking and Lung cancer: Cigarette Smoking analyses
Studies in North America and Europe only
Initial analysis by region

Europe

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
Subtotal	THREEC					19.99	(13.94- 28.68)
*VLAGT	1	164	2420	0	567	77.14~	(4.81-1236.55)
*VLAGT	4	-	-	-	-	9.27	(4.45- 19.28)
Subtotal	VLAGT					10.64	(5.24- 21.62)
Partial Totals		3290	209278	559	713650		

*prospective study

Multi

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*CHANCES	2	-	-	-	-	13.10	(9.90- 17.30)
Partial Totals		0	0	0	0		

*prospective study

	Region				Total
	1 N America	2 Europe	3 Japan	4 Multi	

RR Data

N	34	21		1	56
NS	26	14		1	41
Wt	2720.98	1274.00		49.32	4044.30
Het Chi	563.74	253.31		0.00	838.77
Het df	33	20		0	55
Het P	***	***		N.S.	***
Fixed RR	17.16	14.78		13.10	16.32
RRl	16.53	13.99		9.91	15.83
RRu	17.82	15.62		17.32	16.83
P	+++	+++		+++	+++
Random RR	15.15	12.30		13.10	14.01
RRl	12.77	9.77		9.91	12.27
RRu	17.96	15.49		17.32	15.99
P	+++	+++		+++	+++
Asymm P	N.S.	(*)			*
Between Chi		19.32		3.54	21.73
Between df		1		1	2
Between P		---	N.S.	(-)	***
Btwn (F) P		N.S.	N.S.	N.S.	N.S.
Btwn (R) P		N.S.	N.S.	N.S.	N.S.

Table 23
Smoking and Lung cancer: Cigarette Smoking analyses
Studies in North America and Europe only
Initial analysis by study population

International

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*CHANCES	2	-	-	-	-	13.10	(9.90- 17.30)
*EPIC	3	-	-	-	-	32.00	(21.38- 47.90)
*EPIC	6	-	-	-	-	7.53	(5.87- 9.66)
Subtotal EPIC						11.23	(9.08- 13.88)
Partial Totals		0	0	0	0		

*prospective study

National

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*BIOBANK	2	329	22934	78	98319	18.08	(14.13- 23.14)
*BIOBANK	1	244	19464	127	134209	13.25	(10.70- 16.41)
Subtotal BIOBANK						15.14	(12.88- 17.80)
*BWHS	3	-	-	-	-	11.78	(8.55- 16.24)
*CPSI	5	-	-	-	-	12.22	(9.59- 15.58)
*CPSI	6	-	-	-	-	2.73	(2.07- 3.61)
Subtotal CPSI						6.39	(5.33- 7.68)
*CPSII	5	-	-	-	-	23.81	(19.85- 28.57)
*CPSII	6	-	-	-	-	12.65	(11.15- 14.34)
Subtotal CPSII						15.52	(13.99- 17.21)
*MWOMEN	3	-	-	-	-	21.20	(19.50- 23.10)
*NHANES	1	144	2374	17	4853	17.32	(10.50- 28.56)
*NHIS	6	-	-	-	-	14.60	(9.10- 23.40)
*NHIS	5	-	-	-	-	17.80	(11.40- 27.80)
Subtotal NHIS						16.21	(11.72- 22.42)
*NLCS	4	1502	9069	95	4345	7.57	(6.18- 9.29)
*NLCS	5	275	6540	103	20158	8.23	(6.57- 10.30)
Subtotal NLCS						7.86	(6.76- 9.15)
*NLMS	4	-	-	-	-	11.82	(10.73- 13.03)
*NOWAC	3	-	-	-	-	11.89	(9.66- 14.64)
*QRESEAR	3	-	-	-	-	7.35	(4.54- 11.90)
*QRESEAR	4	-	-	-	-	7.13	(4.47- 11.37)
Subtotal QRESEAR						7.24	(5.17- 10.12)
*THIN	1	372	134000	112	437000	10.83	(8.77- 13.38)
*USA5	5	-	-	-	-	24.97	(22.20- 28.09)
*USA5	6	-	-	-	-	25.66	(23.17- 28.40)
Subtotal USA5						25.36	(23.48- 27.39)
*WHI	3	-	-	-	-	13.44	(10.80- 16.74)
Partial Totals		2866	194381	532	698884		

*prospective study

Regional

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*ACE	2	-	-	-	-	18.56	(9.07- 37.96)
*AEROBIC	1	100	6840	35	18088	7.56	(5.15- 11.09)
*AGRICAN	1	-	-	-	-	28.84	(20.35- 40.87)
*AGRICAN	2	-	-	-	-	16.53	(9.44- 28.95)
Subtotal AGRICAN						24.69	(18.36- 33.20)
*ARIC	3	-	-	-	-	41.41	(18.36- 93.42)
*ARIC	4	-	-	-	-	13.13	(8.46- 20.41)
Subtotal ARIC						17.03	(11.56- 25.09)
*ATP	9	-	-	-	-	9.33	(3.82- 22.84)
*ATP	10	-	-	-	-	23.40	(12.26- 44.63)
Subtotal ATP						17.07	(10.11- 28.82)
ESTHER	1	70	239	17	704	12.13	(7.00- 21.02)
*FRAMING	2	-	-	-	-	7.55	(4.94- 11.55)
*HBC	1	-	-	-	-	4.20	(1.60- 11.10)
*KAISER	2	-	-	-	-	13.20	(11.10- 15.70)
*KRIS	3	-	-	-	-	10.47	(6.74- 16.25)
*NIHAARP	4	-	-	-	-	29.40	(25.20- 34.30)
*NIHAARP	2	-	-	-	-	19.50	(17.20- 22.20)
Subtotal NIHAARP						23.04	(20.89- 25.42)
*PLCO	2	-	-	-	-	31.97	(25.16- 40.63)
SCCS	1	505	1209	22	686	13.02	(8.41- 20.16)
SCCS	2	469	667	54	1203	15.66	(11.64- 21.08)
Subtotal SCCS						14.78	(11.56- 18.89)
*THREEC	5	-	-	-	-	16.78	(10.31- 27.33)
*THREEC	8	273	12388	14	15703	24.72	(14.45- 42.27)
Subtotal THREEC						19.99	(13.94- 28.68)
*VETERAN	1	54	1443	4	1798	16.82	(6.11- 46.34)
*VITAL	1	251	6169	60	36381	24.67	(18.64- 32.65)

Table 23
Smoking and Lung cancer: Cigarette Smoking analyses
Studies in North America and Europe only
Initial analysis by study population

Regional

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*VLAGT	1	164	2420	0	567	77.14~	(4.81-1236.55)
*VLAGT	4	-	-	-	-	9.27	(4.45- 19.28)
Subtotal VLAGT						10.64	(5.24- 21.62)
Partial Totals		1886	31375	206	75130		

*prospective study

Specific

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*AHS	2	-	-	-	-	23.03	(17.34- 30.59)
*AMIANI	1	61	2224	13	2645	5.58	(3.07- 10.13)
*COAL	1	-	-	-	-	9.20	(5.30- 16.00)
*HPFS	3	-	-	-	-	12.56	(6.02- 26.22)
*NHS	2	-	-	-	-	23.30	(19.00- 28.80)
*NLST	2	-	-	-	-	24.32	(10.98- 53.85)
NONMET	2	-	-	-	-	7.97	(4.17- 15.27)
*SHEETME	1	410	4400	53	4503	7.92	(5.97- 10.51)
Partial Totals		471	6624	66	7148		

*prospective study

	Study population				Total
	1	2	3	4	
	Internati	National	Regional	Specific	

RR Data

N	3	21	24	8	56
NS	2	14	17	8	41
Wt	134.86	2758.58	920.72	230.14	4044.30
Het Chi	36.53	546.92	153.79	64.16	838.77
Het df	2	20	23	7	55
Het P	***	***	***	***	***
Fixed RR	11.88	15.83	18.96	15.53	16.32
RR1	10.03	15.25	17.77	13.65	15.83
RRu	14.06	16.44	20.22	17.67	16.83
P	+++	+++	+++	+++	+++
Random RR	14.45	12.66	16.27	12.46	14.01
RR1	6.85	10.29	13.39	8.03	12.27
RRu	30.50	15.56	19.77	19.33	15.99
P	+++	+++	+++	+++	+++
Asymm P	N.S.	*	N.S.	N.S.	*
Between Chi		10.62	25.70	6.11	37.36
Between df		1	1	1	3
Between P		++	+++	+	***
Btwn (F) P		N.S.	(+)	N.S.	N.S.
Btwn (R) P		N.S.	N.S.	N.S.	N.S.

Table 24
Smoking and Lung cancer: Cigarette Smoking analyses
Studies in North America and Europe only
Initial analysis by year of start of baseline

<1980

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*AEROBIC	1	100	6840	35	18088	7.56	(5.15- 11.09)
*COAL	1	-	-	-	-	9.20	(5.30- 16.00)
*CPSI	5	-	-	-	-	12.22	(9.59- 15.58)
*CPSI	6	-	-	-	-	2.73	(2.07- 3.61)
Subtotal CPSI						6.39	(5.33- 7.68)
*FRAMING	2	-	-	-	-	7.55	(4.94- 11.55)
*KAISER	2	-	-	-	-	13.20	(11.10- 15.70)
*KRIS	3	-	-	-	-	10.47	(6.74- 16.25)
NONMET	2	-	-	-	-	7.97	(4.17- 15.27)
*THREEC	5	-	-	-	-	16.78	(10.31- 27.33)
*THREEC	8	273	12388	14	15703	24.72	(14.45- 42.27)
Subtotal THREEC						19.99	(13.94- 28.68)
*VLAGT	1	164	2420	0	567	77.14	(4.81-1236.55)
*VLAGT	4	-	-	-	-	9.27	(4.45- 19.28)
Subtotal VLAGT						10.64	(5.24- 21.62)
Partial Totals		537	21648	49	34358		

*prospective study

1980-89

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*ARIC	3	-	-	-	-	41.41	(18.36- 93.42)
*ARIC	4	-	-	-	-	13.13	(8.46- 20.41)
Subtotal ARIC						17.03	(11.56- 25.09)
*CHANCES	2	-	-	-	-	13.10	(9.90- 17.30)
*CPSII	5	-	-	-	-	23.81	(19.85- 28.57)
*CPSII	6	-	-	-	-	12.65	(11.15- 14.34)
Subtotal CPSII						15.52	(13.99- 17.21)
*HPFS	3	-	-	-	-	12.56	(6.02- 26.22)
*NHANES	1	144	2374	17	4853	17.32	(10.50- 28.56)
*NHIS	6	-	-	-	-	14.60	(9.10- 23.40)
*NHIS	5	-	-	-	-	17.80	(11.40- 27.80)
Subtotal NHIS						16.21	(11.72- 22.42)
*NHS	2	-	-	-	-	23.30	(19.00- 28.80)
*NLCS	4	1502	9069	95	4345	7.57	(6.18- 9.29)
*NLCS	5	275	6540	103	20158	8.23	(6.57- 10.30)
Subtotal NLCS						7.86	(6.76- 9.15)
*NLMS	4	-	-	-	-	11.82	(10.73- 13.03)
*SHEETME	1	410	4400	53	4503	7.92	(5.97- 10.51)
*USA5	5	-	-	-	-	24.97	(22.20- 28.09)
*USA5	6	-	-	-	-	25.66	(23.17- 28.40)
Subtotal USA5						25.36	(23.48- 27.39)
*VETERAN	1	54	1443	4	1798	16.82	(6.11- 46.34)
Partial Totals		2385	23826	272	35657		

*prospective study

1990-99

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*ACE	2	-	-	-	-	18.56	(9.07- 37.96)
*AHS	2	-	-	-	-	23.03	(17.34- 30.59)
*BWHS	3	-	-	-	-	11.78	(8.55- 16.24)
*EPIC	3	-	-	-	-	32.00	(21.38- 47.90)
*EPIC	6	-	-	-	-	7.53	(5.87- 9.66)
Subtotal EPIC						11.23	(9.08- 13.88)
*MWOMEN	3	-	-	-	-	21.20	(19.50- 23.10)
*NIHAARP	4	-	-	-	-	29.40	(25.20- 34.30)
*NIHAARP	2	-	-	-	-	19.50	(17.20- 22.20)
Subtotal NIHAARP						23.04	(20.89- 25.42)
*NLST	2	-	-	-	-	24.32	(10.98- 53.85)
*NOWAC	3	-	-	-	-	11.89	(9.66- 14.64)
*PLCO	2	-	-	-	-	31.97	(25.16- 40.63)
*QRESEAR	3	-	-	-	-	7.35	(4.54- 11.90)
*QRESEAR	4	-	-	-	-	7.13	(4.47- 11.37)
Subtotal QRESEAR						7.24	(5.17- 10.12)
*WHI	3	-	-	-	-	13.44	(10.80- 16.74)
Partial Totals		0	0	0	0		

*prospective study

Table 24
Smoking and Lung cancer: Cigarette Smoking analyses
Studies in North America and Europe only
Initial analysis by year of start of baseline

2000+'

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*AGRICAN	1	-	-	-	-	28.84 (20.35- 40.87)	
*AGRICAN	2	-	-	-	-	16.53 (9.44- 28.95)	
Subtotal AGRICAN						24.69 (18.36- 33.20)	
*AMIANT	1	61	2224	13	2645	5.58 (3.07- 10.13)	
*ATP	9	-	-	-	-	9.33 (3.82- 22.84)	
*ATP	10	-	-	-	-	23.40 (12.26- 44.63)	
Subtotal ATP						17.07 (10.11- 28.82)	
*BIOBANK	2	329	22934	78	98319	18.08 (14.13- 23.14)	
*BIOBANK	1	244	19464	127	134209	13.25 (10.70- 16.41)	
Subtotal BIOBANK						15.14 (12.88- 17.80)	
ESTHER	1	70	239	17	704	12.13 (7.00- 21.02)	
*HBC	1	-	-	-	-	4.20 (1.60- 11.10)	
SCCS	1	505	1209	22	686	13.02 (8.41- 20.16)	
SCCS	2	469	667	54	1203	15.66 (11.64- 21.08)	
Subtotal SCCS						14.78 (11.56- 18.89)	
*THIN	1	372	134000	112	437000	10.83 (8.77- 13.38)	
*VITAL	1	251	6169	60	36381	24.67 (18.64- 32.65)	
Partial Totals		2301	186906	483	711147		

*prospective study

	Year of start of baseline				Total	Trend
	1	2	3	4		
	<1980	1980-89	1990-99	2000+'		

RR Data

N	12	17	14	13	56	
NS	9	12	11	9	41	
Wt	368.82	1857.08	1387.08	431.32	4044.30	
Het Chi	117.62	336.39	186.45	59.52	838.77	
Het df	11	16	13	12	55	
Het P	***	***	***	***	***	
Fixed RR	9.72	16.32	19.21	15.06	16.32	
RRl	8.78	15.59	18.23	13.71	15.83	
RRu	10.76	17.08	20.25	16.55	16.83	
P	+++	+++	+++	+++	+++	
Random RR	9.97	15.19	16.42	14.38	14.01	
RRl	6.85	12.04	13.07	11.40	12.27	
RRu	14.52	19.18	20.63	18.15	15.99	
P	+++	+++	+++	+++	+++	
Asymm P	N.S.	N.S.	N.S.	N.S.	*	
Between Chi		82.60	135.31	38.15	138.79	46.51
Between df		1	1	1	3	1
Between P		+++	+++	+++	***	+++
Btwn (F) P		+	++	+	*	(+)
Btwn (R) P		(+)	+	N.S.	N.S.	N.S.

Table 25
Smoking and Lung cancer: Cigarette Smoking analyses
Studies in North America and Europe only
Initial analysis by number of cases in the study

<500

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*ACE	2	-	-	-	-	18.56 (9.07- 37.96)	
*AEROBIC	1	100	6840	35	18088	7.56 (5.15- 11.09)	
*AMIANANT	1	61	2224	13	2645	5.58 (3.07- 10.13)	
*ARIC	3	-	-	-	-	41.41 (18.36- 93.42)	
*ARIC	4	-	-	-	-	13.13 (8.46- 20.41)	
Subtotal ARIC						17.03 (11.56- 25.09)	
*ATP	9	-	-	-	-	9.33 (3.82- 22.84)	
*ATP	10	-	-	-	-	23.40 (12.26- 44.63)	
Subtotal ATP						17.07 (10.11- 28.82)	
*BWHS	3	-	-	-	-	11.78 (8.55- 16.24)	
ESTHER	1	70	239	17	704	12.13 (7.00- 21.02)	
*FRAMING	2	-	-	-	-	7.55 (4.94- 11.55)	
*HBC	1	-	-	-	-	4.20 (1.60- 11.10)	
*HPFS	3	-	-	-	-	12.56 (6.02- 26.22)	
*KRIS	3	-	-	-	-	10.47 (6.74- 16.25)	
*NHANES	1	144	2374	17	4853	17.32 (10.50- 28.56)	
*NLST	2	-	-	-	-	24.32 (10.98- 53.85)	
NONMET	2	-	-	-	-	7.97 (4.17- 15.27)	
*VETERAN	1	54	1443	4	1798	16.82 (6.11- 46.34)	
*VLAGT	1	164	2420	0	567	77.14~ (4.81-1236.55)	
*VLAGT	4	-	-	-	-	9.27 (4.45- 19.28)	
Subtotal VLAGT						10.64 (5.24- 21.62)	
Partial Totals		593	15540	86	28655		

*prospective study

500-1999

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*AGRICAN	1	-	-	-	-	28.84 (20.35- 40.87)	
*AGRICAN	2	-	-	-	-	16.53 (9.44- 28.95)	
Subtotal AGRICAN						24.69 (18.36- 33.20)	
*AHS	2	-	-	-	-	23.03 (17.34- 30.59)	
*BIOBANK	2	329	22934	78	98319	18.08 (14.13- 23.14)	
*BIOBANK	1	244	19464	127	134209	13.25 (10.70- 16.41)	
Subtotal BIOBANK						15.14 (12.88- 17.80)	
*COAL	1	-	-	-	-	9.20 (5.30- 16.00)	
*CPSI	5	-	-	-	-	12.22 (9.59- 15.58)	
*CPSI	6	-	-	-	-	2.73 (2.07- 3.61)	
Subtotal CPSI						6.39 (5.33- 7.68)	
*KAISER	2	-	-	-	-	13.20 (11.10- 15.70)	
*NHS	2	-	-	-	-	23.30 (19.00- 28.80)	
*NOWAC	3	-	-	-	-	11.89 (9.66- 14.64)	
*PLCO	2	-	-	-	-	31.97 (25.16- 40.63)	
SCCS	1	505	1209	22	686	13.02 (8.41- 20.16)	
SCCS	2	469	667	54	1203	15.66 (11.64- 21.08)	
Subtotal SCCS						14.78 (11.56- 18.89)	
*SHEETME	1	410	4400	53	4503	7.92 (5.97- 10.51)	
*THIN	1	372	134000	112	437000	10.83 (8.77- 13.38)	
*THREEC	5	-	-	-	-	16.78 (10.31- 27.33)	
*THREEC	8	273	12388	14	15703	24.72 (14.45- 42.27)	
Subtotal THREEC						19.99 (13.94- 28.68)	
*VITAL	1	251	6169	60	36381	24.67 (18.64- 32.65)	
*WHI	3	-	-	-	-	13.44 (10.80- 16.74)	
Partial Totals		2853	201231	520	728004		

*prospective study

Table 25
Smoking and Lung cancer: Cigarette Smoking analyses
Studies in North America and Europe only
Initial analysis by number of cases in the study

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*CHANCES	2	-	-	-	-	13.10 (9.90- 17.30)	
*CPSII	5	-	-	-	-	23.81 (19.85- 28.57)	
*CPSII	6	-	-	-	-	12.65 (11.15- 14.34)	
Subtotal CPSII						15.52 (13.99- 17.21)	
*EPIC	3	-	-	-	-	32.00 (21.38- 47.90)	
*EPIC	6	-	-	-	-	7.53 (5.87- 9.66)	
Subtotal EPIC						11.23 (9.08- 13.88)	
*MWOMEN	3	-	-	-	-	21.20 (19.50- 23.10)	
*NHIS	6	-	-	-	-	14.60 (9.10- 23.40)	
*NHIS	5	-	-	-	-	17.80 (11.40- 27.80)	
Subtotal NHIS						16.21 (11.72- 22.42)	
*NIHAARP	4	-	-	-	-	29.40 (25.20- 34.30)	
*NIHAARP	2	-	-	-	-	19.50 (17.20- 22.20)	
Subtotal NIHAARP						23.04 (20.89- 25.42)	
*NLCS	4	1502	9069	95	4345	7.57 (6.18- 9.29)	
*NLCS	5	275	6540	103	20158	8.23 (6.57- 10.30)	
Subtotal NLCS						7.86 (6.76- 9.15)	
*NLMS	4	-	-	-	-	11.82 (10.73- 13.03)	
*QRESEAR	3	-	-	-	-	7.35 (4.54- 11.90)	
*QRESEAR	4	-	-	-	-	7.13 (4.47- 11.37)	
Subtotal QRESEAR						7.24 (5.17- 10.12)	
*USA5	5	-	-	-	-	24.97 (22.20- 28.09)	
*USA5	6	-	-	-	-	25.66 (23.17- 28.40)	
Subtotal USA5						25.36 (23.48- 27.39)	
Partial Totals		1777	15609	198	24503		
*prospective study							

	Number of lung cancer cases			Total	Trend
	1 <500	2 500-1999	3 2000+		

RR Data

N	19	20	17	56	
NS	16	15	10	41	
Wt	228.31	1094.79	2721.20	4044.30	
Het Chi	44.73	282.34	446.26	838.77	
Het df	18	19	16	55	
Het P	***	***	***	***	
Fixed RR	11.30	14.42	17.69	16.32	
RRl	9.93	13.59	17.04	15.83	
RRu	12.86	15.30	18.37	16.83	
P	+++	+++	+++	+++	
Random RR	11.90	14.68	14.99	14.01	
RRl	9.55	11.61	12.13	12.27	
RRu	14.83	18.55	18.51	15.99	
P	+++	+++	+++	+++	
Asymm P	N.S.	N.S.	N.S.	*	
Between Chi		11.21	42.35	65.44	65.26
Between df		1	1	2	1
Between P		+++	+++	***	+++
Btwn (F) P		N.S.	(+)	N.S.	+
Btwn (R) P		N.S.	N.S.	N.S.	N.S.

Table 26
Smoking and Lung cancer: Cigarette Smoking analyses
Studies in North America and Europe only
Initial analysis by cigarette smoking exclusively or not

absent

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*ACE	2	-	-	-	-	18.56 (9.07- 37.96)	
*AEROBIC	1	100	6840	35	18088	7.56 (5.15- 11.09)	
*AGRICAN	1	-	-	-	-	28.84 (20.35- 40.87)	
*AGRICAN	2	-	-	-	-	16.53 (9.44- 28.95)	
Subtotal AGRICAN						24.69 (18.36- 33.20)	
*AMIANT	1	61	2224	13	2645	5.58 (3.07- 10.13)	
*ARIC	3	-	-	-	-	41.41 (18.36- 93.42)	
*ARIC	4	-	-	-	-	13.13 (8.46- 20.41)	
Subtotal ARIC						17.03 (11.56- 25.09)	
*ATP	9	-	-	-	-	9.33 (3.82- 22.84)	
*ATP	10	-	-	-	-	23.40 (12.26- 44.63)	
Subtotal ATP						17.07 (10.11- 28.82)	
*BIOBANK	2	329	22934	78	98319	18.08 (14.13- 23.14)	
*BIOBANK	1	244	19464	127	134209	13.25 (10.70- 16.41)	
Subtotal BIOBANK						15.14 (12.88- 17.80)	
*BWHS	3	-	-	-	-	11.78 (8.55- 16.24)	
*CHANCES	2	-	-	-	-	13.10 (9.90- 17.30)	
*COAL	1	-	-	-	-	9.20 (5.30- 16.00)	
*EPIC	6	-	-	-	-	7.53 (5.87- 9.66)	
ESTHER	1	70	239	17	704	12.13 (7.00- 21.02)	
*FRAMING	2	-	-	-	-	7.55 (4.94- 11.55)	
*HBC	1	-	-	-	-	4.20 (1.60- 11.10)	
*HPFS	3	-	-	-	-	12.56 (6.02- 26.22)	
*KAISER	2	-	-	-	-	13.20 (11.10- 15.70)	
*KRIS	3	-	-	-	-	10.47 (6.74- 16.25)	
*NHANES	1	144	2374	17	4853	17.32 (10.50- 28.56)	
*NHIS	6	-	-	-	-	14.60 (9.10- 23.40)	
*NHIS	5	-	-	-	-	17.80 (11.40- 27.80)	
Subtotal NHIS						16.21 (11.72- 22.42)	
*NHS	2	-	-	-	-	23.30 (19.00- 28.80)	
*NLCS	4	1502	9069	95	4345	7.57 (6.18- 9.29)	
*NLCS	5	275	6540	103	20158	8.23 (6.57- 10.30)	
Subtotal NLCS						7.86 (6.76- 9.15)	
*NLST	2	-	-	-	-	24.32 (10.98- 53.85)	
NONMET	2	-	-	-	-	7.97 (4.17- 15.27)	
*NOWAC	3	-	-	-	-	11.89 (9.66- 14.64)	
*PLCO	2	-	-	-	-	31.97 (25.16- 40.63)	
*QRESEAR	3	-	-	-	-	7.35 (4.54- 11.90)	
*QRESEAR	4	-	-	-	-	7.13 (4.47- 11.37)	
Subtotal QRESEAR						7.24 (5.17- 10.12)	
SCCS	1	505	1209	22	686	13.02 (8.41- 20.16)	
SCCS	2	469	667	54	1203	15.66 (11.64- 21.08)	
Subtotal SCCS						14.78 (11.56- 18.89)	
*SHEETME	1	410	4400	53	4503	7.92 (5.97- 10.51)	
*THIN	1	372	134000	112	437000	10.83 (8.77- 13.38)	
*THREEC	8	273	12388	14	15703	24.72 (14.45- 42.27)	
*USA5	5	-	-	-	-	24.97 (22.20- 28.09)	
*USA5	6	-	-	-	-	25.66 (23.17- 28.40)	
Subtotal USA5						25.36 (23.48- 27.39)	
*VETERAN	1	54	1443	4	1798	16.82 (6.11- 46.34)	
*VITAL	1	251	6169	60	36381	24.67 (18.64- 32.65)	
*VLAGT	1	164	2420	0	567	77.14~(4.81-1236.55)	
*VLAGT	4	-	-	-	-	9.27 (4.45- 19.28)	
Subtotal VLAGT						10.64 (5.24- 21.62)	
*WHI	3	-	-	-	-	13.44 (10.80- 16.74)	
Partial Totals		5223	232380	804	781162		
*prospective study							

Table 26
Smoking and Lung cancer: Cigarette Smoking analyses
Studies in North America and Europe only
Initial analysis by cigarette smoking exclusively or not

present

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*AHS	2	-	-	-	-	23.03	(17.34- 30.59)
*CPSI	5	-	-	-	-	12.22	(9.59- 15.58)
*CPSI	6	-	-	-	-	2.73	(2.07- 3.61)
Subtotal CPSI						6.39	(5.33- 7.68)
*CPSII	5	-	-	-	-	23.81	(19.85- 28.57)
*CPSII	6	-	-	-	-	12.65	(11.15- 14.34)
Subtotal CPSII						15.52	(13.99- 17.21)
*EPIC	3	-	-	-	-	32.00	(21.38- 47.90)
*MWOMEN	3	-	-	-	-	21.20	(19.50- 23.10)
*NIHAARP	4	-	-	-	-	29.40	(25.20- 34.30)
*NIHAARP	2	-	-	-	-	19.50	(17.20- 22.20)
Subtotal NIHAARP						23.04	(20.89- 25.42)
*NLMS	4	-	-	-	-	11.82	(10.73- 13.03)
*THREEC	5	-	-	-	-	16.78	(10.31- 27.33)
Partial Totals		0	0	0	0		
*prospective study							

RR Description: Exclusive use of the product
1 2
absent present Total

RR Data

N	45	11	56
NS	35	8	43
Wt	2142.95	1901.35	4044.30
Het Chi	482.02	354.01	838.77
Het df	44	10	55
Het P	***	***	***
Fixed RR	15.92	16.78	16.32
RRl	15.26	16.04	15.83
RRu	16.61	17.55	16.83
P	+++	+++	+++
Random RR	13.47	15.99	14.01
RRl	11.55	12.02	12.27
RRu	15.72	21.29	15.99
P	+++	+++	+++
Asymm P	*	N.S.	*
Between Chi		2.75	2.75
Between df		1	1
Between P		(+)	(*)
Btwn (F) P		N.S.	N.S.
Btwn (R) P		N.S.	N.S.

Table 27
Smoking and Lung cancer: Cigarette Smoking analyses
Studies in North America and Europe only
Initial analysis by latency rule used or not

absent							
STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*ACE	2	-	-	-	-	18.56 (9.07- 37.96)	
*AEROBIC	1	100	6840	35	18088	7.56 (5.15- 11.09)	
*AGRICAN	1	-	-	-	-	28.84 (20.35- 40.87)	
*AGRICAN	2	-	-	-	-	16.53 (9.44- 28.95)	
Subtotal AGRICAN						24.69 (18.36- 33.20)	
*AHS	2	-	-	-	-	23.03 (17.34- 30.59)	
*AMIAANT	1	61	2224	13	2645	5.58 (3.07- 10.13)	
*ARIC	3	-	-	-	-	41.41 (18.36- 93.42)	
*ARIC	4	-	-	-	-	13.13 (8.46- 20.41)	
Subtotal ARIC						17.03 (11.56- 25.09)	
*BIOBANK	2	329	22934	78	98319	18.08 (14.13- 23.14)	
*BIOBANK	1	244	19464	127	134209	13.25 (10.70- 16.41)	
Subtotal BIOBANK						15.14 (12.88- 17.80)	
*BWHS	3	-	-	-	-	11.78 (8.55- 16.24)	
*CHANCES	2	-	-	-	-	13.10 (9.90- 17.30)	
*COAL	1	-	-	-	-	9.20 (5.30- 16.00)	
*CPSI	5	-	-	-	-	12.22 (9.59- 15.58)	
*CPSI	6	-	-	-	-	2.73 (2.07- 3.61)	
Subtotal CPSI						6.39 (5.33- 7.68)	
*CPSII	5	-	-	-	-	23.81 (19.85- 28.57)	
*CPSII	6	-	-	-	-	12.65 (11.15- 14.34)	
Subtotal CPSII						15.52 (13.99- 17.21)	
*EPIC	3	-	-	-	-	32.00 (21.38- 47.90)	
*EPIC	6	-	-	-	-	7.53 (5.87- 9.66)	
Subtotal EPIC						11.23 (9.08- 13.88)	
ESTHER	1	70	239	17	704	12.13 (7.00- 21.02)	
*FRAMING	2	-	-	-	-	7.55 (4.94- 11.55)	
*HBC	1	-	-	-	-	4.20 (1.60- 11.10)	
*HPFS	3	-	-	-	-	12.56 (6.02- 26.22)	
*KAISER	2	-	-	-	-	13.20 (11.10- 15.70)	
*NHANES	1	144	2374	17	4853	17.32 (10.50- 28.56)	
*NHS	2	-	-	-	-	23.30 (19.00- 28.80)	
*NLCS	4	1502	9069	95	4345	7.57 (6.18- 9.29)	
*NLCS	5	275	6540	103	20158	8.23 (6.57- 10.30)	
Subtotal NLCS						7.86 (6.76- 9.15)	
*NLMS	4	-	-	-	-	11.82 (10.73- 13.03)	
*NLST	2	-	-	-	-	24.32 (10.98- 53.85)	
*NONMET	2	-	-	-	-	7.97 (4.17- 15.27)	
*NOWAC	3	-	-	-	-	11.89 (9.66- 14.64)	
*PLCO	2	-	-	-	-	31.97 (25.16- 40.63)	
*QRESEAR	3	-	-	-	-	7.35 (4.54- 11.90)	
*QRESEAR	4	-	-	-	-	7.13 (4.47- 11.37)	
Subtotal QRESEAR						7.24 (5.17- 10.12)	
SCCS	1	505	1209	22	686	13.02 (8.41- 20.16)	
SCCS	2	469	667	54	1203	15.66 (11.64- 21.08)	
Subtotal SCCS						14.78 (11.56- 18.89)	
*SHEETME	1	410	4400	53	4503	7.92 (5.97- 10.51)	
*THIN	1	372	134000	112	437000	10.83 (8.77- 13.38)	
*THREEC	5	-	-	-	-	16.78 (10.31- 27.33)	
*USA5	5	-	-	-	-	24.97 (22.20- 28.09)	
*USA5	6	-	-	-	-	25.66 (23.17- 28.40)	
Subtotal USA5						25.36 (23.48- 27.39)	
*VETERAN	1	54	1443	4	1798	16.82 (6.11- 46.34)	
*VITAL	1	251	6169	60	36381	24.67 (18.64- 32.65)	
*VLAGT	1	164	2420	0	567	77.14~(4.81-1236.55)	
*VLAGT	4	-	-	-	-	9.27 (4.45- 19.28)	
Subtotal VLAGT						10.64 (5.24- 21.62)	
*WHI	3	-	-	-	-	13.44 (10.80- 16.74)	
Partial Totals		4950	219992	790	765459		
*prospective study							

Table 27
Smoking and Lung cancer: Cigarette Smoking analyses
Studies in North America and Europe only
Initial analysis by latency rule used or not

present

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*ATP	9	-	-	-	-	9.33 (3.82- 22.84)	
*ATP	10	-	-	-	-	23.40 (12.26- 44.63)	
Subtotal ATP						17.07 (10.11- 28.82)	
*KRIS	3	-	-	-	-	10.47 (6.74- 16.25)	
*MWOMEN	3	-	-	-	-	21.20 (19.50- 23.10)	
*NHIS	6	-	-	-	-	14.60 (9.10- 23.40)	
*NHIS	5	-	-	-	-	17.80 (11.40- 27.80)	
Subtotal NHIS						16.21 (11.72- 22.42)	
*NIHAARP	4	-	-	-	-	29.40 (25.20- 34.30)	
*NIHAARP	2	-	-	-	-	19.50 (17.20- 22.20)	
Subtotal NIHAARP						23.04 (20.89- 25.42)	
*THREEC	8	273	12388	14	15703	24.72 (14.45- 42.27)	
Partial Totals		273	12388	14	15703		

*prospective study

RR Description: Latency rule applied in case definition

	1	2	Total
	absent	present	

RR Data

	N	47	9	56
	NS	36	6	42
Wt	3027.57	1016.73	4044.30	
Het Chi	704.58	35.37	838.77	
Het df	46	8	55	
Het P	***	***	***	
Fixed RR	14.91	21.37	16.32	
RRl	14.39	20.10	15.83	
RRu	15.45	22.73	16.83	
P	+++	+++	+++	
Random RR	13.29	19.52	14.01	
RRl	11.42	16.27	12.27	
RRu	15.46	23.42	15.99	
P	+++	+++	+++	
Asymm P	N.S.	N.S.	*	
Between Chi		98.83	98.83	
Between df		1	1	
Between P		+++	***	
Btwn (F) P		++	**	
Btwn (R) P		++	**	

Table 28
Smoking and Lung cancer: Cigarette Smoking analyses
Studies in North America and Europe only
Initial analysis by study design

Cohort	STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
			Case	Cont	Case	Cont		
	*ACE	2	-	-	-	-	18.56 (9.07- 37.96)	
	*AEROBIC	1	100	6840	35	18088	7.56 (5.15- 11.09)	
	*AGRICAN	1	-	-	-	-	28.84 (20.35- 40.87)	
	*AGRICAN	2	-	-	-	-	16.53 (9.44- 28.95)	
	Subtotal AGRICAN						24.69 (18.36- 33.20)	
	*AHS	2	-	-	-	-	23.03 (17.34- 30.59)	
	*AMIAANT	1	61	2224	13	2645	5.58 (3.07- 10.13)	
	*ARIC	3	-	-	-	-	41.41 (18.36- 93.42)	
	*ARIC	4	-	-	-	-	13.13 (8.46- 20.41)	
	Subtotal ARIC						17.03 (11.56- 25.09)	
	*ATP	9	-	-	-	-	9.33 (3.82- 22.84)	
	*ATP	10	-	-	-	-	23.40 (12.26- 44.63)	
	Subtotal ATP						17.07 (10.11- 28.82)	
	*BIOBANK	2	329	22934	78	98319	18.08 (14.13- 23.14)	
	*BIOBANK	1	244	19464	127	134209	13.25 (10.70- 16.41)	
	Subtotal BIOBANK						15.14 (12.88- 17.80)	
	*BWHS	3	-	-	-	-	11.78 (8.55- 16.24)	
	*CHANCES	2	-	-	-	-	13.10 (9.90- 17.30)	
	*COAL	1	-	-	-	-	9.20 (5.30- 16.00)	
	*CPSI	5	-	-	-	-	12.22 (9.59- 15.58)	
	*CPSI	6	-	-	-	-	2.73 (2.07- 3.61)	
	Subtotal CPSI						6.39 (5.33- 7.68)	
	*CPSII	5	-	-	-	-	23.81 (19.85- 28.57)	
	*CPSII	6	-	-	-	-	12.65 (11.15- 14.34)	
	Subtotal CPSII						15.52 (13.99- 17.21)	
	*EPIC	3	-	-	-	-	32.00 (21.38- 47.90)	
	*EPIC	6	-	-	-	-	7.53 (5.87- 9.66)	
	Subtotal EPIC						11.23 (9.08- 13.88)	
	*FRAMING	2	-	-	-	-	7.55 (4.94- 11.55)	
	*HBC	1	-	-	-	-	4.20 (1.60- 11.10)	
	*KAISER	2	-	-	-	-	13.20 (11.10- 15.70)	
	*KRIS	3	-	-	-	-	10.47 (6.74- 16.25)	
	*MWOMEN	3	-	-	-	-	21.20 (19.50- 23.10)	
	*NHANES	1	144	2374	17	4853	17.32 (10.50- 28.56)	
	*NHIS	6	-	-	-	-	14.60 (9.10- 23.40)	
	*NHIS	5	-	-	-	-	17.80 (11.40- 27.80)	
	Subtotal NHIS						16.21 (11.72- 22.42)	
	*NHS	2	-	-	-	-	23.30 (19.00- 28.80)	
	*NIHAARP	4	-	-	-	-	29.40 (25.20- 34.30)	
	*NIHAARP	2	-	-	-	-	19.50 (17.20- 22.20)	
	Subtotal NIHAARP						23.04 (20.89- 25.42)	
	*NLMS	4	-	-	-	-	11.82 (10.73- 13.03)	
	*NLST	2	-	-	-	-	24.32 (10.98- 53.85)	
	*NOWAC	3	-	-	-	-	11.89 (9.66- 14.64)	
	*PLCO	2	-	-	-	-	31.97 (25.16- 40.63)	
	*QRESEAR	3	-	-	-	-	7.35 (4.54- 11.90)	
	*QRESEAR	4	-	-	-	-	7.13 (4.47- 11.37)	
	Subtotal QRESEAR						7.24 (5.17- 10.12)	
	*SHEETME	1	410	4400	53	4503	7.92 (5.97- 10.51)	
	*THIN	1	372	134000	112	437000	10.83 (8.77- 13.38)	
	*THREEC	5	-	-	-	-	16.78 (10.31- 27.33)	
	*THREEC	8	273	12388	14	15703	24.72 (14.45- 42.27)	
	Subtotal THREEC						19.99 (13.94- 28.68)	
	*USA5	5	-	-	-	-	24.97 (22.20- 28.09)	
	*USA5	6	-	-	-	-	25.66 (23.17- 28.40)	
	Subtotal USA5						25.36 (23.48- 27.39)	
	*VETERAN	1	54	1443	4	1798	16.82 (6.11- 46.34)	
	*VITAL	1	251	6169	60	36381	24.67 (18.64- 32.65)	
	*VLAGT	1	164	2420	0	567	77.14~ (4.81-1236.55)	
	*VLAGT	4	-	-	-	-	9.27 (4.45- 19.28)	
	Subtotal VLAGT						10.64 (5.24- 21.62)	
	*WHI	3	-	-	-	-	13.44 (10.80- 16.74)	
	Partial Totals		2402	214656	513	754066		
	*prospective study							

Table 28
Smoking and Lung cancer: Cigarette Smoking analyses
Studies in North America and Europe only
Initial analysis by study design

Nested CC

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
ESTHER	1	70	239	17	704	12.13	(7.00- 21.02)
*HPFS	3	-	-	-	-	12.56	(6.02- 26.22)
*NLCS	4	1502	9069	95	4345	7.57	(6.18- 9.29)
*NLCS	5	275	6540	103	20158	8.23	(6.57- 10.30)
Subtotal NLCS						7.86	(6.76- 9.15)
NONMET	2	-	-	-	-	7.97	(4.17- 15.27)
SCCS	1	505	1209	22	686	13.02	(8.41- 20.16)
SCCS	2	469	667	54	1203	15.66	(11.64- 21.08)
Subtotal SCCS						14.78	(11.56- 18.89)
Partial Totals		2821	17724	291	27096		

*prospective study

RR Description: Study design
1 2
Cohort Nested CC Total

RR Data

N	49	7	56
NS	36	5	41
Wt	3783.51	260.79	4044.30
Het Chi	736.13	20.77	838.77
Het df	48	6	55
Het P	***	**	***
Fixed RR	16.94	9.49	16.32
RRl	16.41	8.41	15.83
RRu	17.49	10.72	16.83
P	+++	+++	+++
Random RR	14.58	10.41	14.01
RRl	12.71	8.04	12.27
RRu	16.74	13.48	15.99
P	+++	+++	+++
Asymm P	(*)	N.S.	*
Between Chi		81.87	81.87
Between df		1	1
Between P		---	***
Btwn (F) P		-	*
Btwn (R) P		-	*

Table 29
Smoking and Lung cancer: Cigarette Smoking analyses
Studies in North America and Europe only
Initial analysis by lowest age considered in the study

<30

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*ACE	2	-	-	-	-	18.56 (9.07- 37.96)	
*AEROBIC	1	100	6840	35	18088	7.56 (5.15- 11.09)	
*AGRICAN	1	-	-	-	-	28.84 (20.35- 40.87)	
*AGRICAN	2	-	-	-	-	16.53 (9.44- 28.95)	
Subtotal AGRICAN						24.69 (18.36- 33.20)	
*BWHS	3	-	-	-	-	11.78 (8.55- 16.24)	
*NHIS	6	-	-	-	-	14.60 (9.10- 23.40)	
*NHIS	5	-	-	-	-	17.80 (11.40- 27.80)	
Subtotal NHIS						16.21 (11.72- 22.42)	
*QRESEAR	3	-	-	-	-	7.35 (4.54- 11.90)	
*QRESEAR	4	-	-	-	-	7.13 (4.47- 11.37)	
Subtotal QRESEAR						7.24 (5.17- 10.12)	
*THREEC	5	-	-	-	-	16.78 (10.31- 27.33)	
*VETERAN	1	54	1443	4	1798	16.82 (6.11- 46.34)	
*VLAGT	1	164	2420	0	567	77.14~ (4.81-1236.55)	
*VLAGT	4	-	-	-	-	9.27 (4.45- 19.28)	
Subtotal VLAGT						10.64 (5.24- 21.62)	
Partial Totals		318	10703	39	20453		

*prospective study

30-39

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*ATP	9	-	-	-	-	9.33 (3.82- 22.84)	
*ATP	10	-	-	-	-	23.40 (12.26- 44.63)	
Subtotal ATP						17.07 (10.11- 28.82)	
*EPIC	3	-	-	-	-	32.00 (21.38- 47.90)	
*EPIC	6	-	-	-	-	7.53 (5.87- 9.66)	
Subtotal EPIC						11.23 (9.08- 13.88)	
*NHS	2	-	-	-	-	23.30 (19.00- 28.80)	
*NLMS	4	-	-	-	-	11.82 (10.73- 13.03)	
*NOWAC	3	-	-	-	-	11.89 (9.66- 14.64)	
*THIN	1	372	134000	112	437000	10.83 (8.77- 13.38)	
*THREEC	8	273	12388	14	15703	24.72 (14.45- 42.27)	
Partial Totals		645	146388	126	452703		

*prospective study

40-48

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*ARIC	3	-	-	-	-	41.41 (18.36- 93.42)	
*ARIC	4	-	-	-	-	13.13 (8.46- 20.41)	
Subtotal ARIC						17.03 (11.56- 25.09)	
*BIOBANK	2	329	22934	78	98319	18.08 (14.13- 23.14)	
*BIOBANK	1	244	19464	127	134209	13.25 (10.70- 16.41)	
Subtotal BIOBANK						15.14 (12.88- 17.80)	
*CHANCES	2	-	-	-	-	13.10 (9.90- 17.30)	
*HPFS	3	-	-	-	-	12.56 (6.02- 26.22)	
*KRIS	3	-	-	-	-	10.47 (6.74- 16.25)	
*NHANES	1	144	2374	17	4853	17.32 (10.50- 28.56)	
SCCS	1	505	1209	22	686	13.02 (8.41- 20.16)	
SCCS	2	469	667	54	1203	15.66 (11.64- 21.08)	
Subtotal SCCS						14.78 (11.56- 18.89)	
*USA5	5	-	-	-	-	24.97 (22.20- 28.09)	
*USA5	6	-	-	-	-	25.66 (23.17- 28.40)	
Subtotal USA5						25.36 (23.48- 27.39)	
Partial Totals		1691	46648	298	239270		

*prospective study

Table 29
Smoking and Lung cancer: Cigarette Smoking analyses
Studies in North America and Europe only
Initial analysis by lowest age considered in the study

49+

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*CPSI	5	-	-	-	-	12.22 (9.59- 15.58)	
*CPSI	6	-	-	-	-	2.73 (2.07- 3.61)	
Subtotal CPSI						6.39 (5.33- 7.68)	
*CPSII	5	-	-	-	-	23.81 (19.85- 28.57)	
*CPSII	6	-	-	-	-	12.65 (11.15- 14.34)	
Subtotal CPSII						15.52 (13.99- 17.21)	
ESTHER	1	70	239	17	704	12.13 (7.00- 21.02)	
*HBC	1	-	-	-	-	4.20 (1.60- 11.10)	
*MWOMEN	3	-	-	-	-	21.20 (19.50- 23.10)	
*NIHAARP	4	-	-	-	-	29.40 (25.20- 34.30)	
*NIHAARP	2	-	-	-	-	19.50 (17.20- 22.20)	
Subtotal NIHAARP						23.04 (20.89- 25.42)	
*NLCS	4	1502	9069	95	4345	7.57 (6.18- 9.29)	
*NLCS	5	275	6540	103	20158	8.23 (6.57- 10.30)	
Subtotal NLCS						7.86 (6.76- 9.15)	
*PLCO	2	-	-	-	-	31.97 (25.16- 40.63)	
*VITAL	1	251	6169	60	36381	24.67 (18.64- 32.65)	
*WHI	3	-	-	-	-	13.44 (10.80- 16.74)	
Partial Totals		2098	22017	275	61588		

*prospective study

Missing

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*AHS	2	-	-	-	-	23.03 (17.34- 30.59)	
*AMIANANT	1	61	2224	13	2645	5.58 (3.07- 10.13)	
*COAL	1	-	-	-	-	9.20 (5.30- 16.00)	
*FRAMING	2	-	-	-	-	7.55 (4.94- 11.55)	
*KAISER	2	-	-	-	-	13.20 (11.10- 15.70)	
*NLST	2	-	-	-	-	24.32 (10.98- 53.85)	
*NONMET	2	-	-	-	-	7.97 (4.17- 15.27)	
*SHEETME	1	410	4400	53	4503	7.92 (5.97- 10.51)	
Partial Totals		471	6624	66	7148		

*prospective study

Lowest age included, grouped

1 2 3 4 5
<30 30-39 40-48 49+ Missing Total

RR Data

N	13	9	12	14	8	56
NS	9	7	8	10	8	42
Wt	213.03	784.14	976.47	1787.31	283.35	4044.30
Het Chi	47.24	84.20	80.86	434.27	46.06	838.77
Het df	12	8	11	13	7	55
Het P	***	***	***	***	***	***
Fixed RR	13.28	12.82	21.06	16.96	12.10	16.32
RRl	11.61	11.96	19.78	16.19	10.77	15.83
RRu	15.19	13.75	22.42	17.77	13.60	16.83
P	+++	+++	+++	+++	+++	+++
Random RR	13.33	15.02	16.74	13.62	10.79	14.01
RRl	10.01	11.37	13.63	10.22	7.64	12.27
RRu	17.74	19.83	20.55	18.16	15.23	15.99
P	+++	+++	+++	+++	+++	+++
Asymm P	N.S.	N.S.	*	N.S.	N.S.	*
Between Chi		0.21	37.16	11.38	1.05	146.14
Between df		1	1	1	1	4
Between P		N.S.	+++	+++	N.S.	***
Btwn (F) P		N.S.	+	N.S.	N.S.	*
Btwn (R) P		N.S.	N.S.	N.S.	N.S.	N.S.

Table 30
Smoking and Lung cancer: Cigarette Smoking analyses
Studies in North America and Europe only
Initial analysis by lowest age considered: trend without 'Missing'

<30

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*ACE	2	-	-	-	-	18.56 (9.07- 37.96)	
*AEROBIC	1	100	6840	35	18088	7.56 (5.15- 11.09)	
*AGRICAN	1	-	-	-	-	28.84 (20.35- 40.87)	
*AGRICAN	2	-	-	-	-	16.53 (9.44- 28.95)	
Subtotal AGRICAN						24.69 (18.36- 33.20)	
*BWHS	3	-	-	-	-	11.78 (8.55- 16.24)	
*NHIS	6	-	-	-	-	14.60 (9.10- 23.40)	
*NHIS	5	-	-	-	-	17.80 (11.40- 27.80)	
Subtotal NHIS						16.21 (11.72- 22.42)	
*QRESEAR	3	-	-	-	-	7.35 (4.54- 11.90)	
*QRESEAR	4	-	-	-	-	7.13 (4.47- 11.37)	
Subtotal QRESEAR						7.24 (5.17- 10.12)	
*THREEC	5	-	-	-	-	16.78 (10.31- 27.33)	
*VETERAN	1	54	1443	4	1798	16.82 (6.11- 46.34)	
*VLAGT	1	164	2420	0	567	77.14~ (4.81-1236.55)	
*VLAGT	4	-	-	-	-	9.27 (4.45- 19.28)	
Subtotal VLAGT						10.64 (5.24- 21.62)	
Partial Totals		318	10703	39	20453		

*prospective study

30-39

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*ATP	9	-	-	-	-	9.33 (3.82- 22.84)	
*ATP	10	-	-	-	-	23.40 (12.26- 44.63)	
Subtotal ATP						17.07 (10.11- 28.82)	
*EPIC	3	-	-	-	-	32.00 (21.38- 47.90)	
*EPIC	6	-	-	-	-	7.53 (5.87- 9.66)	
Subtotal EPIC						11.23 (9.08- 13.88)	
*NHS	2	-	-	-	-	23.30 (19.00- 28.80)	
*NLMS	4	-	-	-	-	11.82 (10.73- 13.03)	
*NOWAC	3	-	-	-	-	11.89 (9.66- 14.64)	
*THIN	1	372	134000	112	437000	10.83 (8.77- 13.38)	
*THREEC	8	273	12388	14	15703	24.72 (14.45- 42.27)	
Partial Totals		645	146388	126	452703		

*prospective study

40-48

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*ARIC	3	-	-	-	-	41.41 (18.36- 93.42)	
*ARIC	4	-	-	-	-	13.13 (8.46- 20.41)	
Subtotal ARIC						17.03 (11.56- 25.09)	
*BIOBANK	2	329	22934	78	98319	18.08 (14.13- 23.14)	
*BIOBANK	1	244	19464	127	134209	13.25 (10.70- 16.41)	
Subtotal BIOBANK						15.14 (12.88- 17.80)	
*CHANCES	2	-	-	-	-	13.10 (9.90- 17.30)	
*HPFS	3	-	-	-	-	12.56 (6.02- 26.22)	
*KRIS	3	-	-	-	-	10.47 (6.74- 16.25)	
*NHANES	1	144	2374	17	4853	17.32 (10.50- 28.56)	
SCCS	1	505	1209	22	686	13.02 (8.41- 20.16)	
SCCS	2	469	667	54	1203	15.66 (11.64- 21.08)	
Subtotal SCCS						14.78 (11.56- 18.89)	
*USA5	5	-	-	-	-	24.97 (22.20- 28.09)	
*USA5	6	-	-	-	-	25.66 (23.17- 28.40)	
Subtotal USA5						25.36 (23.48- 27.39)	
Partial Totals		1691	46648	298	239270		

*prospective study

Table 30
Smoking and Lung cancer: Cigarette Smoking analyses
Studies in North America and Europe only
Initial analysis by lowest age considered: trend without 'Missing'

49+

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*CPSI	5	-	-	-	-	12.22 (9.59- 15.58)	
*CPSI	6	-	-	-	-	2.73 (2.07- 3.61)	
Subtotal CPSI						6.39 (5.33- 7.68)	
*CPSII	5	-	-	-	-	23.81 (19.85- 28.57)	
*CPSII	6	-	-	-	-	12.65 (11.15- 14.34)	
Subtotal CPSII						15.52 (13.99- 17.21)	
ESTHER	1	70	239	17	704	12.13 (7.00- 21.02)	
*HBC	1	-	-	-	-	4.20 (1.60- 11.10)	
*MWOMEN	3	-	-	-	-	21.20 (19.50- 23.10)	
*NIHAARP	4	-	-	-	-	29.40 (25.20- 34.30)	
*NIHAARP	2	-	-	-	-	19.50 (17.20- 22.20)	
Subtotal NIHAARP						23.04 (20.89- 25.42)	
*NLCS	4	1502	9069	95	4345	7.57 (6.18- 9.29)	
*NLCS	5	275	6540	103	20158	8.23 (6.57- 10.30)	
Subtotal NLCS						7.86 (6.76- 9.15)	
*PLCO	2	-	-	-	-	31.97 (25.16- 40.63)	
*VITAL	1	251	6169	60	36381	24.67 (18.64- 32.65)	
*WHI	3	-	-	-	-	13.44 (10.80- 16.74)	
Partial Totals		2098	22017	275	61588		

*prospective study

Lowest age included, grouped, excluding Missing

	1	2	3	4	Total	Trend
	<30	30-39	40-48	49+		

RR Data

	N	13	9	12	14	48
NS		9	7	8	10	34
Wt		213.03	784.14	976.47	1787.31	3760.95
Het Chi		47.24	84.20	80.86	434.27	765.46
Het df		12	8	11	13	47
Het P		***	***	***	***	***
Fixed RR		13.28	12.82	21.06	16.96	16.69
RR1		11.61	11.96	19.78	16.19	16.17
RRu		15.19	13.75	22.42	17.77	17.24
P		+++	+++	+++	+++	+++
Random RR		13.33	15.02	16.74	13.62	14.61
RR1		10.01	11.37	13.63	10.22	12.67
RRu		17.74	19.83	20.55	18.16	16.83
P		+++	+++	+++	+++	+++
Asymm P		N.S.	N.S.	*	N.S.	(*)
Between Chi			0.21	37.16	11.38	118.88
Between df			1	1	1	3
Between P			N.S.	+++	+++	***
Btwn (F) P			N.S.	+	N.S.	(*)
Btwn (R) P			N.S.	N.S.	N.S.	N.S.

Table 31
Smoking and Lung cancer: Cigarette Smoking analyses
Studies in North America and Europe only
Initial analysis by years of follow-up

<10

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*AGRICAN	1	-	-	-	-	28.84	(20.35- 40.87)
*AGRICAN	2	-	-	-	-	16.53	(9.44- 28.95)
Subtotal AGRICAN						24.69	(18.36- 33.20)
*CPSI	5	-	-	-	-	12.22	(9.59- 15.58)
*CPSI	6	-	-	-	-	2.73	(2.07- 3.61)
Subtotal CPSI						6.39	(5.33- 7.68)
*CPSII	5	-	-	-	-	23.81	(19.85- 28.57)
*CPSII	6	-	-	-	-	12.65	(11.15- 14.34)
Subtotal CPSII						15.52	(13.99- 17.21)
*EPIC	6	-	-	-	-	7.53	(5.87- 9.66)
*HBC	1	-	-	-	-	4.20	(1.60- 11.10)
*NHIS	6	-	-	-	-	14.60	(9.10- 23.40)
*NHIS	5	-	-	-	-	17.80	(11.40- 27.80)
Subtotal NHIS						16.21	(11.72- 22.42)
*VITAL	1	251	6169	60	36381	24.67	(18.64- 32.65)
Partial Totals		251	6169	60	36381		
*prospective study							

10-<15

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*ACE	2	-	-	-	-	18.56	(9.07- 37.96)
*AMIANT	1	61	2224	13	2645	5.58	(3.07- 10.13)
*BIOBANK	2	329	22934	78	98319	18.08	(14.13- 23.14)
*BIOBANK	1	244	19464	127	134209	13.25	(10.70- 16.41)
Subtotal BIOBANK						15.14	(12.88- 17.80)
*EPIC	3	-	-	-	-	32.00	(21.38- 47.90)
*HFPS	3	-	-	-	-	12.56	(6.02- 26.22)
*NIHAARP	4	-	-	-	-	29.40	(25.20- 34.30)
*NIHAARP	2	-	-	-	-	19.50	(17.20- 22.20)
Subtotal NIHAARP						23.04	(20.89- 25.42)
SCCS	1	505	1209	22	686	13.02	(8.41- 20.16)
SCCS	2	469	667	54	1203	15.66	(11.64- 21.08)
Subtotal SCCS						14.78	(11.56- 18.89)
*THIN	1	372	134000	112	437000	10.83	(8.77- 13.38)
Partial Totals		1980	180498	406	674062		
*prospective study							

15-<20

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*AHS	2	-	-	-	-	23.03	(17.34- 30.59)
*ARIC	3	-	-	-	-	41.41	(18.36- 93.42)
*ARIC	4	-	-	-	-	13.13	(8.46- 20.41)
Subtotal ARIC						17.03	(11.56- 25.09)
*ATP	9	-	-	-	-	9.33	(3.82- 22.84)
*ATP	10	-	-	-	-	23.40	(12.26- 44.63)
Subtotal ATP						17.07	(10.11- 28.82)
*BWHS	3	-	-	-	-	11.78	(8.55- 16.24)
ESTHER	1	70	239	17	704	12.13	(7.00- 21.02)
*MWOMEN	3	-	-	-	-	21.20	(19.50- 23.10)
*NHANES	1	144	2374	17	4853	17.32	(10.50- 28.56)
*NLST	2	-	-	-	-	24.32	(10.98- 53.85)
*PLCO	2	-	-	-	-	31.97	(25.16- 40.63)
*QRESEAR	3	-	-	-	-	7.35	(4.54- 11.90)
*QRESEAR	4	-	-	-	-	7.13	(4.47- 11.37)
Subtotal QRESEAR						7.24	(5.17- 10.12)
*WHI	3	-	-	-	-	13.44	(10.80- 16.74)
Partial Totals		214	2613	34	5557		
*prospective study							

Table 31
Smoking and Lung cancer: Cigarette Smoking analyses
Studies in North America and Europe only
Initial analysis by years of follow-up

20-<30

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*AEROBIC	1	100	6840	35	18088	7.56	(5.15- 11.09)
*CHANCES	2	-	-	-	-	13.10	(9.90- 17.30)
*NHS	2	-	-	-	-	23.30	(19.00- 28.80)
*NLCS	4	1502	9069	95	4345	7.57	(6.18- 9.29)
*NLCS	5	275	6540	103	20158	8.23	(6.57- 10.30)
Subtotal NLCS						7.86	(6.76- 9.15)
*NLMS	4	-	-	-	-	11.82	(10.73- 13.03)
*NOWAC	3	-	-	-	-	11.89	(9.66- 14.64)
*SHEETME	1	410	4400	53	4503	7.92	(5.97- 10.51)
*USA5	5	-	-	-	-	24.97	(22.20- 28.09)
*USA5	6	-	-	-	-	25.66	(23.17- 28.40)
Subtotal USA5						25.36	(23.48- 27.39)
*VETERAN	1	54	1443	4	1798	16.82	(6.11- 46.34)
Partial Totals		2341	28292	290	48892		

*prospective study

30+

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*COAL	1	-	-	-	-	9.20	(5.30- 16.00)
*FRAMING	2	-	-	-	-	7.55	(4.94- 11.55)
*KAISER	2	-	-	-	-	13.20	(11.10- 15.70)
*KRIS	3	-	-	-	-	10.47	(6.74- 16.25)
NONMET	2	-	-	-	-	7.97	(4.17- 15.27)
*THREEC	5	-	-	-	-	16.78	(10.31- 27.33)
*THREEC	8	273	12388	14	15703	24.72	(14.45- 42.27)
Subtotal THREEC						19.99	(13.94- 28.68)
*VLAGT	1	164	2420	0	567	77.14	(4.81-1236.55)
*VLAGT	4	-	-	-	-	9.27	(4.45- 19.28)
Subtotal VLAGT						10.64	(5.24- 21.62)
Partial Totals		437	14808	14	16270		

*prospective study

Years follow-up, grouped

1 2 3 4 5
<10 10-<15 15-<20 20-<30 30+ Total Trend

RR Data

	N	11	11	14	11	9	56	
	NS	7	8	11	9	7	42	
	Wt	668.81	743.64	875.21	1528.82	227.83	4044.30	
	Het Chi	230.34	96.75	88.18	321.01	19.31	838.77	
	Het df	10	10	13	10	8	55	
	Het P	***	***	***	***	*	***	
	Fixed RR	13.22	18.37	19.31	16.00	12.36	16.32	
	RRl	12.25	17.09	18.07	15.22	10.85	15.83	
	RRu	14.26	19.74	20.63	16.82	14.07	16.83	
	P	+++	+++	+++	+++	+++	+++	
	Random RR	12.63	16.05	16.05	12.93	11.86	14.01	
	RRl	8.49	12.48	12.69	9.50	9.18	12.27	
	RRu	18.80	20.65	20.30	17.61	15.31	15.99	
	P	+++	+++	+++	+++	+++	+++	
	Asymm P	N.S.	N.S.	N.S.	N.S.	N.S.	*	
	Between Chi		38.16	54.52	17.00	0.77	83.18	0.24
	Between df		1	1	1	1	4	1
	Between P		+++	+++	+++	N.S.	***	N.S.
	Btwn (F) P		N.S.	(+)	N.S.	N.S.	N.S.	N.S.
	Btwn (R) P		N.S.	N.S.	N.S.	N.S.	N.S.	N.S.

Table 32
Smoking and Lung cancer: Cigarette Smoking analyses
Studies in North America and Europe only
Initial analysis by endpoint

Died							
STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*ACE	2	-	-	-	-	18.56 (9.07- 37.96)	
*AEROBIC	1	100	6840	35	18088	7.56 (5.15- 11.09)	
*COAL	1	-	-	-	-	9.20 (5.30- 16.00)	
*CPSI	5	-	-	-	-	12.22 (9.59- 15.58)	
*CPSI	6	-	-	-	-	2.73 (2.07- 3.61)	
Subtotal CPSI						6.39 (5.33- 7.68)	
*CPSII	5	-	-	-	-	23.81 (19.85- 28.57)	
*CPSII	6	-	-	-	-	12.65 (11.15- 14.34)	
Subtotal CPSII						15.52 (13.99- 17.21)	
*MWOMEN	3	-	-	-	-	21.20 (19.50- 23.10)	
*NHANES	1	144	2374	17	4853	17.32 (10.50- 28.56)	
*NHIS	6	-	-	-	-	14.60 (9.10- 23.40)	
*NHIS	5	-	-	-	-	17.80 (11.40- 27.80)	
Subtotal NHIS						16.21 (11.72- 22.42)	
*NHS	2	-	-	-	-	23.30 (19.00- 28.80)	
*NLMS	4	-	-	-	-	11.82 (10.73- 13.03)	
*NLST	2	-	-	-	-	24.32 (10.98- 53.85)	
NONMET	2	-	-	-	-	7.97 (4.17- 15.27)	
*PLCO	2	-	-	-	-	31.97 (25.16- 40.63)	
*SHEETME	1	410	4400	53	4503	7.92 (5.97- 10.51)	
*THREEC	5	-	-	-	-	16.78 (10.31- 27.33)	
*THREEC	8	273	12388	14	15703	24.72 (14.45- 42.27)	
Subtotal THREEC						19.99 (13.94- 28.68)	
*USA5	5	-	-	-	-	24.97 (22.20- 28.09)	
*USA5	6	-	-	-	-	25.66 (23.17- 28.40)	
Subtotal USA5						25.36 (23.48- 27.39)	
*VLAGT	1	164	2420	0	567	77.14~ (4.81-1236.55)	
*VLAGT	4	-	-	-	-	9.27 (4.45- 19.28)	
Subtotal VLAGT						10.64 (5.24- 21.62)	
Partial Totals		1091	28422	119	43714		
*prospective study							
Diagnosed							
STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*AGRICAN	1	-	-	-	-	28.84 (20.35- 40.87)	
*AGRICAN	2	-	-	-	-	16.53 (9.44- 28.95)	
Subtotal AGRICAN						24.69 (18.36- 33.20)	
*AHS	2	-	-	-	-	23.03 (17.34- 30.59)	
*AMIANANT	1	61	2224	13	2645	5.58 (3.07- 10.13)	
*ARIC	3	-	-	-	-	41.41 (18.36- 93.42)	
*ARIC	4	-	-	-	-	13.13 (8.46- 20.41)	
Subtotal ARIC						17.03 (11.56- 25.09)	
*ATP	9	-	-	-	-	9.33 (3.82- 22.84)	
*ATP	10	-	-	-	-	23.40 (12.26- 44.63)	
Subtotal ATP						17.07 (10.11- 28.82)	
*BIOBANK	2	329	22934	78	98319	18.08 (14.13- 23.14)	
*BIOBANK	1	244	19464	127	134209	13.25 (10.70- 16.41)	
Subtotal BIOBANK						15.14 (12.88- 17.80)	
*BWHS	3	-	-	-	-	11.78 (8.55- 16.24)	
*CHANCES	2	-	-	-	-	13.10 (9.90- 17.30)	
*EPIC	3	-	-	-	-	32.00 (21.38- 47.90)	
*EPIC	6	-	-	-	-	7.53 (5.87- 9.66)	
Subtotal EPIC						11.23 (9.08- 13.88)	
ESTHER	1	70	239	17	704	12.13 (7.00- 21.02)	
*FRAMING	2	-	-	-	-	7.55 (4.94- 11.55)	
*HBC	1	-	-	-	-	4.20 (1.60- 11.10)	
*HPFS	3	-	-	-	-	12.56 (6.02- 26.22)	
*KAISER	2	-	-	-	-	13.20 (11.10- 15.70)	
*KRIS	3	-	-	-	-	10.47 (6.74- 16.25)	
*NIHAARP	4	-	-	-	-	29.40 (25.20- 34.30)	
*NIHAARP	2	-	-	-	-	19.50 (17.20- 22.20)	
Subtotal NIHAARP						23.04 (20.89- 25.42)	
*NLCS	4	1502	9069	95	4345	7.57 (6.18- 9.29)	
*NLCS	5	275	6540	103	20158	8.23 (6.57- 10.30)	
Subtotal NLCS						7.86 (6.76- 9.15)	
*NOWAC	3	-	-	-	-	11.89 (9.66- 14.64)	
*QRESEAR	3	-	-	-	-	7.35 (4.54- 11.90)	
*QRESEAR	4	-	-	-	-	7.13 (4.47- 11.37)	
Subtotal QRESEAR						7.24 (5.17- 10.12)	
SCCS	1	505	1209	22	686	13.02 (8.41- 20.16)	
SCCS	2	469	667	54	1203	15.66 (11.64- 21.08)	

Table 32
Smoking and Lung cancer: Cigarette Smoking analyses
Studies in North America and Europe only
Initial analysis by endpoint

Diagnosed

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
Subtotal	SCCS					14.78	(11.56- 18.89)
*THIN	1	372	134000	112	437000	10.83	(8.77- 13.38)
*VETERAN	1	54	1443	4	1798	16.82	(6.11- 46.34)
*VITAL	1	251	6169	60	36381	24.67	(18.64- 32.65)
*WHI	3	-	-	-	-	13.44	(10.80- 16.74)
Partial Totals		4132	203958	685	737448		

*prospective study

RR Description:Endpoint reported
1 2
Died Diagnosed Total

RR Data

	N	23	33	56
	NS	17	24	41
	Wt	2418.74	1625.55	4044.30
Het	Chi	486.00	318.15	838.77
Het	df	22	32	55
Het	P	***	***	***
Fixed	RR	17.61	14.58	16.32
	RRl	16.92	13.89	15.83
	RRu	18.32	15.31	16.83
	P	+++	+++	+++
Random	RR	14.85	13.47	14.01
	RRl	11.99	11.41	12.27
	RRu	18.38	15.89	15.99
	P	+++	+++	+++
Asymm	P	N.S.	N.S.	*
Between	Chi		34.62	34.62
Between	df		1	1
Between	P		---	***
Btwn (F)	P		N.S.	N.S.
Btwn (R)	P		N.S.	N.S.

Table 33
Smoking and Lung cancer: Cigarette Smoking analyses
Studies in North America and Europe only
Initial analysis by number of adjustment factors

Unadj		Numbers exposed		Non-exposed		RR	95.00%CI
STUDY	NRR	Case	Cont	Case	Cont		
*AEROBIC	1	100	6840	35	18088	7.56	(5.15- 11.09)
*AMIAANT	1	61	2224	13	2645	5.58	(3.07- 10.13)
*BIOBANK	2	329	22934	78	98319	18.08	(14.13- 23.14)
*BIOBANK	1	244	19464	127	134209	13.25	(10.70- 16.41)
Subtotal BIOBANK						15.14	(12.88- 17.80)
ESTHER	1	70	239	17	704	12.13	(7.00- 21.02)
*NHANES	1	144	2374	17	4853	17.32	(10.50- 28.56)
*NLCS	4	1502	9069	95	4345	7.57	(6.18- 9.29)
*NLCS	5	275	6540	103	20158	8.23	(6.57- 10.30)
Subtotal NLCS						7.86	(6.76- 9.15)
SCCS	1	505	1209	22	686	13.02	(8.41- 20.16)
SCCS	2	469	667	54	1203	15.66	(11.64- 21.08)
Subtotal SCCS						14.78	(11.56- 18.89)
*SHEETME	1	410	4400	53	4503	7.92	(5.97- 10.51)
*THIN	1	372	134000	112	437000	10.83	(8.77- 13.38)
*THREEC	8	273	12388	14	15703	24.72	(14.45- 42.27)
*VETERAN	1	54	1443	4	1798	16.82	(6.11- 46.34)
*VITAL	1	251	6169	60	36381	24.67	(18.64- 32.65)
*VLAGT	1	164	2420	0	567	77.14~	(4.81-1236.55)
Totals		5223	232380	804	781162		
*prospective study							
Age-only		Numbers exposed		Non-exposed		RR	95.00%CI
STUDY	NRR	Case	Cont	Case	Cont		
*AGRICAN	1	-	-	-	-	28.84	(20.35- 40.87)
*AGRICAN	2	-	-	-	-	16.53	(9.44- 28.95)
Subtotal AGRICAN						24.69	(18.36- 33.20)
*FRAMING	2	-	-	-	-	7.55	(4.94- 11.55)
*HBC	1	-	-	-	-	4.20	(1.60- 11.10)
Partial Totals		0	0	0	0		
*prospective study							
More adj		Numbers exposed		Non-exposed		RR	95.00%CI
STUDY	NRR	Case	Cont	Case	Cont		
*ACE	2	-	-	-	-	18.56	(9.07- 37.96)
*AHS	2	-	-	-	-	23.03	(17.34- 30.59)
*ARIC	3	-	-	-	-	41.41	(18.36- 93.42)
*ARIC	4	-	-	-	-	13.13	(8.46- 20.41)
Subtotal ARIC						17.03	(11.56- 25.09)
*ATP	9	-	-	-	-	9.33	(3.82- 22.84)
*ATP	10	-	-	-	-	23.40	(12.26- 44.63)
Subtotal ATP						17.07	(10.11- 28.82)
*BWHS	3	-	-	-	-	11.78	(8.55- 16.24)
*CHANCES	2	-	-	-	-	13.10	(9.90- 17.30)
*COAL	1	-	-	-	-	9.20	(5.30- 16.00)
*CPSI	5	-	-	-	-	12.22	(9.59- 15.58)
*CPSI	6	-	-	-	-	2.73	(2.07- 3.61)
Subtotal CPSI						6.39	(5.33- 7.68)
*CPSII	5	-	-	-	-	23.81	(19.85- 28.57)
*CPSII	6	-	-	-	-	12.65	(11.15- 14.34)
Subtotal CPSII						15.52	(13.99- 17.21)
*EPIC	3	-	-	-	-	32.00	(21.38- 47.90)
*EPIC	6	-	-	-	-	7.53	(5.87- 9.66)
Subtotal EPIC						11.23	(9.08- 13.88)
*HPFS	3	-	-	-	-	12.56	(6.02- 26.22)
*KAISER	2	-	-	-	-	13.20	(11.10- 15.70)
*KRIS	3	-	-	-	-	10.47	(6.74- 16.25)
*MWOMEN	3	-	-	-	-	21.20	(19.50- 23.10)
*NHIS	6	-	-	-	-	14.60	(9.10- 23.40)
*NHIS	5	-	-	-	-	17.80	(11.40- 27.80)
Subtotal NHIS						16.21	(11.72- 22.42)
*NHS	2	-	-	-	-	23.30	(19.00- 28.80)
*NIHAARP	4	-	-	-	-	29.40	(25.20- 34.30)
*NIHAARP	2	-	-	-	-	19.50	(17.20- 22.20)
Subtotal NIHAARP						23.04	(20.89- 25.42)
*NLMS	4	-	-	-	-	11.82	(10.73- 13.03)
*NLST	2	-	-	-	-	24.32	(10.98- 53.85)
*NONMET	2	-	-	-	-	7.97	(4.17- 15.27)
*NOWAC	3	-	-	-	-	11.89	(9.66- 14.64)
*PLCO	2	-	-	-	-	31.97	(25.16- 40.63)

Table 33
Smoking and Lung cancer: Cigarette Smoking analyses
Studies in North America and Europe only
Initial analysis by number of adjustment factors

More adj

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*QRESEAR	3	-	-	-	-	7.35 (4.54- 11.90)	
*QRESEAR	4	-	-	-	-	7.13 (4.47- 11.37)	
Subtotal QRESEAR						7.24 (5.17- 10.12)	
*THREEC	5	-	-	-	-	16.78 (10.31- 27.33)	
*USA5	5	-	-	-	-	24.97 (22.20- 28.09)	
*USA5	6	-	-	-	-	25.66 (23.17- 28.40)	
Subtotal USA5						25.36 (23.48- 27.39)	
*VLAGT	4	-	-	-	-	9.27 (4.45- 19.28)	
*WHI	3	-	-	-	-	13.44 (10.80- 16.74)	
Partial Totals		0	0	0	0		

*prospective study

Number of adjustment factors, grouped

1 2 3
Unadj Age-only More adj Total Trend

RR Data

N	16	4	36	56	
NS	13	3	27	43	
Wt	644.56	69.23	3330.51	4044.30	
Het Chi	102.09	30.24	617.63	838.77	
Het df	15	3	35	55	
Het P	***	***	***	***	
Fixed RR	11.64	15.44	17.45	16.32	
RRl	10.77	12.20	16.86	15.83	
RRu	12.57	19.54	18.05	16.83	
P	+++	+++	+++	+++	
Random RR	12.31	11.80	14.92	14.01	
RRl	9.88	5.24	12.75	12.27	
RRu	15.35	26.56	17.46	15.99	
P	+++	+++	+++	+++	
Asymm P	N.S.	N.S.	N.S.	*	
Between Chi		5.01	88.60	88.82	88.38
Between df		1	1	2	1
Between P		+	+++	***	+++
Btwn (F) P		N.S.	+	(*)	+
Btwn (R) P		N.S.	N.S.	N.S.	N.S.

Table 34
 Smoking and Lung cancer: Cigarette Smoking analyses
 Studies in North America and Europe only
List of the selected results with RR values for male/female (M/F) ratio - Current cigarette smokers versus never smokers

Study ID	NRR M	RR Male	RRL M	RRU M	NRR F	RR Female	RRL F	RRU F	RR M/F	RRL M/F	RRU M/F
AGRICAN	1	28.84	20.35	40.87	2	16.53	9.44	28.95	1.74	0.90	3.38
ARIC	3	41.41	18.36	93.42	4	13.13	8.46	20.41	3.15	1.25	7.95
ATP	9	9.33	3.82	22.84	10	23.40	12.26	44.63	0.40	0.13	1.20
BIOBANK	2	18.08	14.13	23.14	1	13.25	10.70	16.41	1.36	0.98	1.89
CPSI	5	12.22	9.59	15.58	6	2.73	2.07	3.61	4.48	3.09	6.47
CPSII	5	23.81	19.85	28.57	6	12.65	11.15	14.34	1.88	1.51	2.35
EPIC	5	23.30	16.40	33.20	6	7.53	5.87	9.66	3.09	2.01	4.76
NHIS	6	14.60	9.10	23.40	5	17.80	11.40	27.80	0.82	0.43	1.57
NIHAARP	4	29.40	25.20	34.30	2	19.50	17.20	22.20	1.51	1.23	1.84
NLCS	4	7.57	6.18	9.29	5	8.23	6.57	10.30	0.92	0.68	1.25
QRESEAR	3	7.35	4.54	11.90	4	7.13	4.47	11.37	1.03	0.53	2.02
SCCS	1	13.02	8.41	20.16	2	15.66	11.64	21.08	0.83	0.49	1.41
THREEC	7	44.18	19.77	98.75	8	24.72	14.45	42.27	1.79	0.68	4.70
USA5	5	24.97	22.20	28.09	6	25.66	23.17	28.40	0.97	0.83	1.14
VLGT	1	77.14	4.81	1236.55	2	4.47	2.30	8.67	17.25	1.00	299.01

Table 35
Smoking and Lung cancer: Cigarette Smoking analyses
Studies in North America and Europe only
Meta-analysis analysis of M/F ratio

1

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*AGRICAN	2	-	-	-	-	1.74 (0.90- 3.38)	
*ARIC	4	-	-	-	-	3.15 (1.25- 7.95)	
*ATP	10	-	-	-	-	0.40 (0.13- 1.20)	
*BIOBANK	1	-	-	-	-	1.36 (0.98- 1.89)	
*CPSI	6	-	-	-	-	4.48 (3.09- 6.47)	
*CPSII	6	-	-	-	-	1.88 (1.51- 2.35)	
*EPIC	6	-	-	-	-	3.09 (2.01- 4.76)	
*NHIS	5	-	-	-	-	0.82 (0.43- 1.57)	
*NIHAARP	2	-	-	-	-	1.51 (1.23- 1.84)	
*NLCS	5	-	-	-	-	0.92 (0.68- 1.25)	
*QRESEAR	4	-	-	-	-	1.03 (0.53- 2.02)	
SCCS	2	-	-	-	-	0.83 (0.49- 1.41)	
*THREEC	8	-	-	-	-	1.79 (0.68- 4.70)	
*USA5	6	-	-	-	-	0.97 (0.83- 1.14)	
*VLAGT	2	-	-	-	-	17.25 (1.00- 299.01)	
Partial Totals		0.00	0.00	0.00	0.00		

*prospective study

Group
1
1 Total

M/F ratio

N	15	15
NS	15	15
Wt	512.12	512.12
Het Chi	105.44	105.44
Het df	14	14
Het P	***	***
Fixed RR	1.38	1.38
RRl	1.27	1.27
RRu	1.50	1.50
P	+++	+++
Random RR	1.49	1.49
RRl	1.13	1.13
RRu	1.98	1.98
P	++	++
Asymm P	N.S.	N.S.
Between Chi		
Between df		
Between P		N.S.
Btwn (F) P		N.S.
Btwn (R) P		N.S.

Table 36
 Smoking and Lung cancer: Cigarette Smoking analyses
 Studies in North America and Europe only
List of the selected results together with the ratio of the RR values for multiply-adjusted/unadjusted - Current cigarette

Study ID	Sex	NRR adjust	Adj	RR adjust	NRR unadj	RR unadj	adj/unadj RR ratio
ACE	b	2	8	18.56	1	16.00	1.16
AHS	b	2	8	23.03	1	24.50	0.94
ARIC	m	3	3	41.41	1	37.73	1.10
ARIC	f	4	3	13.13	2	11.70	1.12
ATP	m	9	7	9.33	7	11.63	0.80
ATP	f	10	7	23.40	8	17.20	1.36
BWHS	f	3	7	11.78	1	17.12	0.69
CHANCES	b	2	7	13.10	1	17.18	0.76
CPSI	m	5	3	12.22	1	12.96	0.94
CPSI	f	6	3	2.73	2	2.35	1.16
CPSII	m	5	3	23.81	1	21.58	1.10
CPSII	f	6	3	12.65	2	11.03	1.15
EPIC	m	3	5	32.00	1	32.12	1.00
HPFS	m	3	4	12.56	1	29.72	0.42
KAISER	b	2	6	13.20	1	10.60	1.24
KRIS	m	3	4	10.47	1	12.07	0.87
MWOMEN	f	2	10	21.40	1	21.52	0.99
NHIS	f	5	4	17.80	3	9.86	1.80
NHIS	m	6	4	14.60	4	11.71	1.25
NIHAARP	f	2	5	19.50	1	17.30	1.13
NIHAARP	m	4	5	29.40	3	26.64	1.10
NLMS	b	4	5	11.82	1	11.86	1.00
NLST	m	2	2	24.32	1	36.59	0.66
NONMET	m	2	7	7.97	1	6.86	1.16
NOWAC	f	3	3	11.89	1	10.73	1.11
QRESEAR	m	3	6	7.35	1	7.15	1.03
QRESEAR	f	4	6	7.13	2	6.81	1.05
THREEC	m	5	10	16.78	1	32.58	0.52
USA5	m	5	3	24.97	1	15.86	1.57
USA5	f	6	3	25.66	2	14.71	1.74
VLGT	f	4	3	9.27	2	4.47	2.07
WHI	f	3	15	13.44	1	12.06	1.11

**Evidence relating cigarette, cigar and pipe smoking to lung cancer and COPD.
Meta-analysing recent data from three regions.**

Supplementary File 2

Authors

Peter N Lee, Katharine J Coombs, Jan S Hamling

This supplementary file provides the detailed output from the meta-analyses of smoking and COPD. This relates to cigarette smoking only as the data on pipe and cigar smoking was too limited to make meta-analysis of these smoking products feasible.

Smoking and COPD: Cigarette Smoking analyses

These analyses are restricted to results for current cigarette smokers versus never smokers.

In the initial analyses, if multiple results are available for a single study the results to be included in meta-analysis are selected by applying the following criteria:

- 1) Exclusive cigarette smoking rather than non-exclusive.
- 2) A latency rule was applied rather than none being used.
- 3) The greatest amount of adjustment for possible confounding factors.

In additional analyses,

the ratio of results for males and females within a single study are reported and meta-analysed;
and the ratios of adjusted to unadjusted results for a single study are reported,
but not meta-analysed because these are not independent findings.

Key:

Study ID: Identifier assigned to the study

NRR: Sequence number assigned to the risk estimates within a study

REFID: Identifier assigned to the published paper

Study population: Population considered by the study; National or Regional

YRST: Year of start of baseline

NCASES: Number of COPD cases in the study; the number included in a single analysis will be less

ProductSm: Product smoked

Excl: Exclusive use of the product: 0 = No; x = Yes

Latent: A latency rule was applied, such as ignoring COPD cases identified in the first two or five years after smoking data were gathered: 0 = No; x = Yes

Study design: Cohort or Nested case control design

Sex: Gender reported by the risk estimate; b = both sexes combined, m = male, f = female

LowAge, HighAge: Age range reported by the risk estimate

YrsFU: Number of years of follow up reported by the risk estimate

COPD: Definition of COPD: 1: Self-report, 2: ICD-10 J40-J44, 3: GP notes and ICD-10 J41-J44,
4: ICD-9 491 492 494-496, 5: Participant used anticholinergics, 6: ICD-10 J41-J44 J47,
7: ICD-9 490-2,4,6 ICD-10 J40-J44 J47, 8: ICD-10 J44, 9: GP notes and ICD codes not specified

Endpoint: The way the COPD cases were identified: by diagnosis or by reported death

Adj: Number of adjustment factors applied to the risk estimate

CA1, CA0, CO1, CO0: Numbers of cases (CA)/controls or at risk (CO), exposed (1)/unexposed (0)

RR, RRL, RRU: Relative risk (RR) and confidence interval (RRL to RRU)

Smoking and COPD: Cigarette Smoking analyses

CONTENTS

Table 1: List of all the results - Current cigarette smokers versus never smokers	3
Table 2: List of all the risk estimates - Current cigarette smokers versus never smokers	5
Initial analyses	
Table 3: List of selected results - Current cigarette smokers versus never smokers	7
Table 4: Initial analysis by sex	8
Table 5: Initial analysis by region	9
Table 6: Initial analysis by study population	10
Table 7: Initial analysis by year of start of baseline	11
Table 8: Initial analysis by number of cases in study	12
Table 9: Initial analysis by cigarette smoking exclusively	13
Table 10: Initial analysis by latency rule used	14
Table 11: Initial analysis by lowest age considered in the study	15
Table 12: Initial analysis by lowest age considered: trend without 'Missing'	17
Table 13: Initial analysis by years of follow-up	18
Table 14: Initial analysis by COPD definition	20
Table 15: Initial analysis by endpoint (died or diagnosed)	21
Table 16: Initial analysis by number of adjustment factors	22
Additional analysis of male/female ratio	
Table 17: List of selected results	23
Table 18: Analysis of the ratio of results for males and females	24
Additional analysis by number of adjustment factors	
Table 19: List of unadjusted and multiply-adjusted results and their ratio, within study	25

Table 1
Smoking and COPD: Cigarette Smoking analyses
List of all the results (not all to be included in any one meta-analysis) - Current cigarette smokers versus never smokers

Study ID	NRR	REFID	Country	Study population	YRST	NCASES	Product Sm	Excl	Latent	Study design	Sex	LowAge	HighAge	YrsFU	COP D	Endpoint	Adj
CPRD	1	ATKINS2015	UK	Regional	2003	14446	Cigarettes	0	0	Cohort	b	40	89	4	3	Diagnosed	0
CPS-I	1	THUN2013	USA	National	1959	782	Cigarettes	0	0	Cohort	m	49	999	6	*	Died	0
CPS-I	2	THUN2013	USA	National	1959	782	Cigarettes	x	0	Cohort	f	49	999	6	*	Died	0
CPS-I	3	THUN2013	USA	National	1959	782	Cigarettes	x	0	Cohort	f	49	999	6	*	Died	1
CPS-I	4	THUN2013	USA	National	1959	782	Cigarettes	x	0	Cohort	f	49	999	6	*	Died	3
CPS-I	5	THUN2013	USA	National	1959	782	Cigarettes	0	0	Cohort	m	49	999	6	*	Died	1
CPS-I	6	THUN2013	USA	National	1959	782	Cigarettes	0	0	Cohort	m	49	999	6	*	Died	3
CPS-II	1	THUN2013	USA	National	1982	2128	Cigarettes	0	0	Cohort	m	49	999	6	*	Died	0
CPS-II	2	THUN2013	USA	National	1982	2128	Cigarettes	0	0	Cohort	f	49	999	6	*	Died	0
CPS-II	3	THUN2013	USA	National	1982	2128	Cigarettes	x	0	Cohort	f	49	999	6	*	Died	1
CPS-II	4	THUN2013	USA	National	1982	2128	Cigarettes	x	0	Cohort	f	49	999	6	*	Died	3
CPS-II	5	THUN2013	USA	National	1982	2128	Cigarettes	0	0	Cohort	m	49	999	6	*	Died	1
CPS-II	6	THUN2013	USA	National	1982	2128	Cigarettes	0	0	Cohort	m	49	999	6	*	Died	3
FinnTwins	1	HUKKIN2012	Finland	National	1975	511	Cigarettes	0	0	Cohort	b	17	999	27	5	Diagnosed	0
FinnTwins	2	HUKKIN2012	Finland	National	1975	511	Cigarettes	0	0	Cohort	b	17	999	27	5	Diagnosed	2
JACC	1	LI2012E	Japan	National	1988	285	Cigarettes	0	0	Cohort	m	40	79	20	6	Died	0
JACC	2	LI2012E	Japan	National	1988	285	Cigarettes	0	0	Cohort	m	40	79	20	6	Died	1
JACC	3	LI2012E	Japan	National	1988	285	Cigarettes	0	0	Cohort	m	40	79	20	6	Died	9
JACC	4	LI2012E	Japan	National	1988	285	Cigarettes	0	0	Cohort	f	40	79	20	6	Died	0
JACC	5	LI2012E	Japan	National	1988	285	Cigarettes	0	0	Cohort	f	40	79	20	6	Died	1
JACC	6	LI2012E	Japan	National	1988	285	Cigarettes	0	0	Cohort	f	40	79	20	6	Died	9
KAISER	1	TRAN2011	USA	Regional	1978	778	Cigarettes	0	0	Cohort	b	*	*	28	4	Diagnosed	0
KAISER	2	TRAN2011	USA	Regional	1978	778	Cigarettes	0	0	Cohort	b	*	*	28	4	Diagnosed	6
MWOMEN	1	PIRIE2013	UK	National	1996	1910	Cigarettes	x	0	Cohort	f	50	69	15	2	Died	0
MWOMEN	2	PIRIE2013	UK	National	1996	1910	Cigarettes	x	0	Cohort	f	50	69	15	2	Died	5
MWOMEN	3	PIRIE2013	UK	National	1996	1910	Cigarettes	x	x	Cohort	f	50	69	15	2	Died	5
NHS_HPFS	1	VARRAS2010	USA	Regional	1976	832	Cigarettes	0	0	Cohort	b	30	75	24	1	Diagnosed	0
NIH-AARP	1	BEHREN2014	USA	Regional	1995	3648	Cigarettes	0	0	Cohort	b	50	70	11	1	Diagnosed	0
NLMS	1	CHRIST2018	USA	National	1985	2091	Cigarettes	x	0	Cohort	b	35	80	26	2	Died	0
NLMS	4	CHRIST2018	USA	National	1985	2091	Cigarettes	x	0	Cohort	b	35	80	26	2	Died	1
NLMS	5	CHRIST2018	USA	National	1985	2091	Cigarettes	x	0	Cohort	b	35	80	26	2	Died	5
NOWAC	1	GRAM2013	Norway	National	1991	68	Cigarettes	x	0	Cohort	f	26	71	17	2	Died	1
NOWAC	2	GRAM2013	Norway	National	1991	68	Cigarettes	x	0	Cohort	f	26	71	17	2	Died	6
PATH	1	BHATTA2020	USA	National	2013	319	Cigarettes	0	0	Cohort	b	18	999	3	1	Diagnosed	0
SMC	1	KALUZA2018	Sweden	Regional	1997	1495	Cigarettes	x	x	Cohort	f	48	83	17	8	Diagnosed	0
THIN	1	HORSFA2014	UK	National	2000	3901	Cigarettes	0	0	Cohort	b	30	99	12	9	Diagnosed	0
USA5	1	THUN2013	USA	Regional	1986	9246	Cigarettes	0	0	Cohort	m	50	999	24	*	Died	0
USA5	2	THUN2013	USA	Regional	1986	9246	Cigarettes	x	0	Cohort	f	50	999	24	*	Died	0
USA5	3	THUN2013	USA	Regional	1986	9246	Cigarettes	x	0	Cohort	f	50	999	24	*	Died	1
USA5	4	THUN2013	USA	Regional	1986	9246	Cigarettes	x	0	Cohort	f	50	999	24	*	Died	3

Table 1
 Smoking and COPD: Cigarette Smoking analyses
List of all the results (not all to be included in any one meta-analysis) - Current cigarette smokers versus never smokers

Study ID	NRR	REFID	Country	Study population	YRST	NCASES	Product Sm	Excl	Latent	Study design	Sex	LowAge	HighAge	YrsFU	COP D	Endpoint	Adj
USA5	5	THUN2013	USA	Regional	1986	9246	Cigarettes	0	0	Cohort	m	50	999	24	*	Died	1
USA5	6	THUN2013	USA	Regional	1986	9246	Cigarettes	0	0	Cohort	m	50	999	24	*	Died	3
USA5	7	CARTER2015	USA	Regional	1986	9246	Cigarettes	0	0	Cohort	m	50	999	25	2	Died	0
USA5	8	CARTER2015	USA	Regional	1986	9246	Cigarettes	x	0	Cohort	f	50	999	25	2	Died	0
USA5	9	CARTER2015	USA	Regional	1986	9246	Cigarettes	x	0	Cohort	f	50	999	25	2	Died	5
USA5	10	CARTER2015	USA	Regional	1986	9246	Cigarettes	0	0	Cohort	m	50	999	25	2	Died	5
VLAGT	1	TAGHIZ2016	Netherlands	Regional	1965	313	Cigarettes	x	0	Cohort	f	*	*	43	7	Died	0
VLAGT	2	TAGHIZ2016	Netherlands	Regional	1965	313	Cigarettes	0	0	Cohort	m	*	*	43	7	Died	0
VLAGT	3	TAGHIZ2016	Netherlands	Regional	1965	313	Cigarettes	x	0	Cohort	f	*	*	43	7	Died	3
VLAGT	4	TAGHIZ2016	Netherlands	Regional	1965	313	Cigarettes	0	0	Cohort	m	*	*	43	7	Died	3
WHI	1	NAGASA2020	USA	Regional	1993	4959	Cigarettes	x	0	Cohort	f	50	79	22	1	Diagnosed	0
WHS	1	AGLER2011	USA	Regional	1993	1604	Cigarettes	x	0	Cohort	f	45	999	11	1	Diagnosed	0

Table 2
Smoking and COPD: Cigarette Smoking analyses
List of all the risk estimates (not all to be included in any one meta-analysis) - Current cigarette smokers versus never smokers

Study ID	NRR	REFID	CA1	CA0	CO1	CO0	RR	RRL	RRU	Derived
CPRD	1	ATKINS2015	6650	2781	153926	381579	5.93	5.67	6.19	From numbers
CPS-I	1	THUN2013	338	82	72309	79631	4.54	3.57	5.78	From numbers
CPS-I	2	THUN2013	66	136	51060	272097	2.59	1.93	3.47	From numbers
CPS-I	3	THUN2013	-	-	-	-	3.93	2.88	5.38	Given in the paper
CPS-I	4	THUN2013	-	-	-	-	3.95	2.89	5.41	Given in the paper
CPS-I	5	THUN2013	-	-	-	-	5.61	4.38	7.20	Given in the paper
CPS-I	6	THUN2013	-	-	-	-	5.52	4.30	7.08	Given in the paper
CPS-II	1	THUN2013	462	94	68994	98647	7.03	5.63	8.77	From numbers
CPS-II	2	THUN2013	367	192	81521	277171	6.50	5.46	7.74	From numbers
CPS-II	3	THUN2013	-	-	-	-	10.31	8.60	12.36	Given in the paper
CPS-II	4	THUN2013	-	-	-	-	10.35	8.63	12.41	Given in the paper
CPS-II	5	THUN2013	-	-	-	-	10.50	8.39	13.13	Given in the paper
CPS-II	6	THUN2013	-	-	-	-	9.98	7.97	12.49	Given in the paper
FinnTwins	1	HUKKIN2012	341	91	5703	9852	6.47	5.15	8.14	From numbers
FinnTwins	2	HUKKIN2012	-	-	-	-	8.08	6.20	10.53	Using RREst
JACC	1	LI2012E	165	18	346870	138752	3.67	2.25	5.96	From numbers
JACC	2	LI2012E	-	-	-	-	4.84	2.97	7.88	Given in the paper
JACC	3	LI2012E	-	-	-	-	4.46	2.72	7.29	Given in the paper
JACC	4	LI2012E	10	20	44454	796017	8.95	4.19	19.13	From numbers
JACC	5	LI2012E	-	-	-	-	10.10	4.71	21.60	Given in the paper
JACC	6	LI2012E	-	-	-	-	9.26	4.19	20.50	Given in the paper
KAISER	1	TRAN2011	488	94	499000	981000	10.21	8.18	12.73	From numbers
KAISER	2	TRAN2011	-	-	-	-	12.59	10.11	15.67	Using RREst
MWOMEN	1	PIRIE2013	1789	121	232461	619774	39.42	32.79	47.38	From numbers
MWOMEN	2	PIRIE2013	-	-	-	-	35.30	29.20	42.50	Given in the paper
MWOMEN	3	PIRIE2013	-	-	-	-	36.70	30.20	44.70	Given in the paper
NHS_HPFS	1	VARRAS2010	508	98	162249	316309	10.11	8.14	12.54	From numbers
NIH-AARP	1	BEHREN2014	1325	603	9970	47874	10.55	9.61	11.59	From numbers
NLMS	1	CHRIST2018	924	378	66665	203071	7.45	6.61	8.39	From numbers
NLMS	4	CHRIST2018	-	-	-	-	8.94	7.93	10.08	Given in the paper
NLMS	5	CHRIST2018	-	-	-	-	11.01	9.72	12.46	Given in the paper
NOWAC	1	GRAM2013	-	-	-	-	22.00	7.91	61.22	Given in the paper
NOWAC	2	GRAM2013	-	-	-	-	17.00	5.90	48.78	Given in the paper
PATH	1	BHATTA2020	161	34	6916	10730	7.35	5.08	10.62	From numbers
SMC	1	KALUZA2018	989	182	7805	18438	12.84	10.98	15.00	From numbers
THIN	1	HORSFA2014	1364	643	115000	411000	7.58	6.90	8.32	From numbers
USA5	1	THUN2013	656	183	39218	152656	13.95	11.85	16.43	From numbers
USA5	2	THUN2013	720	320	51900	263782	11.44	10.03	13.04	From numbers
USA5	3	THUN2013	-	-	-	-	23.03	20.15	26.31	Given in the paper
USA5	4	THUN2013	-	-	-	-	22.35	19.55	25.55	Given in the paper

Table 2
 Smoking and COPD: Cigarette Smoking analyses
List of all the risk estimates (not all to be included in any one meta-analysis) - Current cigarette smokers versus never smokers

Study ID	NRR	REFID	CA1	CA0	CO1	CO0	RR	RRL	RRU	Derived
USA5	5	THUN2013	-	-	-	-	28.97	24.55	34.16	Given in the paper
USA5	6	THUN2013	-	-	-	-	25.61	21.68	30.25	Given in the paper
USA5	7	CARTER2015	825	259	38128	136613	11.41	9.93	13.12	From numbers
USA5	8	CARTER2015	941	410	50488	259659	11.80	10.52	13.25	From numbers
USA5	9	CARTER2015	-	-	-	-	25.00	22.20	28.10	Given in the paper
USA5	10	CARTER2015	-	-	-	-	27.80	24.10	32.00	Given in the paper
VLAGT	1	TAGHIZ2016	33	32	1222	2115	1.78	1.10	2.89	From numbers
VLAGT	2	TAGHIZ2016	157	2	2421	567	18.38	4.57	73.94	From numbers
VLAGT	3	TAGHIZ2016	-	-	-	-	5.65	3.22	9.93	Using RREst
VLAGT	4	TAGHIZ2016	-	-	-	-	12.00	3.00	48.07	Using RREst
WHI	1	NAGASA2020	746	2038	5191	45474	3.21	2.96	3.47	From numbers
WHS	1	AGLER2011	540	550	4925	19877	3.96	3.53	4.44	From numbers

Table 3
Smoking and COPD: Cigarette Smoking analyses
List of the selected results - Initial analyses. Current cigarette smokers versus never smokers. no overlapping results for any study

Study ID	NRR	REFID	Country	Study population	YRST	NCASES	Product Sm	Excl	Latent	Study design	Sex	LowAge	HighAge	YrsFU	COP D	Endpoint	Adj
CPRD	1	ATKINS2015	UK	Regional	2003	14446	Cigarettes	0	0	Cohort	b	40	89	4	3	Diagnosed	0
CPS-I	4	THUN2013	USA	National	1959	782	Cigarettes	x	0	Cohort	f	49	999	6	*	Died	3
CPS-I	6	THUN2013	USA	National	1959	782	Cigarettes	0	0	Cohort	m	49	999	6	*	Died	3
CPS-II	4	THUN2013	USA	National	1982	2128	Cigarettes	x	0	Cohort	f	49	999	6	*	Died	3
CPS-II	6	THUN2013	USA	National	1982	2128	Cigarettes	0	0	Cohort	m	49	999	6	*	Died	3
FinnTwins	2	HUKKIN2012	Finland	National	1975	511	Cigarettes	0	0	Cohort	b	17	999	27	5	Diagnosed	2
JACC	3	LI2012E	Japan	National	1988	285	Cigarettes	0	0	Cohort	m	40	79	20	6	Died	9
JACC	6	LI2012E	Japan	National	1988	285	Cigarettes	0	0	Cohort	f	40	79	20	6	Died	9
KAISER	2	TRAN2011	USA	Regional	1978	778	Cigarettes	0	0	Cohort	b	*	*	28	4	Diagnosed	6
MWOMEN	3	PIRIE2013	UK	National	1996	1910	Cigarettes	x	x	Cohort	f	50	69	15	2	Died	5
NHS_HPFS	1	VARRAS2010	USA	Regional	1976	832	Cigarettes	0	0	Cohort	b	30	75	24	1	Diagnosed	0
NIH-AARP	1	BEHREN2014	USA	Regional	1995	3648	Cigarettes	0	0	Cohort	b	50	70	11	1	Diagnosed	0
NLMS	5	CHRIST2018	USA	National	1985	2091	Cigarettes	x	0	Cohort	b	35	80	26	2	Died	5
NOWAC	2	GRAM2013	Norway	National	1991	68	Cigarettes	x	0	Cohort	f	26	71	17	2	Died	6
PATH	1	BHATTA2020	USA	National	2013	319	Cigarettes	0	0	Cohort	b	18	999	3	1	Diagnosed	0
SMC	1	KALUZA2018	Sweden	Regional	1997	1495	Cigarettes	x	x	Cohort	f	48	83	17	8	Diagnosed	0
THIN	1	HORSFA2014	UK	National	2000	3901	Cigarettes	0	0	Cohort	b	30	99	12	9	Diagnosed	0
USA5	9	CARTER2015	USA	Regional	1986	9246	Cigarettes	x	0	Cohort	f	50	999	25	2	Died	5
USA5	10	CARTER2015	USA	Regional	1986	9246	Cigarettes	0	0	Cohort	m	50	999	25	2	Died	5
VLAGT	3	TAGHIZ2016	Netherlands	Regional	1965	313	Cigarettes	x	0	Cohort	f	*	*	43	7	Died	3
VLAGT	4	TAGHIZ2016	Netherlands	Regional	1965	313	Cigarettes	0	0	Cohort	m	*	*	43	7	Died	3
WHI	1	NAGASA2020	USA	Regional	1993	4959	Cigarettes	x	0	Cohort	f	50	79	22	1	Diagnosed	0
WHS	1	AGLER2011	USA	Regional	1993	1604	Cigarettes	x	0	Cohort	f	45	999	11	1	Diagnosed	0

Table 4
Smoking and COPD: Cigarette Smoking analyses
Initial analysis by sex

Combined

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*CPRD	1	6650	153926	2781	381579	5.93	(5.67- 6.19)
FinnTwins	2	-	-	-	-	8.08	(6.20- 10.53)
*KAISER	2	-	-	-	-	12.59	(10.11- 15.67)
*NHS_HPFS	1	508	162249	98	316309	10.11	(8.14- 12.54)
*NIH-AARP	1	1325	9970	603	47874	10.55	(9.61- 11.59)
*NLMS	5	-	-	-	-	11.01	(9.72- 12.46)
*PATH	1	161	6916	34	10730	7.35	(5.08- 10.62)
*THIN	1	1364	115000	643	411000	7.58	(6.90- 8.32)
Partial Totals		10008	448061	4159	1167492		

*prospective study

Male

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*CPS-I	6	-	-	-	-	5.52	(4.30- 7.08)
*CPS-II	6	-	-	-	-	9.98	(7.97- 12.49)
*JACC	3	-	-	-	-	4.46	(2.72- 7.29)
*USA5	10	-	-	-	-	27.80	(24.10- 32.00)
*VLAGT	4	-	-	-	-	12.00	(3.00- 48.07)
Partial Totals		0	0	0	0		

*prospective study

Female

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*CPS-I	4	-	-	-	-	3.95	(2.89- 5.41)
*CPS-II	4	-	-	-	-	10.35	(8.63- 12.41)
*JACC	6	-	-	-	-	9.26	(4.19- 20.50)
*MWOMEN	3	-	-	-	-	36.70	(30.20- 44.70)
*NOWAC	2	-	-	-	-	17.00	(5.90- 48.78)
*SMC	1	989	7805	182	18438	12.84	(10.98- 15.00)
*USA5	9	-	-	-	-	25.00	(22.20- 28.10)
*VLAGT	3	-	-	-	-	5.65	(3.22- 9.93)
*WHI	1	746	5191	2038	45474	3.21	(2.96- 3.47)
*WHS	1	540	4925	550	19877	3.96	(3.53- 4.44)
Partial Totals		2275	17921	2770	83789		

*prospective study

	RR Sex			Total
	1 Combined	2 Male	3 Female	

RR Data

N	8	5	10	23
NS	8	5	10	23
Wt	3366.50	346.89	1623.20	5336.59
Het Chi	220.44	170.43	1286.85	1867.99
Het df	7	4	9	22
Het P	***	***	***	***
Fixed RR	7.17	15.24	6.95	7.46
RRl	6.93	13.72	6.62	7.26
RRu	7.42	16.93	7.30	7.66
P	+++	+++	+++	+++
Random RR	8.91	9.56	9.33	9.19
RRl	7.05	4.22	4.91	6.97
RRu	11.26	21.64	17.71	12.13
P	+++	+++	+++	+++
Asymm P	(*)	N.S.	N.S.	N.S.
Between Chi		178.74	1.03	190.27
Between df		1	1	2
Between P		+++	N.S.	***
Btwn (F) P		+	N.S.	N.S.
Btwn (R) P		N.S.	N.S.	N.S.

Table 5
Smoking and COPD: Cigarette Smoking analyses
Initial analysis by region

N America

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*CPS-I	6	-	-	-	-	5.52 (4.30- 7.08)	
*CPS-I	4	-	-	-	-	3.95 (2.89- 5.41)	
Subtotal CPS-I						4.85 (3.99- 5.89)	
*CPS-II	6	-	-	-	-	9.98 (7.97- 12.49)	
*CPS-II	4	-	-	-	-	10.35 (8.63- 12.41)	
Subtotal CPS-II						10.20 (8.86- 11.75)	
*KAISER	2	-	-	-	-	12.59 (10.11- 15.67)	
*NHS_HPFS	1	508	162249	98	316309	10.11 (8.14- 12.54)	
*NIH-AARP	1	1325	9970	603	47874	10.55 (9.61- 11.59)	
*NLMS	5	-	-	-	-	11.01 (9.72- 12.46)	
*PATH	1	161	6916	34	10730	7.35 (5.08- 10.62)	
*USA5	10	-	-	-	-	27.80 (24.10- 32.00)	
*USA5	9	-	-	-	-	25.00 (22.20- 28.10)	
Subtotal USA5						26.11 (23.85- 28.58)	
*WHI	1	746	5191	2038	45474	3.21 (2.96- 3.47)	
*WHS	1	540	4925	550	19877	3.96 (3.53- 4.44)	
Partial Totals		3280	189251	3323	440264		

*prospective study

Europe

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*CPRD	1	6650	153926	2781	381579	5.93 (5.67- 6.19)	
FinnTwins	2	-	-	-	-	8.08 (6.20- 10.53)	
*MWOMEN	3	-	-	-	-	36.70 (30.20- 44.70)	
*NOWAC	2	-	-	-	-	17.00 (5.90- 48.78)	
*SMC	1	989	7805	182	18438	12.84 (10.98- 15.00)	
*THIN	1	1364	115000	643	411000	7.58 (6.90- 8.32)	
*VLAGT	4	-	-	-	-	12.00 (3.00- 48.07)	
*VLAGT	3	-	-	-	-	5.65 (3.22- 9.93)	
Subtotal VLAGT						6.29 (3.73- 10.59)	
Partial Totals		9003	276731	3606	811017		

*prospective study

Japan

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*JACC	3	-	-	-	-	4.46 (2.72- 7.29)	
*JACC	6	-	-	-	-	9.26 (4.19- 20.50)	
Subtotal JACC						5.47 (3.60- 8.31)	
Partial Totals		0	0	0	0		

*prospective study

Region

	1	2	3	Total
	N America	Europe	Japan	

RR Data

N	13	8	2	23
NS	10	7	1	18
Wt	2548.51	2766.17	21.90	5336.59
Het Chi	1436.25	395.20	2.35	1867.99
Het df	12	7	1	22
Het P	***	***	N.S.	***
Fixed RR	8.10	6.93	5.47	7.46
RRl	7.79	6.68	3.60	7.26
RRu	8.42	7.20	8.31	7.66
P	+++	+++	+++	+++
Random RR	8.91	10.63	6.00	9.19
RRl	5.73	6.93	2.97	6.97
RRu	13.84	16.29	12.12	12.13
P	+++	+++	+++	+++
Asymm P	N.S.	N.S.		N.S.
Between Chi		32.06	3.36	34.19
Between df		1	1	2
Between P		---	(-)	***
Btwn (F) P		N.S.	N.S.	N.S.
Btwn (R) P		N.S.	N.S.	N.S.

Table 6
Smoking and COPD: Cigarette Smoking analyses
Initial analysis by study population

National

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*CPS-I	6	-	-	-	-	5.52 (4.30- 7.08)	
*CPS-I	4	-	-	-	-	3.95 (2.89- 5.41)	
Subtotal CPS-I						4.85 (3.99- 5.89)	
*CPS-II	6	-	-	-	-	9.98 (7.97- 12.49)	
*CPS-II	4	-	-	-	-	10.35 (8.63- 12.41)	
Subtotal CPS-II						10.20 (8.86- 11.75)	
FinnTwins	2	-	-	-	-	8.08 (6.20- 10.53)	
*JACC	3	-	-	-	-	4.46 (2.72- 7.29)	
*JACC	6	-	-	-	-	9.26 (4.19- 20.50)	
Subtotal JACC						5.47 (3.60- 8.31)	
*MWOMEN	3	-	-	-	-	36.70 (30.20- 44.70)	
*NLMS	5	-	-	-	-	11.01 (9.72- 12.46)	
*NOWAC	2	-	-	-	-	17.00 (5.90- 48.78)	
*PATH	1	161	6916	34	10730	7.35 (5.08- 10.62)	
*THIN	1	1364	115000	643	411000	7.58 (6.90- 8.32)	
Partial Totals		1525	121916	677	421730		

*prospective study

Regional

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*CPRD	1	6650	153926	2781	381579	5.93 (5.67- 6.19)	
*KAISER	2	-	-	-	-	12.59 (10.11- 15.67)	
*NHS_HPFS	1	508	162249	98	316309	10.11 (8.14- 12.54)	
*NIH_AARP	1	1325	9970	603	47874	10.55 (9.61- 11.59)	
*SMC	1	989	7805	182	18438	12.84 (10.98- 15.00)	
*USA5	10	-	-	-	-	27.80 (24.10- 32.00)	
*USA5	9	-	-	-	-	25.00 (22.20- 28.10)	
Subtotal USA5						26.11 (23.85- 28.58)	
*VLAGT	4	-	-	-	-	12.00 (3.00- 48.07)	
*VLAGT	3	-	-	-	-	5.65 (3.22- 9.93)	
Subtotal VLAGT						6.29 (3.73- 10.59)	
*WHI	1	746	5191	2038	45474	3.21 (2.96- 3.47)	
*WHS	1	540	4925	550	19877	3.96 (3.53- 4.44)	
Partial Totals		10758	344066	6252	829551		

*prospective study

Study Population

	1	2	
	National	Regional	Total

RR Data

N	12	11	23
NS	9	9	18
Wt	1190.06	4146.53	5336.59
Het Chi	273.11	1510.20	1867.99
Het df	11	10	22
Het P	***	***	***
Fixed RR	9.44	6.97	7.46
RRl	8.92	6.77	7.26
RRu	9.99	7.19	7.66
P	+++	+++	+++
Random RR	8.90	9.51	9.19
RRl	6.47	6.16	6.97
RRu	12.24	14.66	12.13
P	+++	+++	+++
Asymm P	N.S.	N.S.	N.S.
Between Chi		84.68	84.68
Between df		1	1
Between P		---	***
Btwn (F) P		N.S.	N.S.
Btwn (R) P		N.S.	N.S.

Table 7
Smoking and COPD: Cigarette Smoking analyses
Initial analysis by year of start of baseline

<1988

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*CPS-I	6	-	-	-	-	5.52 (4.30- 7.08)	
*CPS-I	4	-	-	-	-	3.95 (2.89- 5.41)	
Subtotal CPS-I						4.85 (3.99- 5.89)	
*CPS-II	6	-	-	-	-	9.98 (7.97- 12.49)	
*CPS-II	4	-	-	-	-	10.35 (8.63- 12.41)	
Subtotal CPS-II						10.20 (8.86- 11.75)	
FinnTwins	2	-	-	-	-	8.08 (6.20- 10.53)	
*KAISER	2	-	-	-	-	12.59 (10.11- 15.67)	
*NHS HPFS	1	508	162249	98	316309	10.11 (8.14- 12.54)	
*NLMS	5	-	-	-	-	11.01 (9.72- 12.46)	
*USA5	10	-	-	-	-	27.80 (24.10- 32.00)	
*USA5	9	-	-	-	-	25.00 (22.20- 28.10)	
Subtotal USA5						26.11 (23.85- 28.58)	
*VLAGT	4	-	-	-	-	12.00 (3.00- 48.07)	
*VLAGT	3	-	-	-	-	5.65 (3.22- 9.93)	
Subtotal VLAGT						6.29 (3.73- 10.59)	
Partial Totals		508	162249	98	316309		

*prospective study

1988+

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*CPRD	1	6650	153926	2781	381579	5.93 (5.67- 6.19)	
*JACC	3	-	-	-	-	4.46 (2.72- 7.29)	
*JACC	6	-	-	-	-	9.26 (4.19- 20.50)	
Subtotal JACC						5.47 (3.60- 8.31)	
*MWOMEN	3	-	-	-	-	36.70 (30.20- 44.70)	
*NIH-AARP	1	1325	9970	603	47874	10.55 (9.61- 11.59)	
*NOWAC	2	-	-	-	-	17.00 (5.90- 48.78)	
*PATH	1	161	6916	34	10730	7.35 (5.08- 10.62)	
*SMC	1	989	7805	182	18438	12.84 (10.98- 15.00)	
*THIN	1	1364	115000	643	411000	7.58 (6.90- 8.32)	
*WHI	1	746	5191	2038	45474	3.21 (2.96- 3.47)	
*WHS	1	540	4925	550	19877	3.96 (3.53- 4.44)	
Partial Totals		11775	303733	6831	934972		

*prospective study

Year of start of baseline
1 2
<1988 1988+ Total

RR Data

N	12	11	23
NS	8	10	18
Wt	1241.52	4095.07	5336.59
Het Chi	368.86	879.45	1867.99
Het df	11	10	22
Het P	***	***	***
Fixed RR	13.85	6.19	7.46
RRl	13.11	6.00	7.26
RRu	14.65	6.38	7.66
P	+++	+++	+++
Random RR	10.24	8.14	9.19
RRl	7.26	5.78	6.97
RRu	14.45	11.47	12.13
P	+++	+++	+++
Asymm P	(*)	N.S.	N.S.
Between Chi		619.68	619.68
Between df		1	1
Between P		---	***
Btwn (F) P		--	**
Btwn (R) P		N.S.	N.S.

Table 8
Smoking and COPD: Cigarette Smoking analyses
Initial analysis by number of cases in the study

<1000

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*CPS-I	6	-	-	-	-	5.52 (4.30- 7.08)	
*CPS-I	4	-	-	-	-	3.95 (2.89- 5.41)	
Subtotal CPS-I						4.85 (3.99- 5.89)	
FinnTwins	2	-	-	-	-	8.08 (6.20- 10.53)	
*JACC	3	-	-	-	-	4.46 (2.72- 7.29)	
*JACC	6	-	-	-	-	9.26 (4.19- 20.50)	
Subtotal JACC						5.47 (3.60- 8.31)	
*KAISER	2	-	-	-	-	12.59 (10.11- 15.67)	
*NHS_HFFS	1	508	162249	98	316309	10.11 (8.14- 12.54)	
*NOWAC	2	-	-	-	-	17.00 (5.90- 48.78)	
*PATH	1	161	6916	34	10730	7.35 (5.08- 10.62)	
*VLAGT	4	-	-	-	-	12.00 (3.00- 48.07)	
*VLAGT	3	-	-	-	-	5.65 (3.22- 9.93)	
Subtotal VLAGT						6.29 (3.73- 10.59)	
Partial Totals		669	169165	132	327039		
*prospective study							

1000+

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*CPRD	1	6650	153926	2781	381579	5.93 (5.67- 6.19)	
*CPS-II	6	-	-	-	-	9.98 (7.97- 12.49)	
*CPS-II	4	-	-	-	-	10.35 (8.63- 12.41)	
Subtotal CPS-II						10.20 (8.86- 11.75)	
*MWOMEN	3	-	-	-	-	36.70 (30.20- 44.70)	
*NIH-AARP	1	1325	9970	603	47874	10.55 (9.61- 11.59)	
*NLMS	5	-	-	-	-	11.01 (9.72- 12.46)	
*SMC	1	989	7805	182	18438	12.84 (10.98- 15.00)	
*THIN	1	1364	115000	643	411000	7.58 (6.90- 8.32)	
*USA5	10	-	-	-	-	27.80 (24.10- 32.00)	
*USA5	9	-	-	-	-	25.00 (22.20- 28.10)	
Subtotal USA5						26.11 (23.85- 28.58)	
*WHI	1	746	5191	2038	45474	3.21 (2.96- 3.47)	
*WHS	1	540	4925	550	19877	3.96 (3.53- 4.44)	
Partial Totals		11614	296817	6797	924242		
*prospective study							

	Number of COPD cases		
	1	2	Total
<1000			
1000+			

RR Data

N	11	12	23
NS	8	10	18
Wt	385.60	4950.99	5336.59
Het Chi	58.31	1808.47	1867.99
Het df	10	11	22
Het P	***	***	***
Fixed RR	7.88	7.43	7.46
RRl	7.13	7.23	7.26
RRu	8.70	7.64	7.66
P	+++	+++	+++
Random RR	7.42	10.67	9.19
RRl	5.65	7.26	6.97
RRu	9.74	15.68	12.13
P	+++	+++	+++
Asymm P	N.S.	*	N.S.
Between Chi		1.21	1.21
Between df		1	1
Between P		N.S.	N.S.
Btwn (F) P		N.S.	N.S.
Btwn (R) P		N.S.	N.S.

Table 9
Smoking and COPD: Cigarette Smoking analyses
Initial analysis by cigarette smoking exclusively

absent

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*CPRD	1	6650	153926	2781	381579	5.93	(5.67- 6.19)
*CPS-I	6	-	-	-	-	5.52	(4.30- 7.08)
*CPS-II	6	-	-	-	-	9.98	(7.97- 12.49)
FinnTwins	2	-	-	-	-	8.08	(6.20- 10.53)
*JACC	3	-	-	-	-	4.46	(2.72- 7.29)
*JACC	6	-	-	-	-	9.26	(4.19- 20.50)
Subtotal JACC						5.47	(3.60- 8.31)
*KAISER	2	-	-	-	-	12.59	(10.11- 15.67)
*NHS_HPFS	1	508	162249	98	316309	10.11	(8.14- 12.54)
*NIH-AARP	1	1325	9970	603	47874	10.55	(9.61- 11.59)
*PATH	1	161	6916	34	10730	7.35	(5.08- 10.62)
*THIN	1	1364	115000	643	411000	7.58	(6.90- 8.32)
*USA5	10	-	-	-	-	27.80	(24.10- 32.00)
*VLAGT	4	-	-	-	-	12.00	(3.00- 48.07)
Partial Totals		10008	448061	4159	1167492		

*prospective study

present

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*CPS-I	4	-	-	-	-	3.95	(2.89- 5.41)
*CPS-II	4	-	-	-	-	10.35	(8.63- 12.41)
*MWOMEN	3	-	-	-	-	36.70	(30.20- 44.70)
*NLMS	5	-	-	-	-	11.01	(9.72- 12.46)
*NOWAC	2	-	-	-	-	17.00	(5.90- 48.78)
*SMC	1	989	7805	182	18438	12.84	(10.98- 15.00)
*USA5	9	-	-	-	-	25.00	(22.20- 28.10)
*VLAGT	3	-	-	-	-	5.65	(3.22- 9.93)
*WHI	1	746	5191	2038	45474	3.21	(2.96- 3.47)
*WHS	1	540	4925	550	19877	3.96	(3.53- 4.44)
Partial Totals		2275	17921	2770	83789		

*prospective study

RR Description:Exclusive use of the product

	1	2	Total
absent		present	

RR Data

	N	13	10	23
NS		12	10	22
Wt	3470.33	1866.26	5336.59	
Het Chi	535.59	1332.12	1867.99	
Het df	12	9	22	
Het P	***	***	***	
Fixed RR	7.50	7.39	7.46	
RRl	7.26	7.06	7.26	
RRu	7.76	7.73	7.66	
P	+++	+++	+++	
Random RR	9.02	9.48	9.19	
RRl	6.78	5.25	6.97	
RRu	12.00	17.14	12.13	
P	+++	+++	+++	
Asymm P	N.S.	N.S.	N.S.	
Between Chi		0.28	0.28	
Between df		1	1	
Between P		N.S.	N.S.	
Btwn (F) P		N.S.	N.S.	
Btwn (R) P		N.S.	N.S.	

Table 10
Smoking and COPD: Cigarette Smoking analyses
Initial analysis by latency rule used

absent

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*CPRD	1	6650	153926	2781	381579	5.93	(5.67- 6.19)
*CPS-I	6	-	-	-	-	5.52	(4.30- 7.08)
*CPS-I	4	-	-	-	-	3.95	(2.89- 5.41)
Subtotal CPS-I						4.85	(3.99- 5.89)
*CPS-II	6	-	-	-	-	9.98	(7.97- 12.49)
*CPS-II	4	-	-	-	-	10.35	(8.63- 12.41)
Subtotal CPS-II						10.20	(8.86- 11.75)
FinnTwins	2	-	-	-	-	8.08	(6.20- 10.53)
*JACC	3	-	-	-	-	4.46	(2.72- 7.29)
*JACC	6	-	-	-	-	9.26	(4.19- 20.50)
Subtotal JACC						5.47	(3.60- 8.31)
*KAISER	2	-	-	-	-	12.59	(10.11- 15.67)
*NHS_HPFS	1	508	162249	98	316309	10.11	(8.14- 12.54)
*NIH-AARP	1	1325	9970	603	47874	10.55	(9.61- 11.59)
*NLMS	5	-	-	-	-	11.01	(9.72- 12.46)
*NOWAC	2	-	-	-	-	17.00	(5.90- 48.78)
*PATH	1	161	6916	34	10730	7.35	(5.08- 10.62)
*THIN	1	1364	115000	643	411000	7.58	(6.90- 8.32)
*USA5	10	-	-	-	-	27.80	(24.10- 32.00)
*USA5	9	-	-	-	-	25.00	(22.20- 28.10)
Subtotal USA5						26.11	(23.85- 28.58)
*VLAGT	4	-	-	-	-	12.00	(3.00- 48.07)
*VLAGT	3	-	-	-	-	5.65	(3.22- 9.93)
Subtotal VLAGT						6.29	(3.73- 10.59)
*WHI	1	746	5191	2038	45474	3.21	(2.96- 3.47)
*WHS	1	540	4925	550	19877	3.96	(3.53- 4.44)
Partial Totals		11294	458177	6747	1232843		

*prospective study

present

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*MWOMEN	3	-	-	-	-	36.70	(30.20- 44.70)
*SMC	1	989	7805	182	18438	12.84	(10.98- 15.00)
Partial Totals		989	7805	182	18438		

*prospective study

RR Description: Latency rule applied in case definition

	1	2	
	absent	present	Total

RR Data

N	21	2	23
NS	16	2	18
Wt	5078.51	258.08	5336.59
Het Chi	1556.02	67.57	1867.99
Het df	20	1	22
Het P	***	***	***
Fixed RR	7.11	19.28	7.46
RRl	6.92	17.07	7.26
RRu	7.31	21.78	7.66
P	+++	+++	+++
Random RR	8.41	21.67	9.19
RRl	6.38	7.74	6.97
RRu	11.09	60.66	12.13
P	+++	+++	+++
Asymm P	N.S.		N.S.
Between Chi		244.40	244.40
Between df		1	1
Between P		+++	***
Btwn (F) P		(+)	(*)
Btwn (R) P		(+)	(*)

Table 11
Smoking and COPD: Cigarette Smoking analyses
Initial analysis by lowest age considered in the study

<34

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
FinnTwins	2	-	-	-	-	8.08	(6.20- 10.53)
*NHS_HFFS	1	508	162249	98	316309	10.11	(8.14- 12.54)
*NOWAC	2	-	-	-	-	17.00	(5.90- 48.78)
*PATH	1	161	6916	34	10730	7.35	(5.08- 10.62)
*THIN	1	1364	115000	643	411000	7.58	(6.90- 8.32)
Partial Totals		2033	284165	775	738039		

*prospective study

35-45

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*CPRD	1	6650	153926	2781	381579	5.93	(5.67- 6.19)
*JACC	3	-	-	-	-	4.46	(2.72- 7.29)
*JACC	6	-	-	-	-	9.26	(4.19- 20.50)
Subtotal JACC						5.47	(3.60- 8.31)
*NLMS	5	-	-	-	-	11.01	(9.72- 12.46)
*WHS	1	540	4925	550	19877	3.96	(3.53- 4.44)
Partial Totals		7190	158851	3331	401456		

*prospective study

46-49

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*CPS-I	6	-	-	-	-	5.52	(4.30- 7.08)
*CPS-I	4	-	-	-	-	3.95	(2.89- 5.41)
Subtotal CPS-I						4.85	(3.99- 5.89)
*CPS-II	6	-	-	-	-	9.98	(7.97- 12.49)
*CPS-II	4	-	-	-	-	10.35	(8.63- 12.41)
Subtotal CPS-II						10.20	(8.86- 11.75)
*SMC	1	989	7805	182	18438	12.84	(10.98- 15.00)
Partial Totals		989	7805	182	18438		

*prospective study

50+

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*MWOMEN	3	-	-	-	-	36.70	(30.20- 44.70)
*NIH-AARP	1	1325	9970	603	47874	10.55	(9.61- 11.59)
*USA5	10	-	-	-	-	27.80	(24.10- 32.00)
*USA5	9	-	-	-	-	25.00	(22.20- 28.10)
Subtotal USA5						26.11	(23.85- 28.58)
*WHI	1	746	5191	2038	45474	3.21	(2.96- 3.47)
Partial Totals		2071	15161	2641	93348		

*prospective study

Missing

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*KAISER	2	-	-	-	-	12.59	(10.11- 15.67)
*VLAGT	4	-	-	-	-	12.00	(3.00- 48.07)
*VLAGT	3	-	-	-	-	5.65	(3.22- 9.93)
Subtotal VLAGT						6.29	(3.73- 10.59)
Partial Totals		0	0	0	0		

*prospective study

Table 11
Smoking and COPD: Cigarette Smoking analyses
Initial analysis by lowest age considered in the study
Lowest age included, grouped

	1 <34	2 35-45	3 46-49	4 50+	5 Missing	Total
N	5	5	5	5	3	23
NS	5	4	3	4	2	18
Wt	607.82	2560.38	451.61	1622.65	94.13	5336.59
Het Chi	7.90	145.02	63.60	1396.20	6.76	1867.99
Het df	4	4	4	4	2	22
Het P	(*)	***	***	***	*	***
Fixed RR	7.95	6.01	9.36	9.39	11.34	7.46
RRl	7.34	5.78	8.54	8.95	9.27	7.26
RRu	8.61	6.25	10.27	9.86	13.88	7.66
P	+++	+++	+++	+++	+++	+++
Random RR	8.36	6.26	7.92	15.36	9.33	9.19
RRl	7.13	4.31	5.41	5.95	5.00	6.97
RRu	9.80	9.08	11.58	39.66	17.40	12.13
P	+++	+++	+++	+++	+++	+++
Asymm P	N.S.	N.S.	*	(*)	N.S.	N.S.
Between Chi		38.58	6.92	12.29	10.29	248.52
Between df		1	1	1	1	4
Between P		---	++	+++	++	***
Btwn (F) P		N.S.	N.S.	N.S.	(+)	N.S.
Btwn (R) P		N.S.	N.S.	N.S.	N.S.	N.S.

Table 12
Smoking and COPD: Cigarette Smoking analyses
Initial analysis by lowest age considered: trend without 'Missing'

<30

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
FinnTwins	2	-	-	-	-	8.08 (6.20- 10.53)	
*NOWAC	2	-	-	-	-	17.00 (5.90- 48.78)	
*PATH	1	161	6916	34	10730	7.35 (5.08- 10.62)	
Partial Totals		161	6916	34	10730		

*prospective study

30-<45

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*CPRD	1	6650	153926	2781	381579	5.93 (5.67- 6.19)	
*JACC	3	-	-	-	-	4.46 (2.72- 7.29)	
*JACC	6	-	-	-	-	9.26 (4.19- 20.50)	
Subtotal JACC						5.47 (3.60- 8.31)	
*NHS_HPFS	1	508	162249	98	316309	10.11 (8.14- 12.54)	
*NLMS	5	-	-	-	-	11.01 (9.72- 12.46)	
*THIN	1	1364	115000	643	411000	7.58 (6.90- 8.32)	
Partial Totals		8522	431175	3522	1108888		

*prospective study

45+

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*CPS-I	6	-	-	-	-	5.52 (4.30- 7.08)	
*CPS-I	4	-	-	-	-	3.95 (2.89- 5.41)	
Subtotal CPS-I						4.85 (3.99- 5.89)	
*CPS-II	6	-	-	-	-	9.98 (7.97- 12.49)	
*CPS-II	4	-	-	-	-	10.35 (8.63- 12.41)	
Subtotal CPS-II						10.20 (8.86- 11.75)	
*MWOMEN	3	-	-	-	-	36.70 (30.20- 44.70)	
*NIH-AARP	1	1325	9970	603	47874	10.55 (9.61- 11.59)	
*SMC	1	989	7805	182	18438	12.84 (10.98- 15.00)	
*USA5	10	-	-	-	-	27.80 (24.10- 32.00)	
*USA5	9	-	-	-	-	25.00 (22.20- 28.10)	
Subtotal USA5						26.11 (23.85- 28.58)	
*WHI	1	746	5191	2038	45474	3.21 (2.96- 3.47)	
*WHS	1	540	4925	550	19877	3.96 (3.53- 4.44)	
Partial Totals		3600	27891	3373	131663		

*prospective study

Lowest age included, grouped, excluding Missing

	1	2	3	Total	Trend
	<30	30-<45	45+		

RR Data

N	3	6	11	20	
NS	3	5	8	16	
Wt	86.47	2789.05	2366.94	5242.46	
Het Chi	2.16	114.76	1650.62	1844.41	
Het df	2	5	10	19	
Het P	N.S.	***	***	***	
Fixed RR	8.07	6.61	8.44	7.41	
RRl	6.53	6.37	8.11	7.21	
RRu	9.96	6.86	8.79	7.61	
P	+++	+++	+++	+++	
Random RR	8.09	7.79	10.01	9.18	
RRl	6.45	5.97	5.85	6.83	
RRu	10.16	10.15	17.10	12.34	
P	+++	+++	+++	+++	
Asymm P	N.S.	N.S.	N.S.	N.S.	
Between Chi		3.33	0.17	76.86	62.23
Between df		1	1	2	1
Between P		(-)	N.S.	***	+++
Btwn (F) P		N.S.	N.S.	N.S.	N.S.
Btwn (R) P		N.S.	N.S.	N.S.	N.S.

Table 13
Smoking and COPD: Cigarette Smoking analyses
Initial analysis by years of follow-up

<10

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*CPRD	1	6650	153926	2781	381579	5.93	(5.67- 6.19)
*CPS-I	6	-	-	-	-	5.52	(4.30- 7.08)
*CPS-I	4	-	-	-	-	3.95	(2.89- 5.41)
Subtotal CPS-I						4.85	(3.99- 5.89)
*CPS-II	6	-	-	-	-	9.98	(7.97- 12.49)
*CPS-II	4	-	-	-	-	10.35	(8.63- 12.41)
Subtotal CPS-II						10.20	(8.86- 11.75)
*PATH	1	161	6916	34	10730	7.35	(5.08- 10.62)
Partial Totals		6811	160842	2815	392309		

*prospective study

10-<20

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*MWOMEN	3	-	-	-	-	36.70	(30.20- 44.70)
*NIH-AARP	1	1325	9970	603	47874	10.55	(9.61- 11.59)
*NOWAC	2	-	-	-	-	17.00	(5.90- 48.78)
*SMC	1	989	7805	182	18438	12.84	(10.98- 15.00)
*THIN	1	1364	115000	643	411000	7.58	(6.90- 8.32)
*WHS	1	540	4925	550	19877	3.96	(3.53- 4.44)
Partial Totals		4218	137700	1978	497189		

*prospective study

20-<30

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
FinnTwins	2	-	-	-	-	8.08	(6.20- 10.53)
*JACC	3	-	-	-	-	4.46	(2.72- 7.29)
*JACC	6	-	-	-	-	9.26	(4.19- 20.50)
Subtotal JACC						5.47	(3.60- 8.31)
*KAISER	2	-	-	-	-	12.59	(10.11- 15.67)
*NHS_HPFS	1	508	162249	98	316309	10.11	(8.14- 12.54)
*NLMS	5	-	-	-	-	11.01	(9.72- 12.46)
*USA5	10	-	-	-	-	27.80	(24.10- 32.00)
*USA5	9	-	-	-	-	25.00	(22.20- 28.10)
Subtotal USA5						26.11	(23.85- 28.58)
*WHI	1	746	5191	2038	45474	3.21	(2.96- 3.47)
Partial Totals		1254	167440	2136	361783		

*prospective study

30+

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*VLAGT	4	-	-	-	-	12.00	(3.00- 48.07)
*VLAGT	3	-	-	-	-	5.65	(3.22- 9.93)
Subtotal VLAGT						6.29	(3.73- 10.59)
Partial Totals		0	0	0	0		

*prospective study

Years follow-up, grouped
 1 2 3 4
 <10 10-<20 20-<30 30+ Total Trend

RR Data

N	6	6	9	2	23	
NS	4	6	7	1	18	
Wt	2318.36	1429.65	1574.46	14.11	5336.59	
Het Chi	61.37	438.11	1216.26	0.97	1867.99	
Het df	5	5	8	1	22	
Het P	***	***	***	N.S.	***	
Fixed RR	6.16	8.71	8.61	6.29	7.46	
RRl	5.92	8.27	8.19	3.73	7.26	
RRu	6.42	9.17	9.04	10.59	7.66	
P	+++	+++	+++	+++	+++	
Random RR	6.85	11.32	10.11	6.29	9.19	
RRl	5.24	6.67	5.21	3.73	6.97	
RRu	8.94	19.20	19.60	10.59	12.13	
P	+++	+++	+++	+++	+++	
Asymm P	N.S.	N.S.	N.S.	N.S.	N.S.	
Between Chi		105.60	104.52	0.01	151.28	111.76
Between df		1	1	1	3	1

Table 13
Smoking and COPD: Cigarette Smoking analyses
Initial analysis by years of follow-up

	Years follow-up, grouped				Total	Trend
	1 <10	2 10-<20	3 20-<30	4 30+		

RR Data

Between P		+++	+++	N.S.	***	+++
Btwn (F) P		N.S.	N.S.	N.S.	N.S.	N.S.
Btwn (R) P		(+)	N.S.	N.S.	N.S.	N.S.

Table 14
Smoking and COPD: Cigarette Smoking analyses
Initial analysis by COPD definition

Excl Bronchiectasis

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*CPRD	1	6650	153926	2781	381579	5.93	(5.67- 6.19)
*MWOMEN	3	-	-	-	-	36.70	(30.20- 44.70)
*NLMS	5	-	-	-	-	11.01	(9.72- 12.46)
*NOWAC	2	-	-	-	-	17.00	(5.90- 48.78)
*USA5	10	-	-	-	-	27.80	(24.10- 32.00)
*USA5	9	-	-	-	-	25.00	(22.20- 28.10)
Subtotal USA5						26.11	(23.85- 28.58)
Partial Totals		6650	153926	2781	381579		

*prospective study

Inc Bronchiectasis

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*JACC	3	-	-	-	-	4.46	(2.72- 7.29)
*JACC	6	-	-	-	-	9.26	(4.19- 20.50)
Subtotal JACC						5.47	(3.60- 8.31)
*KAISER	2	-	-	-	-	12.59	(10.11- 15.67)
*VLAGT	4	-	-	-	-	12.00	(3.00- 48.07)
*VLAGT	3	-	-	-	-	5.65	(3.22- 9.93)
Subtotal VLAGT						6.29	(3.73- 10.59)
Partial Totals		0	0	0	0		

*prospective study

Other

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*CPS-I	6	-	-	-	-	5.52	(4.30- 7.08)
*CPS-I	4	-	-	-	-	3.95	(2.89- 5.41)
Subtotal CPS-I						4.85	(3.99- 5.89)
*CPS-II	6	-	-	-	-	9.98	(7.97- 12.49)
*CPS-II	4	-	-	-	-	10.35	(8.63- 12.41)
Subtotal CPS-II						10.20	(8.86- 11.75)
FinnTwins	2	-	-	-	-	8.08	(6.20- 10.53)
*NHS_HPFS	1	508	162249	98	316309	10.11	(8.14- 12.54)
*NIH-AARP	1	1325	9970	603	47874	10.55	(9.61- 11.59)
*PATH	1	161	6916	34	10730	7.35	(5.08- 10.62)
*SMC	1	989	7805	182	18438	12.84	(10.98- 15.00)
*THIN	1	1364	115000	643	411000	7.58	(6.90- 8.32)
*WHI	1	746	5191	2038	45474	3.21	(2.96- 3.47)
*WHS	1	540	4925	550	19877	3.96	(3.53- 4.44)
Partial Totals		5633	312056	4148	869702		

*prospective study

	COPD definition			Total
	1	2	3	
	Excl	Bronc	Inc Bronc	Other

RR Data

N	6	5	12	23
NS	5	3	10	18
Wt	2816.96	116.03	2403.60	5336.59
Het Chi	1081.75	18.59	633.04	1867.99
Het df	5	4	11	22
Het P	***	***	***	***
Fixed RR	8.56	9.88	6.27	7.46
RRl	8.25	8.24	6.02	7.26
RRu	8.88	11.86	6.53	7.66
P	+++	+++	+++	+++
Random RR	17.45	7.83	7.15	9.19
RRl	8.35	4.60	5.19	6.97
RRu	36.44	13.35	9.84	12.13
P	+++	+++	+++	+++
Asymm P	(*)	N.S.	N.S.	N.S.
Between Chi		2.32	125.25	134.62
Between df		1	1	2
Between P		N.S.	---	***
Btwn (F) P		N.S.	N.S.	N.S.
Btwn (R) P		(+)	-	(*)

Table 15
Smoking and COPD: Cigarette Smoking analyses
Initial analysis by endpoint

Died

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*CPS-I	6	-	-	-	-	5.52 (4.30- 7.08)	
*CPS-I	4	-	-	-	-	3.95 (2.89- 5.41)	
Subtotal CPS-I						4.85 (3.99- 5.89)	
*CPS-II	6	-	-	-	-	9.98 (7.97- 12.49)	
*CPS-II	4	-	-	-	-	10.35 (8.63- 12.41)	
Subtotal CPS-II						10.20 (8.86- 11.75)	
*JACC	3	-	-	-	-	4.46 (2.72- 7.29)	
*JACC	6	-	-	-	-	9.26 (4.19- 20.50)	
Subtotal JACC						5.47 (3.60- 8.31)	
*MWOMEN	3	-	-	-	-	36.70 (30.20- 44.70)	
*NLMS	5	-	-	-	-	11.01 (9.72- 12.46)	
*NOWAC	2	-	-	-	-	17.00 (5.90- 48.78)	
*USA5	10	-	-	-	-	27.80 (24.10- 32.00)	
*USA5	9	-	-	-	-	25.00 (22.20- 28.10)	
Subtotal USA5						26.11 (23.85- 28.58)	
*VLAGT	4	-	-	-	-	12.00 (3.00- 48.07)	
*VLAGT	3	-	-	-	-	5.65 (3.22- 9.93)	
Subtotal VLAGT						6.29 (3.73- 10.59)	
Partial Totals		0	0	0	0		
*prospective study							

Diagnosed

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*CPRD	1	6650	153926	2781	381579	5.93 (5.67- 6.19)	
FinnTwins	2	-	-	-	-	8.08 (6.20- 10.53)	
*KAISER	2	-	-	-	-	12.59 (10.11- 15.67)	
*NHS_HPFS	1	508	162249	98	316309	10.11 (8.14- 12.54)	
*NIH-AARP	1	1325	9970	603	47874	10.55 (9.61- 11.59)	
*PATH	1	161	6916	34	10730	7.35 (5.08- 10.62)	
*SMC	1	989	7805	182	18438	12.84 (10.98- 15.00)	
*THIN	1	1364	115000	643	411000	7.58 (6.90- 8.32)	
*WHI	1	746	5191	2038	45474	3.21 (2.96- 3.47)	
*WHS	1	540	4925	550	19877	3.96 (3.53- 4.44)	
Partial Totals		12283	465982	6929	1251281		
*prospective study							

RR Description:Endpoint reported

	1	2	Total
Died	13	10	23
Diagnosed	8	10	18

RR Data

N	13	10	23
NS	8	10	18
Wt	1149.80	4186.79	5336.59
Het Chi	443.05	619.49	1867.99
Het df	12	9	22
Het P	***	***	***
Fixed RR	15.66	6.09	7.46
RRl	14.78	5.91	7.26
RRu	16.59	6.27	7.66
P	+++	+++	+++
Random RR	10.95	7.49	9.19
RRl	7.42	5.63	6.97
RRu	16.15	9.95	12.13
P	+++	+++	+++
Asymm P	N.S.	N.S.	N.S.
Between Chi		805.45	805.45
Between df		1	1
Between P		---	***
Btwn (F) P		---	***
Btwn (R) P		N.S.	N.S.

Table 16
Smoking and COPD: Cigarette Smoking analyses
Initial analysis by number of adjustment factors

Unadj

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*CPRD	1	6650	153926	2781	381579	5.93	(5.67- 6.19)
*NHS_HFFS	1	508	162249	98	316309	10.11	(8.14- 12.54)
*NIH-AARP	1	1325	9970	603	47874	10.55	(9.61- 11.59)
*PATH	1	161	6916	34	10730	7.35	(5.08- 10.62)
*SMC	1	989	7805	182	18438	12.84	(10.98- 15.00)
*THIN	1	1364	115000	643	411000	7.58	(6.90- 8.32)
*WHI	1	746	5191	2038	45474	3.21	(2.96- 3.47)
*WHS	1	540	4925	550	19877	3.96	(3.53- 4.44)
Totals		12283	465982	6929	1251281		

*prospective study

More adj

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*CPS-I	6	-	-	-	-	5.52	(4.30- 7.08)
*CPS-I	4	-	-	-	-	3.95	(2.89- 5.41)
Subtotal CPS-I						4.85	(3.99- 5.89)
*CPS-II	6	-	-	-	-	9.98	(7.97- 12.49)
*CPS-II	4	-	-	-	-	10.35	(8.63- 12.41)
Subtotal CPS-II						10.20	(8.86- 11.75)
FinnTwins	2	-	-	-	-	8.08	(6.20- 10.53)
*JACC	3	-	-	-	-	4.46	(2.72- 7.29)
*JACC	6	-	-	-	-	9.26	(4.19- 20.50)
Subtotal JACC						5.47	(3.60- 8.31)
*KAISER	2	-	-	-	-	12.59	(10.11- 15.67)
*MWOMEN	3	-	-	-	-	36.70	(30.20- 44.70)
*NLMS	5	-	-	-	-	11.01	(9.72- 12.46)
*NOWAC	2	-	-	-	-	17.00	(5.90- 48.78)
*USA5	10	-	-	-	-	27.80	(24.10- 32.00)
*USA5	9	-	-	-	-	25.00	(22.20- 28.10)
Subtotal USA5						26.11	(23.85- 28.58)
*VLAGT	4	-	-	-	-	12.00	(3.00- 48.07)
*VLAGT	3	-	-	-	-	5.65	(3.22- 9.93)
Subtotal VLAGT						6.29	(3.73- 10.59)
Partial Totals		0	0	0	0		

*prospective study

Number of adjustment factors, grouped

	1	2	3	Total
Unadj				
Age-only				
More adj				

RR Data

N	8	15	23
NS	8	10	18
Wt	4052.00	1284.58	5336.59
Het Chi	571.50	468.59	1867.99
Het df	7	14	22
Het P	***	***	***
Fixed RR	5.98	15.02	7.46
RRl	5.80	14.22	7.26
RRu	6.16	15.86	7.66
P	+++	+++	+++
Random RR	6.96	10.83	9.19
RRl	5.09	7.67	6.97
RRu	9.53	15.29	12.13
P	+++	+++	+++
Asymm P	N.S.	N.S.	N.S.
Between Chi		827.90	827.90
Between df		1	1
Between P		N.S.	+++
Btwn (F) P		N.S.	+++
Btwn (R) P		N.S.	(+)

Table 17
 Smoking and COPD: Cigarette Smoking analyses
 List of the selected results with RR values for male/female (M/F) ratio - Current cigarette smokers versus never smokers

Study ID	NRR M	RR Male	RRL M	RRU M	NRR F	RR Female	RRL F	RRU F	RR M/F	RRL M/F	RRU M/F
CPS-I	6	5.52	4.30	7.08	4	3.95	2.89	5.41	1.40	0.94	2.09
CPS-II	6	9.98	7.97	12.49	4	10.35	8.63	12.41	0.96	0.72	1.29
JACC	3	4.46	2.72	7.29	6	9.26	4.19	20.50	0.48	0.19	1.23
USA5	10	27.80	24.10	32.00	9	25.00	22.20	28.10	1.11	0.92	1.34
VLAGT	4	12.00	3.00	48.07	3	5.65	3.22	9.93	2.12	0.48	9.49

Table 18
Smoking and COPD: Cigarette Smoking analyses
Meta-analysis analysis of M/F ratio

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*CPS-I	4	-	-	-	-	1.40 (0.94-	2.09)
*CPS-II	4	-	-	-	-	0.96 (0.72-	1.29)
*JACC	6	-	-	-	-	0.48 (0.19-	1.23)
*USA5	9	-	-	-	-	1.11 (0.92-	1.34)
*VLAGT	3	-	-	-	-	2.12 (0.48-	9.49)
Partial Totals		0.00	0.00	0.00	0.00		

*prospective study

Group	1	Total
	1	

M/F ratio

N	5	5
NS	5	5
Wt	189.13	189.13
Het Chi	5.91	5.91
Het df	4	4
Het P	N.S.	N.S.
Fixed RR	1.09	1.09
RRl	0.95	0.95
RRu	1.26	1.26
P	N.S.	N.S.
Random RR	1.08	1.08
RRl	0.88	0.88
RRu	1.34	1.34
P	N.S.	N.S.
Asymm P	N.S.	N.S.
Between Chi		
Between df		
Between P		N.S.
Btwn (F) P		N.S.
Btwn (R) P		N.S.

Table 19
Smoking and COPD: Cigarette Smoking analyses
List of selected results with ratio of multiply-adjusted/unadjusted RRs - Current cigarette smokers versus never smokers

Study ID	Sex	NRR adjust	Adj RR adjust	NRR unadj	RR unadj	adj/unadj RR ratio	
	b	2	2	4.46			
CPS-I	f	4	3	3.95	2	2.59	1.53
CPS-I	m	6	3	5.52	1	4.54	1.22
CPS-II	f	4	3	10.35	2	6.50	1.59
CPS-II	m	6	3	9.98	1	7.03	1.42
FinnTwins	b	2	2	8.08	1	6.47	1.25
JACC	m	3	9	4.46	1	3.67	1.22
JACC	f	6	9	9.26	4	8.95	1.03
KAISER	b	2	6	12.59	1	10.21	1.23
MWOMEN	f	2	5	35.30	1	39.42	0.90
NLMS	b	5	5	11.01	1	7.45	1.48
USA5	f	9	5	25.00	8	11.80	2.12
USA5	m	10	5	27.80	7	11.41	2.44
VLGT	f	3	3	5.65	1	1.78	3.17
VLGT	m	4	3	12.00	2	18.38	0.65

**Evidence relating cigarette, cigar and pipe smoking to lung cancer and COPD.
Meta-analysing recent data from three regions.**

Supplementary File 3

Authors

Peter N Lee, Katharine J Coombs, Jan S Hamling

This supplementary file gives details of the results available for cigar smoking and lung cancer; and their meta-analyses.

Smoking and Lung cancer: Cigar Smoking analyses

These analyses are restricted to results for current cigar smokers versus never smokers.

In the analyses, if multiple results are available for a single study

the results to be included in meta-analysis are selected by applying the following criterion:

1) The greatest amount of adjustment for possible confounding factors.

Key:

Study ID: Identifier assigned to the study

NRR: Sequence number within the study assigned to the risk estimate

REFID: Identifier assigned to the published paper

YRST: Year of start of baseline

NCASES: Number of lung cancer cases studied

ProductSm: Product smoked

Excl: Exclusive use of the product: 0 = No; 1 = Yes

Latent: A latency rule was applied, such as ignoring lung cancers in the first two or five years after smoking data were gathered: 0 = No; 1 = Yes

Pop analysed: The type of population considered in analysis: Cohort or Nested case control

Sex: Gender reported by the risk estimate; b = both sexes combined, m = male, f = female

LowAge, HighAge: Age range reported by the risk estimate

YrsFU: Number of years of follow up reported by the risk estimate

Endpoint: The way the lung cancer cases were identified: by diagnosis or by reported death

Adj: Number of adjustment factors applied to the risk estimate

CA1, CA0, CO1, CO0: Numbers of cases (CA)/controls (at risk, CO), exposed (1)/unexposed (0)

RR, RRL, RRU: Relative risk (RR) and confidence interval (RRL to RRU)

CONTENTS

Table 1: List of all the results - Current cigar smokers versus never smokers	2
Table 2: List of all the risk estimates - Current cigar smokers versus never smokers	3

Analyses

Table 3: List of selected results - Current cigar smokers versus never smokers	4
Table 4: Analysis by sex	5
Table 5: Analysis by region	6

Table 1
 Smoking and Lung cancer: Cigar Smoking analyses
List of all the results (not all to be included in any one meta-analysis) - Current cigar smokers versus never smokers

Study ID	NRR	REFID	Country	Nature of population	YRST	NCASES	Product Sm	Excl	Latent	Pop analysed	Sex	LowAge	HighAge	YrsFU	Endpoint	Adj
EPIC	7	MCCORM2010	Multiple	International	1991	2995	Cigars	x	0	Cohort	m	30	70	14	Diagnosed	0
EPIC	8	MCCORM2010	Multiple	International	1991	2995	Cigars	x	0	Cohort	m	30	70	14	Diagnosed	5
NLCS	2	HART2015	Netherlands	National	1986	3355	Cigars	0	0	Nested CC	b	55	69	17	Diagnosed	0
NLMS	2	CHRIST2018	USA	National	1985	3890	Cigars	x	0	Cohort	b	35	80	26	Died	0
NLMS	5	CHRIST2018	USA	National	1985	3890	Cigars	x	0	Cohort	b	35	80	26	Died	1
NLMS	6	CHRIST2018	USA	National	1985	3890	Cigars	x	0	Cohort	b	35	80	26	Died	5

Table 2
 Smoking and Lung cancer: Cigar Smoking analyses
List of all the risk estimates (not all to be included in any one meta-analysis) - Current cigarette smokers versus never smokers

Study ID	NRR	REFID	CA1	CA0	CO1	CO0	RR	RRL	RRU	Derived
EPIC	7	MCCORM2010	3	22	1074	37103	4.71	1.41	15.72	Other calculations
EPIC	8	MCCORM2010	-	-	-	-	3.90	1.07	14.27	Other calculations
NLCS	2	HART2015	520	2612	305	4107	2.68	2.31	3.11	From numbers
NLMS	2	CHRIST2018	11	542	1139	203071	3.62	2.00	6.55	From numbers
NLMS	5	CHRIST2018	-	-	-	-	3.58	2.04	6.26	Given in the paper
NLMS	6	CHRIST2018	-	-	-	-	3.26	1.86	5.71	Given in the paper

Table 3
 Smoking and Lung cancer: Cigar Smoking analyses
List of the selected results - Initial analyses. Current cigar smokers versus never smokers, no overlapping results for any study.

Study ID	NRR	REFID	Country	Nature of population	YRST	NCASES	Product Sm	Excl	Latent	Pop analysed	Sex	LowAge	HighAge	YrsFU	Endpoint	Adj
EPIC	8	MCCORM2010	Multiple	International	1991	2995	Cigars	x	0	Cohort	m	30	70	14	Diagnosed	5
NLCS	2	HART2015	Netherlands	National	1986	3355	Cigars	0	0	Nested CC	b	55	69	17	Diagnosed	0
NLMS	6	CHRIST2018	USA	National	1985	3890	Cigars	x	0	Cohort	b	35	80	26	Died	5

Table 4
Smoking and Lung cancer: Cigar Smoking analyses
Analysis by sex

Combined

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
NLCS	2	520	305	2612	4107	2.68	(2.31- 3.11)
*NLMS	6	-	-	-	-	3.26	(1.86- 5.71)
Partial Totals		520	305	2612	4107		

*prospective study

Male

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*EPIC	8	-	-	-	-	3.90	(1.07- 14.27)
Partial Totals		0	0	0	0		

*prospective study

	RR Sex			Total
	1 Combined	2 Male	3 Female	

RR Data

N	2	1	3
NS	2	1	3
Wt	183.80	2.29	186.09
Het Chi	0.44	0.00	0.73
Het df	1	0	2
Het P	N.S.	N.S.	N.S.
Fixed RR	2.72	3.90	2.73
RRl	2.35	1.07	2.36
RRu	3.14	14.24	3.15
P	+++	+	+++
Random RR	2.72	3.90	2.73
RRl	2.35	1.07	2.36
RRu	3.14	14.24	3.15
P	+++	+	+++
Asymm P			N.S.
Between Chi		0.30	0.30
Between df		1	1
Between P		N.S.	N.S.
Btwn (F) P		N.S.	N.S.
Btwn (R) P		N.S.	N.S.

Table 5
Smoking and Lung cancer: Cigar Smoking analyses
Initial analysis by region

N America

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*NLMS	6	-	-	-	-	3.26 (1.86-	5.71)
Partial Totals		0	0	0	0		

*prospective study

Europe

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*EPIC	8	-	-	-	-	3.90 (1.07-	14.27)
NLCS	2	520	305	2612	4107	2.68 (2.31-	3.11)
Partial Totals		520	305	2612	4107		

*prospective study

	Region				Total
	1 N America	2 Europe	3 Japan	4 Multi	

RR Data

N	1	2		3
NS	1	2		3
Wt	12.21	173.87		186.09
Het Chi	0.00	0.32		0.73
Het df	0	1		2
Het P	N.S.	N.S.		N.S.
Fixed RR	3.26	2.69		2.73
RRl	1.86	2.32		2.36
RRu	5.71	3.13		3.15
P	+++	+++		+++
Random RR	3.26	2.69		2.73
RRl	1.86	2.32		2.36
RRu	5.71	3.13		3.15
P	+++	+++		+++
Asymm P				N.S.
Between Chi		0.42		0.42
Between df		1		1
Between P		N.S.	N.S.	N.S.
Btwn (F) P		N.S.	N.S.	N.S.
Btwn (R) P		N.S.	N.S.	N.S.

**Evidence relating cigarette, cigar and pipe smoking to lung cancer and COPD.
Meta-analysing recent data from three regions.**

Supplementary File 4

Authors

Peter N Lee, Katharine J Coombs, Jan S Hamling

This supplementary file gives details of the results available for pipe smoking and lung cancer; and their meta-analyses.

Smoking and Lung cancer: Pipe Smoking analyses

These analyses are restricted to results for current pipe smokers versus never smokers.

In the analyses, if multiple results are available for a single study

the results to be included in meta-analysis are selected by applying the following criterion:

1) The greatest amount of adjustment for possible confounding factors.

Key:

Study ID: Identifier assigned to the study

NRR: Sequence number within the study assigned to the risk estimate

REFID: Identifier assigned to the published paper

YRST: Year of start of baseline

NCASES: Number of lung cancer cases studied

ProductSm: Product smoked

Excl: Exclusive use of the product: 0 = No; 1 = Yes

Latent: A latency rule was applied, such as ignoring lung cancers in the first two or five years after smoking data were gathered: 0 = No; 1 = Yes

Pop analysed: The type of population considered in analysis: Cohort or Nested case control

Sex: Gender reported by the risk estimate; b = both sexes combined, m = male, f = female

LowAge, HighAge: Age range reported by the risk estimate

YrsFU: Number of years of follow up reported by the risk estimate

Endpoint: The way the lung cancer cases were identified: by diagnosis or by reported death

Adj: Number of adjustment factors applied to the risk estimate

CA1, CA0, CO1, CO0: Numbers of cases (CA)/controls (at risk, CO), exposed (1)/unexposed (0)

RR, RRL, RRU: Relative risk (RR) and confidence interval (RRL to RRU)

CONTENTS

Table 1: List of all the results - Current pipe smokers versus never smokers	2
Table 2: List of all the risk estimates - Current pipe smokers versus never smokers	3

Analyses

Table 3: List of selected results - Current pipe smokers versus never smokers	4
Table 4: Analysis by sex	5
Table 5: Analysis by region	6

Table 1
 Smoking and Lung cancer: Pipe Smoking analyses
List of all the results (not all to be included in any one meta-analysis) - Current pipe smokers versus never smokers

Study ID	NRR	REFID	Country	Nature of population	YRST	NCASES	Product Sm	Excl	Latent	Pop analysed	Sex	LowAge	HighAge	YrsFU	Endpoint	Adj
EPIC	2	MCCORM2010	Multiple	International	1991	2995	Pipes	x	0	Cohort	m	35	70	14	Diagnosed	0
EPIC	4	MCCORM2010	Multiple	International	1991	2995	Pipes	x	0	Cohort	m	35	70	14	Diagnosed	5
NLCS	3	HART2015	Netherlands	National	1986	3355	Pipes	0	0	Nested CC	b	55	69	17	Diagnosed	0
NLMS	7	CHRIST2018	USA	National	1985	3890	Pipes	x	0	Cohort	b	35	80	26	Died	1
NLMS	8	CHRIST2018	USA	National	1985	3890	Pipes	x	0	Cohort	b	35	80	26	Died	5
THREEC	2	TVERDA2011	Norway	Regional	1974	858	Pipes	x	0	Cohort	m	20	49	33	Died	0
THREEC	4	TVERDA2011	Norway	Regional	1974	858	Pipes	0	0	Cohort	m	20	49	33	Died	0
THREEC	6	TVERDA2011	Norway	Regional	1974	858	Pipes	x	0	Cohort	m	20	49	33	Died	10

Table 2
 Smoking and Lung cancer: Pipe Smoking analyses
List of all the risk estimates (not all to be included in any one meta-analysis) - Current cigarette smokers versus never smokers

Study ID	NRR	REFID	CA1	CA0	CO1	CO0	RR	RRL	RRU	Derived
EPIC	2	MCCORM2010	9	23	1105	37103	13.14	6.09	28.33	Other calculations
EPIC	4	MCCORM2010	-	-	-	-	13.30	6.23	28.39	Other calculations
NLCS	3	HART2015	278	2961	146	4351	2.80	2.28	3.44	From numbers
NLMS	7	CHRIST2018	-	-	-	-	1.65	0.67	4.09	Given in the paper
NLMS	8	CHRIST2018	-	-	-	-	1.51	0.61	3.74	Given in the paper
THREEC	2	TVERDA2011	25	9	15251	156274	28.46	13.29	60.97	From numbers
THREEC	4	TVERDA2011	43	9	24548	156274	30.42	14.83	62.38	From numbers
THREEC	6	TVERDA2011	-	-	-	-	10.32	5.55	19.18	Given in the paper

Table 3
 Smoking and Lung cancer: Pipe Smoking analyses
List of the selected results - Initial analyses. Current pipe smokers versus never smokers, no overlapping results for any study

Study ID	NRR	REFID	Country	Nature of population	YRST	NCASES	Product Sm	Excl	Latent	Pop analysed	Sex	LowAge	HighAge	YrsFU	Endpoint	Adj
EPIC	4	MCCORM2010	Multiple	International	1991	2995	Pipes	x	0	Cohort	m	35	70	14	Diagnosed	5
NLCS	3	HART2015	Netherlands	National	1986	3355	Pipes	0	0	Nested CC	b	55	69	17	Diagnosed	0
NLMS	8	CHRIST2018	USA	National	1985	3890	Pipes	x	0	Cohort	b	35	80	26	Died	5
THREEC	6	TVERDA2011	Norway	Regional	1974	858	Pipes	x	0	Cohort	m	20	49	33	Died	10

Table 4
Smoking and Lung cancer: Pipe Smoking analyses
Analysis by sex

Combined

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
NLCS	3	278	146	2961	4351	2.80	(2.28- 3.44)
*NLMS	8	-	-	-	-	1.51	(0.61- 3.74)
Partial Totals		278	146	2961	4351		

*prospective study

Male

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*EPIC	4	-	-	-	-	13.30	(6.23- 28.39)
*THREEC	6	-	-	-	-	10.32	(5.55- 19.18)
Partial Totals		0	0	0	0		

*prospective study

	RR Sex			Total
	1 Combined	2 Male	3 Female	

RR Data

N	2	2	4
NS	2	2	4
Wt	95.47	16.67	112.14
Het Chi	1.69	0.26	31.26
Het df	1	1	3
Het P	N.S.	N.S.	***
Fixed RR	2.71	11.42	3.36
RRl	2.22	7.07	2.79
RRu	3.32	18.46	4.04
P	+++	+++	+++
Random RR	2.42	11.42	4.93
RRl	1.45	7.07	1.97
RRu	4.04	18.46	12.32
P	+++	+++	+++
Asymm P			N.S.
Between Chi		29.31	29.31
Between df		1	1
Between P		+++	N.S.
Btwn (F) P		+	N.S.
Btwn (R) P		+++	N.S.

Table 5
Smoking and Lung cancer: Pipe Smoking analyses
Initial analysis by region

N America

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*NLMS	8	-	-	-	-	1.51 (0.61-	3.74)
Partial Totals		0	0	0	0		

*prospective study

Europe

STUDY	NRR	Numbers exposed		Non-exposed		RR	95.00%CI
		Case	Cont	Case	Cont		
*EPIC	4	-	-	-	-	13.30 (6.23-	28.39)
NLCS	3	278	146	2961	4351	2.80 (2.28-	3.44)
*THREEC	6	-	-	-	-	10.32 (5.55-	19.18)
Partial Totals		278	146	2961	4351		

*prospective study

	Region				Total
	1 N America	2 Europe	3 Japan	4 Multi	

RR Data

N	1	3		4
NS	1	3		4
Wt	4.67	107.47		112.14
Het Chi	0.00	28.14		31.26
Het df	0	2		3
Het P	N.S.	***		***
Fixed RR	1.51	3.48		3.36
RRl	0.61	2.88		2.79
RRu	3.74	4.20		4.04
P	N.S.	+++		+++
Random RR	1.51	6.98		4.93
RRl	0.61	2.29		1.97
RRu	3.74	21.30		12.32
P	N.S.	+++		+++
Asymm P		*		N.S.
Between Chi		3.12		3.12
Between df		1		1
Between P		(+)	N.S.	N.S.
Btwn (F) P		N.S.	N.S.	N.S.
Btwn (R) P		+	N.S.	N.S.

**Evidence relating cigarette, cigar and pipe smoking to lung cancer and COPD.
Meta-analysing recent data from three regions.**

Supplementary File 5

Authors

Peter N Lee, Katharine J Coombs, Jan S Hamling

This supplementary file gives details of the results available for cigar and pipe smoking and COPD.

Smoking and COPD: Cigar and Pipe Smoking data

These listings show results for current cigar or pipe smokers versus never smokers.

Key:

Study ID: Identifier assigned to the study

NRR: Sequence number assigned to the risk estimates within a study

REFID: Identifier assigned to the published paper

Nature of pop: Nature of the population; National or Regional

YRST: Year of start of baseline

NCASES: Number of COPD cases in the study; the number included in a single analysis will be less

ClearD: Are the definitions of smoking and product smoked clearly given in the paper? Yes/No

ProductSm: Product smoked

Excl: Exclusive use of the product: 0 = No; x = Yes

Latent: A latency rule was applied, such as ignoring COPD cases identified in the first two or five years after smoking data were gathered: 0 = No; x = Yes

Pop analysed: The type of population considered in analysis: Cohort or Nested case control

Sex: Gender reported by the risk estimate; b = both sexes combined, m = male, f = female

LowAge, HighAge: Age range reported by the risk estimate

YrsFU: Number of years of follow up reported by the risk estimate

COPD: Definition of COPD: 1: GOLD, 2: Severe obstruction, 3: Self-report, 4: ICD-10 J40-J44
5: GP notes and ICD-10 J40-J44, 6: ICD-9 491 492 494-496, 7: Participant used anticholinergics
8: ICD-10 J41-J44 J47, 9: ICD-9 490-2 ICD-10 J40-J44 J47, a: ICD-10 J44

Endpoint: The way the COPD cases were identified: by diagnosis or by reported death

Adj: Number of adjustment factors applied to the risk estimate

CA1: Number of cases among smokers

CA0: Number of cases among never smokers

CO1: Number of controls/at risk smokers

CO0: Number of controls/at risk never-smokers

RR: Relative risk

RRL: Lower 95% confidence limit

RRU: Upper 95% confidence limit

Derived: How the relative risk estimate was derived

CONTENTS

Table 1: List of all the results - Current cigar smokers versus never smokers	2
Table 2: List of all the results - Current pipe smokers versus never smokers	3

Table 1
Smoking and COPD: Cigar and Pipe Smoking data
List of all the results - Current cigar smokers versus never smokers

Study ID	NRR	REFID	Country	Nature of pop	YRST	NCASES	ClearD	Product Sm	Excl	Latent	Pop analysed	Sex	LowAge	HighAge	YrsFU	COPD	Endpoint	Adj
NLMS	2	CHRIST2018	USA	National	1985	2091	Yes	Cigars	x	0	Cohort	b	35	80	26	4	Died	0
NLMS	6	CHRIST2018	USA	National	1985	2091	Yes	Cigars	x	0	Cohort	b	35	80	26	4	Died	1
NLMS	7	CHRIST2018	USA	National	1985	2091	Yes	Cigars	x	0	Cohort	b	35	80	26	4	Died	5

Study ID	NRR	REFID	CA1	CA0	CO1	CO0	RR	RRL	RRU	Derived
NLMS	2	CHRIST2018	5	378	1139	203071	2.36	0.98	5.69	From numbers
NLMS	6	CHRIST2018	-	-	-	-	2.21	0.89	5.47	Given in the paper
NLMS	7	CHRIST2018	-	-	-	-	2.44	0.98	6.05	Given in the paper

Table 2
Smoking and COPD: Cigar and Pipe Smoking data
List of all the results - Current pipe smokers versus never smokers

Study ID	NRR	REFID	Country	Nature of pop	YRST	NCASES	ClearD	Product Sm	Excl	Latent	Pop analysed	Sex	LowAge	HighAge	YrsFU	COPD	Endpoint	Adj
NLMS	3	CHRIST2018	USA	National	1985	2091	Yes	Pipes	x	0	Cohort	b	35	80	26	4	Died	0
NLMS	8	CHRIST2018	USA	National	1985	2091	Yes	Pipes	x	0	Cohort	b	35	80	26	4	Died	1
NLMS	9	CHRIST2018	USA	National	1985	2091	Yes	Pipes	x	0	Cohort	b	35	80	26	4	Died	5

Study ID	NRR	REFID	CA1	CA0	CO1	CO0	RR	RRL	RRU	Derived
NLMS	3	CHRIST2018	2	378	1177	203071	0.91	0.23	3.66	From numbers
NLMS	8	CHRIST2018	-	-	-	-	1.04	0.27	4.10	Given in the paper
NLMS	9	CHRIST2018	-	-	-	-	1.12	0.29	4.40	Given in the paper